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ABSTRACT 
Primary Effusion Lymphoma (PEL) is a lymphoproliferative disease of B cell 
origin associated with HHV -8 infection and characterized by migration of tumor cells to 
serous body cavities. PEL cells originate from post-germinal center B cells yet harbor a 
non-B, non-T phenotype, a characteristic that has not been fully explained. In the 
present study we demonstrate that PEL cells have an impaired expression of B cell-
specific transcription factors and this results in a decreased acti vit y of promoters 
regulating essential B cell genes. PEL cells lack PU.l expression, although its 
transcription partner IRF-4 is highly upregulated, leading to decreased activity of the 
immunoglobulin 'A and K light chain ETS-IRF enhancers. Expression of the B cell 
specific transcription factor Oct-2 and the B cell specific co-activator of octamer factors 
(Bob-l), which are known to regulate PU.l expression, was also impaired. Ectopic 
expression of Oct-2 was able to fully restore PU.l promoter activity in the PEL cellline 
BCBL-l, while PU.l expression also reconstituted the activation ofthe 'AB Ets-IRF site. 
In addition, protein levels of BSAP/Pax-5 and IRF-8/ICSBP were undetectable in PEL 
cells. The pattern of transcription factor ablation observed in PEL was found to be 
comparable to that observed in classical Hodgkin's disease-derived celllines, which also 
lack B cell specific surface markers. Comparative analysis of gene expression by cDNA 
microarray of BCBL-I cells (PEL), L-428 (cHD) and BJAB cells revealed a subset of 
genes that were differentially expressed in PEL cells. Among these, four genes involved 
in cell migration and chemotaxis were strongly upregulated in PEL cells: L T A4H, IL-16, 
TSP-I, and selectin-P ligand. Upregulation of LT~H was investigated at the 
111 
transcriptionallevel. The LTA4H promoter exhibited 50% higher activity in BCBL-1 
cells than in BJAB or L-428 cells. Deletion analysis of the LTA4H promoter revealed a 
positive cis regulatory element active only in BCBL-1 cells in the promoter proximal 
region located between -76 to -40 bp. Formation of a specific DNA-protein complex in 
this region was confirmed by Electromobility Shift Assay (EMSA). Co-culture of 
BCBL-1 cells with ionophore-stimulated primary neutrophils lead to an increased 
production of L TB4 by transcellular biosynthesis compared to L-428 cells, 
demonstrating the functional significance of L T A4H upregulation. BCBL-1 cells also 
demonstrated increased migration even in the absence of chemotactic stimulus compared 
to L-428 cells. These observations indicate that 1) disruption of the B-celI specific 
transcriptional pro gram is likely to contribute to the incomplete B celI phenotype 
characteristic of PEL celIs and 2) upregulation of factors involved in celI migration and 
chemotaxis constitute a unique characteristic of PEL celIs that may contribute to the 
localization of this lymphoma to serous body cavities. 
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RÉSUMÉ 
PEL est un désordre lymphoprolifératif qui dérive des cellules B et est associé avec 
l'infection avec le virus HHV -8. Le PEL est caractérisé par la migration des cellules 
cancéreuses dans les cavités séreuses. Les cellules du PEL dérivent des cellules B à un 
stade de développement postérieur au centre germinal (CG) mais elles présentent un 
phénotype non-B, non-T, une caractéristique qui n'a pas encore été expliqué. Dans cette 
étude, nous démontrons que les cellules du PEL n'expriment pas certains facteurs de 
transcription essentiels à la differentiation lymphocytes B. Les cellules PEL n'expriment 
pas le facteur PU.I, malgré une surexpression de son partenaire de transcription IRF-4. 
Ceci entraine un manque d'activité des éléments Ets-IRF des activateurs à distance dans 
les promoteurs des chaînes légères des immunoglobulines. L'expression du facteur de 
transcription Oct-2 et du co-activateur des facteurs Oct (Bob-1), qui régulent 
l'expression de PU.1, est aussi déficiente dans les cellules PEL. La surexpression de 
Oct-2 est capable de rétablir l'activité du promoteur du gène P U.1 tandis que la 
surexpression de PU.l dans les cellules PEL est suffisante pour activer l'élément Ets-
IRF qui se trouve dans la chaîne légére À. En plus, nous avons décelé un défaut 
d'expression des facteurs de transcription BSAP/Pax-5 et IRF-8/ICSBP dans les cellules 
PEL. Dans l'ensemble, le manque d'expression de facteurs de transcription observé dans 
le PEL ressemble à celui qui a été décrit pour le lymphome de Hodgkin's classique 
(cHD), pour lequel on observe également une ablation de l'expression des marqueurs de 
surface. L'analyse comparative de l'expression génétique par puces à ADN de la lignée 
cellulaire BCBL-I (PEL) et des lignées L-428 (cHD) et BJAB a démontré qu'un nombre 
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réduit de gènes était exprimé de façon différentielle dans les cellules PEL. En particulier, 
l'expression de quatre gènes impliqués dans la migration cellulaire et le chimiotactisme 
est fortement augmentée dans les cellules PEL : hydrolase du leukotriène A4 (L T ~H), 
l'interleukine 16 (IL-16), la thrombospondine 1 (TSP-1) et le ligand de la selectine-P 
(PSGL-1). La surexpression de LTA4H a été étudié au niveau transcriptionel. L'activité 
du promoteur du gène LTA4H était 50% plus élevée dans les cellules BCBL-1 que dans 
les cellules L-428 ou BJAB. L'analyse des fragments de délétion du promoteur LTA4H 
ont révélé la présence d'un élément de régulation cis dans la région proximale du 
promoteur (entre -76 et -40 pb) activé uniquement dans les cellules BCBL-l. La 
formation d'un complexe spécifique protéine-ADN dans ce fragment a été confirmé par 
retard de migration sur gel. La co-culture des cellules BCBL-1 avec des neutrophils 
primaires stimulés avec ionophore a conduit à une production accrue de leukotriène B4 
par synthèse transcellulaire, par rapport aux cellules L-428 ou BJAB. Ces résultats 
suggèrent que la surexpression de L T A4H dans les célulles PEL pourrait avoir des 
implications physiologiques. La migration des cellules BCBL-1 - même en absence de 
stimulus chimiotactic - s'est montrée supérieure à celle des cellules L-428 ou BJAB. 
Dans l'ensemble, nos résultats indiquent que le manque d'expression des facteurs de 
transcription spécifiques aux lymphocytes B contribue au phénotype ambigü des cellules 
du PEL tandis que la surexpression de facteurs impliqués dans la migration et le 
chimiotactisme est une characteristique unique au PEL qui peut contribuer à la 
localisation de ce lymphome dans les cavités sereuses. 
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CHAPTERI 
General Introduction 
1 
1. Primary Effusion Lymphoma 
Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL) are the two most 
common neoplasms occurring in people with AIDS (198). In 1989, Knowles et al. first 
described an AIDS-associated neoplasm characterized by a lymphomatous effusion 
localized to serous body cavities in the absence of a solid tumor mass (149). The 
malignant cells lacked B-cell, T -cell, myeloid or monocyte lineage-restricted antigen 
expression pattern, but exhibited immunoglobulin light and heavy chain rearrangement 
in all cases, thus allowing the classification of this neoplasm as a B-cell lymphoma. 
Several reports with similar findings followed (39, 96, 297), but it was not until 1996 
that Nador et al. proposed the classification of body cavity-based lymphoma (BCBL), 
also named Primary Effusion Lymphoma (PEL), as a distinct clinico-patho1ogic and 
biological entity (198). The conclusion was based on morphologic and 
immunophenotypic characteristic of the cellular infiltrate as weIl as on the strong 
association of KSHV IHHV -8 infection with BCBLIPEL but not with other AIDS-related 
or non-AIDS-associated 1ymphoid neop1asms. Numerous studies have increased our 
understanding of PEL, both at the level of its cellular origin and the involvement of 
HHV -8 in disease deve1opment. In turn, the use of established PEL celllines has been an 
inva1uable too1 in the study of HHV -8 at the mo1ecu1ar leve1, particu1arly because KS 
spindle ce Ils have proven difficult to grow in the in-vitro setting. 
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1.1. Clinical presentation - epidemiology 
PEL presents itself as a lymphomatous effusion spreading along serous membranes in 
the pleural, peritoneal, or pericardial cavities. In general, PEL develops without obvious 
lymphadenopathy, tumor masses or bone marrow involvement. AlI PEL cases are 
associated with HHV -8 infection of the tumor cells. Co-infection with EBV is common 
(70% of cases) and - although not required for PEL development - EBV co-infection is 
thought to help transformation by HHV -8 by a yet undefined mechanism. PEL usually 
develops in male, advanced-stage AIDS patients (265), although a few reports of PEL in 
the absence of HIV -1 infection have been documented (23, 244). In AIDS-related PEL 
cases the median patient age is 40 years, whereas in HIV -negative cases, PEL develops 
much later, with a median patient age around 70 years. In aIl cases survival is poor, with 
a median survival rate of 5 months that remains unaffected by chemotherapy. 
Immunodepletion appears to be a factor in PEL development, because CD4+ cell count 
in HIV patients with PEL are significantly lower than that of patients with other AIDS-
related non-Hodgkin's lymphomas (265). 
1.2. Cellular morphology - cellular origin 
PEL cells are pleomorphic and heterogeneous in Slze, bridging large-cell 
immunoblastic and anaplastie features (198). The majority of cells is significantly larger 
than normal lymphocytes and possess moderate to abundant cytoplasm, basophilie to 
deeply basophilie, and large round or ovoid nuc1ei with one or more large nuc1eoli. A 
3 
prominent perinuclear Golgi zone is also present. A variable number of large 
pleomorphic cells containing markedly irregular, lobated or pleomorphic nuclei and cells 
with immunoblastic features are also present. Finally, sorne bi-nucleated cells 
resembling the Reed-Sternberg cells of Hodgkin's disease are also found in a majority of 
cases (reviewed in (32, 198)) (FIGURE 1). 
PEL cells lack expression of B-cell, T -ceIl, myeloid and monocyte lineage-restricted 
antigens, which initially le ad to its classification as a hematopoietic neoplasm of 
indeterminate origin (149)(96). Expression of leukocyte common antigen (LCA, CD45) 
confirmed that PEL cells belong to the hematopoietic lineage (149). Most cases lack 
expression of B-cell markers such as surface immunoglobulin (sIg), CD19, CD20, and 
CD22 and all cases lack expression of T-cell markers such as CD2, CD3, CD5 
(reviewed in (250)). Cytoplasmic immunoglobulins have been detected in about 20% of 
patients. PEL cells do express sorne activation-associated markers such as EMA, CD30 
(also expressed by 95% of anaplastic large-cell lymphoma and 70% of Hodgkin's 
lymphoma), CD38 and CD71, and the plasma cell marker CD138 (syndecan-1). 
Final classification of PEL as a B-cell lymphoma was based on antigen receptor 
rearrangement analysis that demonstrated light and heavy chain gene rearrangement in 
aIl cases (198). This also demonstrated that PEL originated from a mature B cell, and the 
presence of CD 13 8 suggested that PEL cells had sorne degree of plasma cell 
differentiation. Moreover, PEL cells lack expression of Bcl-6 prote in while exhibiting 
high levels of IRF-4 expression. These characteristics are consistent with a post-
germinal center (post-GC) state of differentiation (reviewed in (35,36)). However, study 
of the somatic hypermutation of the immunoglobulin loci in PEL cells demonstrated that 
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FIGURE 1. Biopsy samples of Primary Effusion Lymphoma. A and B) Wright-Giemsa-stained preparations of HHV -8-positive 
PEL. The cells are considerably larger than normal benign lymphocytes and exhibit cytomorphologic features that appear to bridge 
large ceIl immunoblastic lymphoma and anaplastie large cell lymphoma. The cells display variable polymorphism and generally 
possess moderately abundant amphophilic to deeply basophilie cytoplasm. A prominent clear perinuclear Golgi zone is frequently 
present. Small cytoplasmic vacuoles are occasionally present. The nuclei vary from large and round to highly irregular, multilobated 
and pleomorphic (Original magnification X 630). C) Hematoxilin and eosin-stained section of a PEL case involving the pulmonary 
lymphatics (Original magnification X 630). D) Hematoxilin and eosin-stained pleural fluid cell block of a KSHV -positive case of PEL 
(Original magnification X 400). The neoplastic cells are large but appear more uniform than in other preparations. Courtesy of Blood 
Journal (Nador et al., 1996) 

the hypervariable region could be found either in germline state, actively undergoing 
mutations or mutated and clonaIly expanded, corresponding to pre-Ge, Ge, and post-
Ge states of differentiation (109, 179). In light ofthis, it is possible that HHV-8 infects 
B-ceIls at different stages of differentiation but transformation leads to a phenotype of 
post-Ge, pre-plasma B ceIl. This is comparable to the activation state induced by EBV 
when it infects naïve B cells (reviewed in (310)). 
PEL is not associated with rearrangements in B-Cell CLLllymphoma-1 (Bcl-1), Bcl-2, 
Bcl-6 and cMyc genes, which are common in other aggressive B-celllymphomas. PEL 
cells do not exhibit p53 inactivation. However, mutations in the Bcl-6 5' -non-coding 
region are common in PEL as it is in most AIDS-related lymphomas derived from 
mature B cells (reviewed in (250)). 
1.3. Classification 
Over the years, different classification systems have been used to differentiate 
lymphomas based on morphological characteristics but also on information gathered as 
additional techniques become available. The Working Formulation classification was 
introduced in the 1980s to unify previously developed classification systems. The 
Working Formulation was based on the morphology of H&E stained sections and did 
not take into account the cellular origin of the lymphoma but rather classified it based on 
architectural and cytological features. The advent of immunologic, cytogenetic and 
molecular techniques has broadened the amount of information that can be gathered 
from biopsy samples and used to classify lymphomas. In 2001, the World Health 
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Organization (WHO) classification was published and it is to date the authoritative 
standard oflymphoma classification (reviewed in (40)). The WHO classification groups 
lymphomas based on cellular origin and cytogenetic, morphologic and clinical 
characteristics. Unlike previous methods, the WHO classification does not classify 
lymphomas according to behavior or prognostic categories but rather each lymphoma is 
se en as a separate disease that can be more or less aggressive in individual patients. The 
WHO classification recognizes Primary Effusion Lymphoma as a new type of non-
Hodgkin's lymphoma (NHL) mature B cell neoplasm whereas previous classification 
systems included PEL in the Diffuse Large B-cell Lymphoma category (52). NHL 
mature B cell neoplasms in the WHO classification include, among others, chronic 
lymphocytic leukemia, hairy cellieukemia, plasma cell neoplasms, follicular lymphoma 
and Burkitt' s lymphoma. 
Classical Hodgkin's disease (cHD) is also derived from mature B cells at a similar 
stage of development than PEL cens yet it falls under a different arm of the WHO 
classification system, i.e. Hodgkin's lymphoma (40). PEL and cHD share numerous 
similarities at the molecular level, such as lack expression of B-cell surface markers 
leading to what has been described as a "null" phenotype (11, 114, 233, 288). 
Investigation of transcription factor expression and activity in cHD led to the 
identification of a constitutive activation of NF- KB and AP-1 in the Reed-Sternberg 
(RS) cells that constitute the tumor cens of cHD (reviewed in (284)). PEL cens also 
exhibit constitutive NF-KB and AP-1 activation, owing to the action of HHV-8 viral 
proteins (see below). However, the similarities at the molecular level between PEL and 
cHD do not translate to their clinical presentation. PEL is a 'liquid' lymphoma that 
localizes to the serous body cavities, with >90% of cells being of malignant origin. PEL 
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has extremely poor prognosis and generally does not respond to conventional 
chemotherapy. Median survival rates hover around 6 months (reviewed in (4)). Classical 
Hodgkin's disease, on the other hand, is a lymphoma that localizes exclusively to the 
lymph nodes. Reed-Stemberg cells -the tumor cells of cHD - constitute less than 5% of 
the tumor load, the rest being a mixture of inflammatory cells such as neutrophils, 
macrophages and T cells. Conventional chemotherapy is the treatment of choice for 
cHD, with over 80% survival rates (reviewed in (58)). It is currently unknown which 
features of PEL at the molecular level lead to its particular clinical presentation, such as 
its exclusive localization to body cavities and its resistance to chemotherapy. 
1.4. Treatment of PEL 
Because PEL responds poorly to classical chemotherapy treatment, the focus of 
current research has been the identification of novel therapeutic venues. The use of 
highly active anti-retroviral therapy (HAART) to control HIV-l infection has reduced 
dramatically the incidence of both KS and PEL although it is not clear if this is due to its 
effects on HIV or on HHV -8 infection. One study of five HIV + PEL patients 
demonstrated that chemotherapy and HAART combination treatment lead to a decrease 
in HHV -8 load in four patients, which correlated with an improvement of CD4+ T cell 
counts but not with decreased HIV -1 viralload (266). 
Initial studies on PEL cell lines demonstrated that treatment with NF -KB inhibitors 
induced apoptosis of the tumor cells (144). Treatment with Interferon-a (IFN-a), on the 
other hand, was able to prevent HHV -8 reactivation in PEL cells and reduced HHV-8 
load in cultured peripheral blood mononuclear cells (PBMCs) (193). A breakthrough 
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study by Lee et al. demonstrated that treatment of the PEL cell line BCBL-1 with 
azydothymidine (AZT) and IFN-a induced apoptosis of 70% of cells compared with 10-
20% of apoptosis observed with either treatment alone (158). The synergistic effect of 
AZT and IFN-a in PEL cell apoptosis depended on the induction of TRAIL as 
transfection of the decoy receptor DcR2 abrogated the synergy between IFN-a and 
AZT. Treatment of a 35-year old HIV-1 positive PEL patient with a combination of 
parenteral, twice-daily AZT 1.5 g and IFN-a 5 million units resulted in a complete 
resolution of the pleural effusion after 5 days (90). Six months later, the patient 
remained symptom-free. However, in spite of this initial report of successful treatment 
of PEL by AZT and IFN-a, no further studies have been published on the subject. 
Recently, treatment of a PEL case with intrapleural administration of the anti-viral 
agent cidofovir (3-5 mg/kg) combined with radiation therapy was reported (108). The 
treatment efficiently halted further accumulation of pleural fluid and the patient's 
condition improved substantially. However, 15 months after treatment, the patient still 
had a pleural effusion (albeit minimal), and pleural thickening. A pilot clinical trial at 
the National Institutes of Health will investigate the use of a combination of the 
anticancer agent bortezomib, with zidovudine (AZT) and the anti-viral agent 
valganciclovir in the treatment of PEL (trial number NCI-05-C-0203, 
http://bethesdatrials.cancer.gov). Due to the inherent toxicity of each of the components 
of this treatment, it is likely that such a regime will result in considerable side effects. A 
treatment of PEL that can be routinely used with high efficiency and relatively low 
toxicity is still needed. 
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1.5. Role of HHV -8 in PEL development 
Although HHV -8 infection is recognized to be associated with PEL development, the 
exact mechanism by which HHV -8 transforms B cells remains unknown, partially owing 
to the lack of a good de novo infection model. In PEL cells, the pattern on HHV -8 gene 
expression is very restricted, with virtually all cells (>95%) expressing only the latent 
genes Latent Nuc1ear Antigen-1 (LANA-l), viral Cyclin (vCyc), and viral FLIP 
(vFLIP), and to a lesser extent kaposin/K12 and viral Interferon Regulatory Factor 10.5 
(vlRF 10.5)/Latent Nuclear Antigen-2 (LANA-2). vFLIP, vCyc and LANA-1 genes are 
encoded by open reading frames K13, ORF72 and ORF73, respectively, located in a 
DNA locus with latency-associated gene expression (reviewed in (247) and (61)). 
Analysis of PEL biopsy samples by immunohistochemistry demonstrated that, 
additionally to LANA-1 expression, a limited number of cells (s2-5%) express viral 
Interleukin-6 (vIL-6), and a minority of cells «1 %) expresses lytic proteins (223). 
Microarray analysis of HHV -8 gene transcription in PEL cell lines has allowed a 
detailed study of HHV-8 viral gene expression (132). HHV-8 positive PEL cell lines 
treated with TP A to induce HHV -8 lytic repli cation demonstrated that HHV -8 genes are 
expressed following a discrete pattern and that they can be broadly classified in three 
categories (246). Class 1 genes are expressed in the absence of TP A induction and their 
expression does not change after treatment, constituting "true" latent genes. The latent 
transcripts LTI and LT2, encoding for LANA-l, vCyc and vFLIP, correspond to this 
category. A third 4.5 kb transcript, termed L T3, is also a c1ass 1 but it has not been 
characterized. Class II genes include mRNAs that are detected at different levels without 
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TPA induction and are induced to high levels upon lytic replication. Kaposin (ORF 
KI2), nuclear transcript 1 (nut-l), vIL-6 (ORF K2), vMIP II (ORF K4) and vIRF (ORF 
K9) are examples of Class II genes. Class III genes are detected only after TP A 
induction. These genes encode for lytic genes that are required for efficient viral 
replication and virion particle production. Examples of class III genes include major 
capsid prote in (MCP, ORF 25), DNA polymerase (ORF 6) and glycoprotein H (gH, 
ORF21). 
It should be noted that sorne differences in gene expression have been observed 
between PEL biopsy samples and celllines, particularly pertaining to vIRF expression 
during latency, which was not detected in biopsy samples (223). It is possible that in-
vitro culture conditions somewhat alter HHV -8 gene expression, a phenomenon 
observed also in EBV -infected cell tines. The expression of vIL-6 and vIRF 
10.5/LANA-2 has been suggested to correspond to an alternative latent pro gram 
established in B cells, since the endothelial cells of KS do not express these viral 
proteins (250, 272). The potential role of the major latent proteins LANA-l, vCyc and 
vFLIP as weIl as vIL-6 in cellular transformation is presented below. 
1.5.1 Latent Nuclear Antigen-l (LANA-li ORF 73) 
HHV -8 gene ORF 73 encodes for a 132 kDa prote in, 1 162 amino acids long, known 
as the Latency-associated Nuclear Antigen (LANA, LANA-l, LNA-1). LANA is 
expressed during latency in the nucleus of HHV -8 infected cells where it accumulates in 
speckles referred to as LANA bodies (143). LANA protein tethers the viral chromosome 
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to the host's genome, mediating episome replication and persistence as well as efficient 
segregation of episomes to daughter nuclei. LANA oligomerizes and binds to the 
terminal repeat (TR) region of the circularized HHV -8 DNA via its C-terminal domain 
(150) and simultaneously interacts with cellular histone Hl (54). Furthermore, LANA 
plays an important role in lymphomagenesis, as demonstrated in LANA transgenic mice, 
which show expanded IgM+ IgD+ B cell populations, increased GC formation and 
spontaneous development of lymphomas (76). 
LANA is a transcriptional activator and repressor of both viral and cellular promoters 
(FIGURE 2). Various DNA tumor viruses encode specific proteins that target the p53 
and Retinoblastoma (Rb )1E2F regulatory pathways, such as the simian virus (SV) 40 
large T antigen, adenovirus ElA protein and human papilloma virus (HPV) E7 protein. 
Similarly, HHV -8 LANA physically interacts with p53, inhibiting its transcriptional 
activity and leading to a decrease in p53-mediated apoptosis (85). However, the 
mechanism of inhibition of p53 by LANA is still unclear and it does not involve 
inhibition ofDNA binding by p53 or induction ofp53 degradation. LANA transactivates 
E2F-dependent promoters by binding to the retinoblastoma protein (PRb) when in its 
hypophosphorylated/active state. This effectively prevents the formation of the 
inhibitory Rb/E2F complex and thus promotes E2F-mediated transcription (229). 
LANA is a coactivator of cJun, as demonstrated in 293 cells and BCBL-l primary 
effusion lymphoma cellline. LANA physically associates to cJun and induces binding of 
cFos-cJun heterodimers to the AP-l response element without physically interacting 
with the DNA sequence (7). This transactivation of the AP-l response element by 
LANA induces the activity of the IL-6 promoter, leading to an increase in IL-6 
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FIGURE 2. LANA-l can act as a transcriptional transactivator or repressor. LANA-l promotes cell cycle progression by binding 
to the inhibitor Rb prote in, preventing interactions with E2F. LANA-l physically interacts with cJun and STAT3, enhancing 
transcription of the IL-6 gene. LANA-l aiso increases the transcription of viral promoters containing Sp-l, ATF, CAAT and TATA 
box elements. As an inhibitor, LANA-l represses transcription mediated by p53, CBP and NF-KB. Interaction with p53 inhibits the 
induction ofpro-apoptotic genes, whereas NF-KB inhibition represses the HIV-l LTR. 
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production, as demonstrated in-vitro in 293 and bone marrow stromal cell lines (6). 
LANA physically associates with STAT3 in PEL cells to enhance its transcriptional 
activity, possibly leading to a further upregulation ofIL-6 expression (197). LANA can 
also physically interact with the ubiquitous transcription factor Sp-l and synergistically 
activate Sp-l mediated transcription, as demonstrated for the human telomerase reverse 
transcriptase gene (295). 
LANA can modulate viral gene expression via interactions with the basal transcription 
machinery or additional transcription factors, thus LANA can positively regulate viral 
promoters containing ATF, AP-l, CAAT, and Sp-l binding sites or only a TATA box 
and negatively regulate promoters containing KB sites (235). LANA positively regulates 
its own expression, increasing mRNA levels up to 5.5-fold (134), whereas it inhibits the 
expression of Rta (ORF50) and induction of the lytic cycle (156, 165). In contrast, 
LANA inhibits Epstein-Barr virus (EBV) gene expression by interacting with the mSin3 
correpressor complex (152). The action of LANA on HIV-1 gene expression is less 
clear: LANA was shown to inhibit LTR-mediated transcription by repressing NF-KB 
transactivation (235) yet it was shown to interact with the transactivator prote in Tat to 
stimulate LTR transcription (125). Surprisingly, LANA has been reported to interact 
with CREB-binding protein (CBP) and inhibit its histone acetyl-transferase activity 
(162), although the physiological relevance of such interaction remains unknown. 
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1.5.2 Viral FLICE Inhibitory Protein (vFLIP/ ORF K13) 
The open reading frame ORF711K13 of HHV-8 encodes for vFLIP, a viral prote in 
homologous to the cellular inhibitor of human caspase-8/Fas-associated death domain-
like IL-1 ~-converting enzyme (FLI CE) known as cFLIP (also known as MRIT, Casper, 
I-FLICE, FLAME, CASH, CLARP). Survival of PEL lymphoma cells and spindle cells 
from late stage KS lesions is associated with vFLIP expression (103, 273). 
Downregulation of vFLIP expression by RNA interference in PEL cells leads to 
abrogation of NF-KB activity and enhanced spontaneous cellular apoptosis as well as 
sensitization to the induction of apoptosis by extrinsic stimuli (103). Viral FLIP thus 
appears as a pivotaI protein for the development of HHV -8 associated malignancies. 
Activation of the apoptotic pro gram by ligation of death receptors - such as the tumor 
necrosis factor (TNF) receptor 1 (TNFR-1) or FAS/CD95 - follows a specific cascade of 
signaling events (reviewed in (27)) (FIGURE 3A). Ligand binding to the death 
receptor leads to receptor multimerization and recruitment of adaptor molecules such as 
FADD (Fas-associated Death Domain prote in) and TRADD (TNFR-associated Death 
Domain protein). The adaptor molecules then recruit Caspase 8/FLICE (also known as 
MACH, Mch5), the apical caspase of the caspase cascade, via interaction with their 
Death Effector Domains (DED) to form the Death Inducing Signaling Complex (DISC). 
Recruitment signaIs Caspase 8 to undergo auto activation by proteolytic cleavage and 
relay the apoptotic signal to the effector caspase, Caspase 3. During the assembly of the 
DISC complex, cFLIP can also be recruited via association with F ADD. cFLIP contains 
tandem DED do mains but only partial or no activation domain. Recruitment of cFLIP 
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FIGURE 3. vFLIP is a viral homolog of cFLIP that inhibits apoptosis and activates NF-KB and AP-l. A) Death receptor-
mediated apoptosis involves the recruitment of the apical caspase Caspase 8 to the receptor complex via interaction with adaptor 
molecules such as F ADD, leading to auto-activation by proteolytic c1eavage. Active Caspase 8 can induce the mitochondrial apoptotic 
pathway as weIl as directly activate the effector caspase Caspase 3. Cellular FLIP inhibits recruitment of caspase 8 by FADD to the 
DISC complex. cFLIP can also activate the NF-KB pathway and promote cell survival. B) vFLIP prevents caspase-8-mediated 
apoptosis and activates NF -KB either by recruiting TRAF2 and NIK or by direct interaction with the IKK complex, resulting in 
activation ofboth the c1assical and canonical NF-KB pathways. vFLIP also activates JNK via TRAF2 leading to activation of AP-l 
transcription factors. vFLIP thus enhances transcription ofNF-KB and AP-l regulated genes such as 1L-6. 
A F.AS 
• IrllU:tive œspase C .Active œspase 
B 
F.AS 
nrln,1ii'lill ofNF~1(B and 1iP~ 
~gu!afedgenes {IL..6) 
................ ~. 
does not prevent Caspase-8 association with the DISC complex, but it prevents Caspase-
8 from undergoing a productive proteolytic cleavage. Thus, cFLIP effectively blocks 
caspase 8-mediated apoptosis. Moreover, Chaudhary et al. demonstrated that cFLIP also 
activates the NF-KB pathway by means ofits DED domain (45). 
Viral FLIP efficiently inhibits death receptor-mediated apoptosis of HHV -8 infected 
cells by inhibiting the recruitment of pro-caspase 8 to the DISC complex (19). vFLIP 
activates the classical and alternative NF-KB pathways, effectively triggering the 
transcription of pro-survival and proliferation genes. Indeed, vFLIP physically associates 
with TRAF2, which binds and activates the NF-KB Inducing Kinase (NIK). NIK 
subsequently activates the IKB Kinase (IKK) complex leading to persistent IKK 
activation and phosphorylation ofIKB-a, which frees NF-KB dimers to translocate into 
the nucleus and activate transcription of target genes (46) (FIGURE 3B). Additionally, 
vFLIP has been found to physically associate with the IKK complex presumably through 
interactions requiring IKKyINEMO, the regulatory subunit of the IKK complex, to 
activate NF-KB (164). vFLIP also activates the alternative NF-KB pathway, leading to 
increased pl 00 processing into p52 via IKKa kinase activity (181). 
Additionally, vFLIP can activate the activation protein 1 (AP-l) pathway. Association 
of vFLIP with TRAF2 leads to the activation of cJun N-terminal kinase (JNK), which 
phosphorylates cJun leading to AP-l translocation into the nucleus and transcription of 
target genes (8). Activation of NF-KB and AP-l by vFLIP leads to increased IL-6 
production, a growth factor found in aIl HHV -8-associated neoplasms that contributes to 
tumor cell survival and establishment of an inflammatory milieu (8). 
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1.5.3. Viral Cyelin (vCyel ORF72) 
Cellular cyclins control progression through the cell division cycle by associating with 
members of the Ser/Thr kinase family of CDKs to form active holoenzymes that 
phosphorylate particular substrates to allow checkpoint clearance and progression 
through the cell cycle (reviewed in (260)). Entry from GO to Gland progression to S 
phase requires the sequential action of Cyclin D (CycD)-CDK4/6, Cyclin E (CycE)-
CDK2 and cyclin A (CycA)-CDK2. When GO cells are stimulated with mitogen to re-
enter the cell cycle, active Cyclin D-CDK4/6 complexes start accumulating during G 1 
and phosphorylate the tumor-suppressor Retinoblastoma prote in family (Rb, p107, and 
p 130). Hypophosphorylated Rb is bound to and inhibits the E2F transcription factor, 
which controls the expression of a battery of genes involved in DNA metabolism and 
replication. Phosphorylation of pRb by CycD-CDK4/6 leads to its degradation and 
release of E2F, which can then transactivate target genes. Inhibitory proteins known as 
Cyclin-Dependent Kinase Inhibitors (CDKI) control the activation of Cyc-CDK kinase 
complexes. The KIP/CIP family of CDKI inhibits CycD- and CycE-activated kinases. 
The KIP family includes p21CiP, p27Kip, and p57Kip2, which inhibit CycE/CDK2. 
CycD/CDK4/6 requires binding of p21 Cip or p27KiP to stabilize the complex, leading to a 
titration of the inhibitors that regulates the activation of CycE/CDK2. The INK family -
comprised ofpl6Ink4a, p15Ink4b and p18Ink4c - specifically inhibits the kinase activity of 
CycD-CDK4/6 (FIGURE 4A). 
HHV -8 vCyc has 32% identity and 54% similarity with mammalian cyclin D2 
(CycD2) (43, 161). Association ofvCyc with CDK6, but not CDK4, leads to activation 
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FIGURE 4. vCyclin interacts with CDK6 and promotes disregulated cell cycle progression. A) Cellular cyclin D interacts with 
CDK 4 and 6 to promote progression through G liS. The active CycD/CDK kinase complex exclusively phosphorylates the Rb protein 
family to induce transcription of genes necessary for progression through G liS, such as CycE. CyclinlCDK complexes are tightly 
regulated by the family of KIP/CIP inhibitors: p27Kip1 and p21cip1 inhibit CycE/CDK2, whereas p161nk4a inhibit CycD/CDK4/6. 
Additionally, p27Kip1 and p21 Cipl bind to CycD/CDK4/6 complexes and stabilize them. B) vCyclin preferentially interacts with CDK6 
to form a holloenzyme that does not require p27Kipl/p21cipl for stabilization and is resistant to the inhibitory effects of the KIP/CIP 
proteins p16Ink4a, p21cip1 and p27Kip1 . vCyc/CDK6 promiscuously phosphorylates proteins involved in the GlIS and G2/M transitions, 
including Rb proteins, cdc2SA, Id-2, the apoptosis inhibitor Bcl-2 and p27 Kipl, among others. Phosphorylation of Bcl-2 and p27 Kipl 
triggers the degradation of these inhibitors of the cell cycle. vCycD thus triggers disregulated cell cycle progression. 
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of the kinase activity and efficient phosphorylation of Rb and other substrates such as 
cdc25A -normally a target of CycE/CDK2 -, cdc6, ORCl and physiological substrates 
of CyclinA/CDK2 (173). This is in striking contrast to the cellular CycD3-CDK4/6 
complex that exclusively phosphorylates pRb (92, 161). vCyc is resistant to inhibition 
by p 16Ink4a, p21 Cip and p27Kip and does not require binding of p21 Cip or p27Kip to form 
stable complexes with CDK6 (276). In addition, vCyc-CDK6 can phosphorylate p27Kip, 
leading to prote in destabilization and degradation (70). Thus, vCyc can further promote 
cell cycle progression by relieving CDK2 of the inhibition by p27Kip (FIGURE 4B). In 
this manner, vCyc can mimic the effect of both G l-S and G2-M cyclins (reviewed in 
(155), (296». 
vCyc contributes to HHV -8 infection by promoting cellular entry into S phase, a 
phenomenon that might be required for virus reactivation from latency (111). More 
importantly, vCyc contributes to cellular transformation by overcoming normal cell 
cycle control mechanisms. In a study by Carbone et al., PEL biopsy samples and cell 
lines as weIl as non-HHV -8 associated lymphomatous effusions were analyzed for vCyc, 
the proliferation marker Ki-67, and p27Kip prote in expression (34). PEL cells 
consistently stained positive for aIl three proteins, suggesting that vCyc drives PEL cell 
proliferation regardless of the presence of the inhibitor p27KiP • This was in contrast with 
non-HHV -8 associated neoplasms, were proliferation and p27Kip expression were 
generally inverse1y correlated. 
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1.5.4. Viral Interleukin-6 (vIL-6/ ORFK2) 
HHV-8 viral IL-6 shares 24.8% amino acid sequence identity and 49.7% similarity to 
human IL-6. It is encoded by ORF K2 and it can be detected as a 1.0 kb mRNA in latent 
and lytically infected PEL cells (201). The abundance of vIL-6 mRNA is moderate in 
PEL cells but it increases to high levels upon induction of the lytic cycle by TP A 
treatment. Thus, vIL-6 is a class II gene, according to the classification proposed by 
Sarid et al. (246). 
Human interleukin-6 (hIL-6 or IL-6) is a multifunctional enzyme that promotes 
normal B cell proliferation and terminal differentiation into plasma cells (283, 289) but 
has been implicated in the development of a variety of diseases, including rheumatoid 
arthritis and multiple myeloma (38). IL-6 is implicated in the pathogenesis of HHV-8 
associated diseases: IL-6 can be detected in KS lesions, where it triggers proliferation of 
the spindle cells (73, 188). In multicentric Castelman's disease, IL-6 acts as a B cell 
proliferation factor, and IL-6 levels closely correlate with severity of the disease (210); 
however, the role ofIL-6 in PEL pathogenesis remains controversial (63, 83, 135). 
Human IL-6 signaIs through the IL-6 receptor, which is composed by the common 
chain gp130 and the specific ct subunit IL-6R (gp80). IL-6 binds to IL-6R and this 
complex then associates with gp130, allowing it to homodimerize (160). A hexameric 
complex composed of two molecules of IL-6, two IL-6R and four gp130 then signaIs 
through recruitment of Janus Kinases (JAK) JAK1, JAK2 and/or Tyk2, which 
phosphorylate gp130 (180, 270). Signal Transducers and Activators of Transcription 
(STATs) are recruited to the receptor and are phosphorylated by the JAK kinases, 
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leading to their activation. Phosphorylation and homodimerization of STAT3 leads to its 
activation and binding to hIL-6 response element (IL-6RE) found in IL-6-induced genes 
(106, 243). Heterodimers of STAT1 and STAT3 bind to the GAS (IFNy-activated 
sequence) to activate transcription of additional genes (106). IL-6 signaling also 
activates the Ras-dependent MAPK pathway, ultimately leading to the activation of 
transcription factors AP-1 and NF -IL-6 (154, 200) (FIGURE SA). Binding of human 
IL-6 to IL-6Ra subunit is required for the recruitment of gp 130 and activation of the 
downstream signaling cascade. This provides a regulatory mechanism for the control of 
IL-6 signaling by stimuli such as interferon-a (lFN-a), which can trigger 
downregulation of IL-6Ra expression and shut down IL-6-induced proliferation and 
survival (44). 
HHV-8 encoded vIL-6 can bind to gp130 in the absence of IL6Ra and persistently 
activate transcription via the JAK/STAT and MAPK pathway. Viral IL-6 induces 
recruitment of JAKI to gp130, leading to its phosphorylation and activation. However, 
unlike hIL-6, JAK2 and Tyk2 are not activated by vIL-6. Thus, as a downstream effect, 
only STAT3 is phosphorylated but not STATI (116), meaning that only genes 
containing the IL-6RE but not GAS sequences can be activated by vIL-6. Viral IL-6 
triggers activation of the Ras-dependent MAPK pathway - as demonstrated by the 
phosphorylation of ERK2 and activation of MEK 1 (116) - leading to activation of AP-l 
transcription factors (FIGURE SB). Because vIL-6 does not require the IL-6Ra chain, 
it can escape negative regulation by IFN-a and induce cell proliferation and survival 
even in the presence of this cytokine; moreover, vIL-6 disrupts IFN receptor 
phosphorylation of Tyk2 kinase, leading to decoupling from the Jak/STAT pathway. 
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FIGURE 5. Viral IL-6 signais through gp130 to activate the STAT and Ras signaling pathways. A) Cellular IL-6 binds to IL-6Ru 
(gp80) and recruits gp130 to form the IL-6 receptor. IL-6 activates Ras, leading to activation of the MAPK pathway and AP-l and NF-
IL6 transcription factors. Activation of the STAT pathway by IL-6 proceeds via recruitment of JAKI and JAK2/Tyk2 to gp130, which 
phosphorylate STAT3 and STATl, respectively. STAT3/STATl heterodimers bind to GAS sequences and activate transcription of 
IFN-y-stimulated genes. STAT3 homodimers bind in conjunction with AP-l and NF-IL6 to the IL-6 response element (IL-6RE) to 
activate transcription of IL-6 inducible genes. B) Viral IL-6 (vIL-6) binds to gp130 in the ER and signaIs independently ofIL-6Ru. 
Similar to IL-6, vIL-6 activates the RaslMAPK pathway. vIL-6 signaling recruits JAKI but not JAK2/Tyk2 to the receptor, resulting in 
the activation ofSTAT3 but not STATI. STAT3 homodimers together with NF-IL6 and AP-l activate transcription ofIL-6 and AP-l 
responsive genes but there is no activation ofIFN-y inducible genes, owing to the lack ofSTATl/STAT3 heterodimers. 
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Viral IL-6 protects PEL cells against growth arrest and apoptosis induced by IFN-a. 
PEL cells rapidly upregulate vIL-6 production following exposure to IFN-a directly 
through two Interferon-Stimulated Response Element (ISRE) sequences found in the 
vIL-6 promoter, thus creating a negative feedback loop that allows HHV -8 to respond to 
interferon challenge (44). 
PEL cells are dependent on vIL-6 autocrine signaling for spontaneous growth (135). 
However, exogenous recombinant vIL-6 is required at levels up to 103 times higher -
around 1 !-tg/mL - than hIL-6 to induce proliferation of IL-6 dependent B celllines (28, 
163) yet physiological vIL-6 levels found in PEL samples are much lower than this 
value. This discrepancy led to the investigation by Meads and Medveczky of vIL-6 
postranslational modifications and transport (186). Their results show that vIL-6 binds to 
gp 13 0 in the ER and is transported to the surface along with the receptor (Figure SB). 
This interaction is required for vIL-6 transport because vIL-6 is not secreted in cells 
lacking gp130. Interestingly, vIL-6 can stimulate signaling through gp130 and trigger 
ST AT3 phosphorylation without need for surface expression of the receptor. This is in 
contrast with human IL-6, which is secreted independently of gp130 and cannot signal 
intracellularly. Viral IL-6 can thus efficiently establish an autocrine signaling 
mechanism to promote cell proliferation and survival. 
1.6. Role of EBV co-infection 
Epstein-Barr Virus (EBV) is a y-herpesvirus closely related to HHV -8. EBV primarily 
infects nasopharyngeal epithelia and B lymphocytes. Acute infection with EBV is the 
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cause of infectious mononucleosis, whereas persistent infection with EBV is associated 
with a number of human malignancies, such as nasopharyngeal carcinoma, Burkitt' s 
lymphoma, Hodgkin's disease, immunoblastic lymphomas, etc (reviewed in (147)). In 
most PEL cases, the lymphoma cells are co-infected with HHV-8 and EBV (reviewed in 
(1)) and the quasi-ubiquitous presence of EBV in PEL cells first lead to the suggestion 
of an etiological role for EBV in PEL pathogenesis. Although it has now become clear 
that it is HHV -8 infection that is associated with PEL development and that this 
lymphoma can arise in the absence of EBV but not HHV -8, it is also clear that EBV and 
HHV -8 can interact in the infected B lymphocyte. 
PEL cens co-infected with EBV usually exhibit a type II latency pattern of gene 
expression (31, 121), although sorne reports have found a latency 1 type of expression 
(152, 277). In vivo experiments in severe combined immunodeficiency (SCID) mice 
demonstrated that EBV co-infected HHV -8+ PEL cell lines were able to induce tumor 
formation much more efficiently than the EBV· HHV -8+ cell Hnes (290). Indeed, the 
PEL cell lines BC-3 and CRO-AP/6 infected with recombinant EBV were highly 
tumorigenic in SCID mice when inoculated at 10 X 106 cells and 1 X 106 cens 
respectively. Both doses failed to induce any tumor formation when the parental cell 
lines were used. The dually infected cells expressed EBER-l, EBNA-l and LMP2A but 
lacked EBNA 2-6, corresponding to a latency type II gene expression profile. Sorne cens 
also expressed variable levels of LMPl. It remains to be determined which EBV-
encoded proteins help HHV -8 to induce transformation. 
At the molecular level, somewhat conflicting reports exist of interactions between the 
HHV-8 latent protein LANA-l and the EBV genome. One study (100) found that 
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transiently transfected LANA-1 activated transcription from the EBV major C promoter 
(Cp) in BJAB and 293 cells to the same level as EBNA2. In the same way, LANA-1 
dramatically activated the LMP1 promoter, with up to 45-fold induction. Deletion 
studies of the LMP1 promoter showed that LANA-1 transactivation was mediated by the 
proximal region of the promoter (-204 bp to +40 bp), which contains PU.1, ATFICRE 
and Sp-1 binding sites. LANA-1 has been shown to bind and activate Sp-1 to induce 
transcription of target genes, so it is possible that activation of the LMP-1 promoter 
occurs via Sp-1 and LANA-1 interactions. On the other hand, a study by Krithivas et al. 
(152) found that LANA-1 repressed both Cp and Qp promo ter activity. LANA-1 
blocked JAK-1 induced upregulation of Qp and EBNA2 induced upregulation of Cp, 
although LANA-1 had no effect on the basal activity of these two promoters. The 
negative effects of LANA-1 were at least partially mediated through its association with 
proteins of the mSin3 corepressor complex. 
1.7. Role ofHIV-l co-infection 
Long before the discovery of HHV -8, the association between Kaposi' s sarcoma and 
HIV -1 infection had been established in the clinical setting. In the 1980s, the onset of the 
AIDS epidemic was accompanied by a dramatic increase in KS cases in homosexual 
men. The appearance of KS lesions was one of the hallmarks of the onset of AIDS and 
was used as a clinical marker of infection with HIV -1 (91). Similarly, PEL cases are 
more common in AIDS patients than in the rest of the population, suggesting sorne level 
of co-operation between HHV -8 and HIV -1 in promoting PEL. Clearly, the 
immunosuppression induced by HIV infection plays an indirect role in PEL and KS 
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pathogenesis, as other immunosuppressed states -such as in transplant patients - also 
correlate with increased PEL/KS incidence (reviewed in (1)). 
The Tat prote in of HIV -1 has been put forth as a viral prote in that promotes KS 
development due to its pro-angiogenic properties (17). Tat can also directly promote 
growth of KS cells (71). Tat and basic fibroblast growth factor (bFGF) synergistically 
induce the proliferation of endothelial cells (72) and Tat can increase activated 
endothelial cell adhesion (16). Because inflammatory cytokines play such an essential 
role in KS development, it has been suggested that immune modulation, rather than 
immune suppression, by HIV -1 is a factor in KS development. 
In the case of PEL, although association between disease development and late stage 
AIDS is striking, few studies exist on the role of HIV -1 in PEL development. HIV -1 can 
induce HHV -8 reactivation in PEL cell Hnes by inducing Rta expression and Tat can 
promote increased migration of PEL cells (50, 294). Thus, a certain level of interaction 
between viral proteins exists but the full extent of co-operation between HIV -1 and 
HHV -8 in PEL development still remains to be investigated. 
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2. PEL ce Ils and the B cell transcriptional program 
Lymphomagenesis is a complex process involving multiple molecular pathways that 
culminate in the transformation of mature lymphoid cells. As we have seen in the 
previous section, infection of B lymphocytes with HHV -8 is associated with the 
development of PEL; however, the study of HHV -8 viral products is insufficient to 
explain the development and clinical presentation of PEL. The study of PEL lymphoma 
histogenesis is necessary to identify the normal B lymphocyte counterpart of the PEL 
cell and the molecular changes associated with cancer development. As seen above, PEL 
has been characterized as being of late-GC or post-GC origin, owing to the expression of 
IRF-4 and CD138/syndecan-l and the lack of expression of Bcl-6. To put these findings 
into context, we give an overview of B lymphocyte development and of specifie 
transcription factors that play an essential role in this process. 
2.1. The Development of B Lymphocytes 
The development of B lymphocytes proceeds through a series of tightly regulated 
stages that can be described based on a unique constellation of surface markers as weIl 
as Ig gene rearrangement (267) (FIGURE 6). For an in-depth review in lymphocyte 
development, please refer to (94). B cell development starts in the bone marrow, with 
the common lymphoid progenitor (CLP) giving rise to the pro-B cell by expressing the 
IL-7 and Flk2/Flt3 cytokine receptors at its surface via the combined action of PU.l and 
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FIGURE 6. Schematic representation of surface marker and transcription factor expression during B cell development. The 
development of B lymphocytes can be described as a series of stages characterized by the rearrangement of immunoglobulin genes 
(bottom) and the stepwise expression of surface markers (top). This process is orchestrated by specific transcription factors that 
positively or negatively regulate gene expression (bottom). The transcription factors PU.1 and Ikaros (transiently expressed) regulate 
the expression of the IL-7 receptor, required for the emergence of the Pro-B cell from the common lymphoid progenitor (CLP). PU.l, 
E2A, EBF and BSAPlPax-5 are the master regulators of the earliest stages ofB cell development and are joined at the Pre-B 1 stage by 
octamer factors (Oct-1I-2) and the co-activator Bob-l. Transient expression of IRF-4 during the Pre-B II stage is required for the 
rearrangement of the immunoglobulin light chains. The naïve mature B cell can be distinguished by the expression of a fully mature B 
cell receptor (BCR) - composed of an IgM or IgD molecule, Iga and Ig~ chains - and a constellation of surface markers (CDI9, CD21, 
etc.) as well as by the expression ofPU.I, E2A, EBF, BSAPlPax-5, Oct-l/2 and Bob-l transcription factors. 
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Ikaros transcription factors. During the pro-B cell stage, rearrangement of the 
immunoglobulin heavy chain takes place. Expression of genes essential to B cell 
development such as mb-l, À5, VpreB and Ragl/2 is driven by the transcription factors 
E2A and EBF. The presence of the pre-B cell receptor, composed of the newly 
rearranged heavy chain and the surrogate light chain A5 or VpreB, marks passage to the 
pre-B cell stage. The transcription factor Pax-5/BSAP controls the expression of CD19, 
Blnk and mb-l genes, which encode for essential components of the B cell receptor 
(BCR) and co-receptor complexes. At the pre-B cell stage, rearrangement of the 
immunoglobulin light chain takes place and successful rearrangement leads to the 
expression of a complete immunoglobulin molecule at the cell surface. This signaIs the 
end of the pre-B cell stage and passage to the immature B cell stage. Therefore, an 
immature B cell is characterized by surface expression of the mature BCR - composed 
of one IgM molecule, two Iga and two Igj3 chains -, the B cell co-receptor complex -
composed ofCD19, CD21 and CD81 -, and CD45, a tyrosine phosphatase that helps in 
the amplification of downstream signaling. At this point, self-reacting B lymphocytes 
are eliminated or inactivated by negative selection. B cells that successfully complete 
negative selection are termed mature B cells. The naïve mature B cells exit the bone 
marrow and circulate in the periphery, where pro-survival signaIs are further delivered to 
the pool of naïve B cells that successfully enter the lymphoid follicles. 
The circulating naive mature B lymphocyte can encounter antigens from invading 
pathogens. If the antigen encountered is specifically recognized by the BCR, the B 
lymphocyte can become activated. Antigens can be of two sorts: thymus-dependent 
(proteins) or thymus-independent (LPS, lipids). The first sort requires the interaction of 
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the B lymphocyte with a T helper cell to fully activate the antibody response whereas the 
latter type can activate the B lymphocyte without T cell help. In the thymus-dependent 
response, cross-linking of surface Ig molecules by specifie antigen triggers signaling by 
the Iga and Igj3 components of the BCR. This results in the entry to G 1 phase of the cell 
cycle and up-regulation of co-stimulatory molecules such as B7-1 and B7-2. 
Additionally, the B cell endocytoses and processes antigen to present it on its surface 
bound to MHC class II molecules. The activated B cell migrates to the lymph nodes 
where it can find its cognate antigen-primed T helper cell. Cognate T cell-B cell 
recognition involves 1) specifie recognition of MHC class II -bound antigen at the B cell 
surface by the T cell receptor, 2) expression of CD40 ligand by the T cell which binds to 
CD40 on the B lymphocyte and 3) secretion of IL-4, IL-6 and IL-5 by the helper T cell. 
Together CD40L and IL-4 stimulate clonaI expansion of the activated B cell. At this 
stage, the activated B cell also undergoes isotype switching. 
The activated B cell then migrates to the primary follicles where it forms a germinal 
center (FIGURE 7). The rapidly dividing B cells known as centroblasts form the dark 
zone of the germinal center. These cells are large, have an expanded cytoplasm that 
stains intensely for RNA and have diffuse chromatin in the nucleus. During this stage, 
the cells undergo somatic hypermutation of the Ig hypervariable region, so that the 
progeny cells, the small centrocytes express slightly different Ig molecules. Centrocytes 
are then selected for high affinity recognition of antigen displayed by CD4+ T 
lymphocytes (positive selection). B cells that fail to recognize antigen die by apoptosis, 
whereas B cells that successfully bind to their specifie epitope undergo a new round of 
clonaI expansion before differentiating into plasma or memory B cells. Thus, B 
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FIGURE 7. PEL cells are derived from B lymphocytes at a post-Ge stage of differentiation with a partial plasma cell 
phenotype. During the GC reaction, B lymphocytes can be differentiated based on the configuration of the hypervariable region of the 
Ig genes (top) and on expression of specific molecular markers (bottom). Previous to GC formation, the activated B cell has a 
hypervariable region in germline configuration, whereas centroblast that are actively undergoing somatic hypermutation will exhibit 
numerous unique sequences containing point mutations. Centrocytes and post-GC B cells represent a clonaI expansion of such mutated 
clones. During the GC reaction, B cells express Bcl-6 but only a few express IRF -4, whereas cells that successfully exit the GC lose 
Bcl-6 expression and upregulate IRF-4. B cells that undergo plasma cell differentiation also express the surface marker 
CD138/syndecan-1 and upregulate the transcription factor XBP-l. Both PEL and cHD share the expression of IRF-4 and CD-138 
whereas they lack Bcl-6 expression. FDC= follicular dendritic cell. Adapted from (Carbone et al., 2001 (34)). 
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lymphocytes in the germinal center can be distinguished based on the sequence of their 
BCR: pre-GC B cells have an identical germline sequence, centroblasts and early 
centrocytes have somatic hypermutations in the IgV region so that each cell has slightly 
different BCR sequences and late centrocytes and post-GC B cells present a clonaI 
expansion of a mutated BCR. In addition, transcription factor expression tightly 
regulates germinal center progression. Expression of the transcription factor Bcl-6, in 
particular, is a hallmark of GC B cells and it is expressed at high levels by centroblasts. 
Centrocytes downregulate Bcl-6 expression and activate the expression of Blimp-l and 
IRF-4. 
Cells that successfully exit the germinal center differentiate into long-lived plasma 
cells that reside in the bone marrow or into memory cells. Plasma cells express low 
levels of surface Ig and no MHC class II but are rather poised to produce and secrete 
large amounts of antibody. Plasma cells have abundant cytoplasm with multi-Iayered 
rough endoplasmic reticulum, prominent Golgi apparatus and a nucleus with peripheral 
chromatin condensation. Ten to 20% of an protein produced corresponds to 
immunoglobulin molecules. Alternatively, the B cell can become a memory B cell that 
can be rapidly reactivated upon subsequent antigen challenge. Plasma cens are 
characterized by the expression of Oct-2, Blimp-l, XBP-l and IRF -4 transcription 
factors, whereas Pax-5 and Bcl-6 - which can repress transcription ofXBP-l and Blimp-
1 respectively - are down-regulated in plasma cens (36, 293). 
2.2. The B cell transcriptional Program 
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2.2.1. PU.1 
The Ets-family transcription factor PU.1 plays an essential role in the development of 
both Iymphoid and myeloid lineages (185, 252). High expression of PU.1 favors the 
development of macrophages whereas Iow Ieveis of PU.1 induce B cell generation from 
hematopietic progenitors (57). PU.1 knockout mice die of severe septicemia 48 hours 
after birth and reveai a Iack of mature macrophages, neutrophils, B cells and T cells. The 
Iack of PU.1 was not essentiai for Iymphocytic and myeloid commitment, since the K. 
O. mice couid develop limited numbers of T cells and neutrophiis that couid be detected 
in antibiotic-treated animaIs, but generation of B cells and macrophages was compietely 
impaired (185). In humans, heterozygous mutations of the PU.1 gene are associated 
with acute myeloid Ieukemia (AML). AML blast cells are arrested at a very early stage 
ofmyeloid development, reminiscent ofmyeloid cells from the PU. 1-1- mouse (196). 
Low-ievei expression of Pu. 1 favors the expression of the IL-7 receptor (IL-7R) and 
the generation of common Iymphoid precursors (CLP) from hematopoietic stem cells 
(HSC) (56). During B cell development, Pu. 1 regulates the expression of the Ig fA- heavy 
chain (202), Ig light chain (À. and K) (68, 227), mb-l (Iga) (107), B29 (Ig~) (211), CD20 
(117), Btk (118), and Ig J chain (261), among other genes. Moreover, murine knockout 
studies have demonstrated that regulation of c-rel promoter activity by PU.1 and Spi-B 
is essentiai for mature B cell survival (122), possibly due to the anti-apoptotic properties 
of c-rel. PU.1 expression is aiso important during the GC reaction and high leveis can be 
detected in centroblasts, where it regulates the expression of Bcl-6 (287). 
PU.1 expression is regulated by a highly conserved region that surrounds the 
transcriptionai start site (47). The 0.5 kb mouse promoter is overall 88% identical to the 
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same region in the human PU.l promoter whereas the region between -70 bp to + 134 bp 
is even more highly conserved (95% similarity). Both murine and human promoters 
demonstrated specifie activity in myeloid and B cells. The region located between -61 
and +34 bp, contains single functional binding sites for PU.l, Octamer binding factors, 
GAT A and Sp-l (FIGURE 8B). In vivo studies in murine myeloid cens demonstrated 
that the PU.l binding site is occupied in these cells, leading to the establishment of an 
auto-regulatory loop, whereas the octamer and Sp-l sites appear vacant (47). In B cells, 
both the PU.1 and the octamer site are occupied, demonstrating that octamer binding 
(Oct) factors along with the B cell specifie co-activator Bob-1 regulate the expression of 
PU.l in B lymphocytes (48). 
PU.l prote in is 272 aa long and it is composed of an acidic domain, a glutamine-rich 
domain, a PEST (proline, glutamate, serine, threonine rich) domain and aC-terminal Ets 
domain that confers DNA binding specificity (FIGURE 8A). The PEST domain 
contains regulatory Ser 148 that is required for protein-protein interactions (228) whereas 
Ser41 in the N-terminal transactivation domain is phosphorylated in response to 
activation of the Ras-PB kinase-PKB pathway (236) leading to increased PU.l 
transcriptional activity. The protein kinase CK2 has been shown to specifically 
phosphorylate PU.l at serine residues 41, 45, 132, 133, and 148 (228). 
Interactions between PU.1 and Interferon regulatory factor-4 (IRF -4/Pip/I CSA T /NF-
EMS) to activate transcription were first described by Pongubala et al. (227, 228). This 
group identified a novel transcription factor, that they named NF-EMS, that co-
operatively bound with PU.1 to the immunoglobulin KE3' enhancer (FIGURE 8C). The 
composite Ets-IRF binding site had the sequence 5' -GAGGAANNGAAAAC-3' on the 
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FIGURE 8. Structure, regulation and function ofthe transcription factor PU.1. A) Schematic representation ofPU.l protein. The 
acidic domain and the glutamine (Q)-rich domain located at the N-terminus as weIl as the central proline- glutamate- serine- threonine-
rich (PEST) domain and the C-terminal ETS domain are indicated. Numbers indicate amino acid residues at domain boundaries. 
Domain functions are indicated in brackets. The regulatory serine S148 - required for PU.l/IRF-4 interactions - is indicated. ® 
denotes phosphorylation. B) Regulation of the PU.l promoter. In macrophages, PU.l expression is regulated mainly through an auto-
regulatory loop, leading to high levels ofprotein expression. In B lymphocytes, both the Octamer binding site (Oct) and the PU.l site 
are essential for PU.l transcription but only lead to low levels of protein expression. C) PU.l interacts with IRF-4 to activate 
transcription via cooperative binding to the Ets-IRF composite element (EICE). Binding oflRF-4 to PU.l leads to a conformational 
change in IRF-4 that unmasks the DNA-binding domain and allows interaction with the partial IRF site of the EICE element. 
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KE3' enhancer. Interaction with IRF-4 was mediated by the PEST domain ofPU.1 (227) 
and required phosphorylation of Ser148. Later, similar co-operation between PU.1 and 
IRF -4 was found to exist on the À.2-4 light chain enhancer (68) and on the CD20 
promoter (117). Binding to the composite ETS-IRF site by PU.1 and IRF-4 is co-
operative: IRF-4 requires the presence of PU.l to be able to bind DNA and activate 
transcription (68). Interaction between the PEST do main of PU.1 and the C-terminal 
domain of IRF-4 induces a conformational change in IRF-4 that exposes the DNA-
binding domain, allowing it to recognize its target sequence. Alternatively, in the 
composite Ets-IRF site found in the CD20 promoter, it is PU.1 that requires the presence 
of IRF-4 to form a stable protein-DNA complex (117). Co-operation between PU.1 and 
Interferon Regulatory Factor-8 (IRF-8/ICSBP) has been also characterized and it is 
established in much the same way as with IRF-4. PU.l and IRF-8 interactions are 
important for the expression of gp91 phox (69) and TLRA (234). More extensive co-
operation between PU.1 and IRFs has been identified in the IL-l~ gene, where PU.l 
interacts with IRF-4 to bind to a composite ETS-IRF site found in the IL-l~ enhancer 
(177). The PU.lIIRF-4 complex also interacts with IRF-l and IRF-2 to form an 
enhanceosome that allows maximal expression of IL-l ~ following LPS or cytokine 
stimulation. 
PU.l plays an essential role in B-Iymphocyte and macrophage development by 
regulating the expression of multiple genes essential for lineage differentiation. In B 
cells, pu.t positively regulates the expression of fundamental genes such as IL-7 and the 
immunoglobulin chains, constituting a pivotaI transcription factor in B lymphoid 
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development. As such, PU.l expression can be detected as early as the CLP and its 
expression is not extinguished until the plasma cell stage (reviewed in (267),(199)). 
2.2.2. IRF -4 and IRF-8 
Interferon Regulatory Factors (IRFs) constitute a family of transcription factors that 
regulate the transcription of IFN genes as weIl as other target genes in response to IFN-
a/j3 or IFNy stimulation. IRFs are characterized by a common amino-terminal DNA-
binding domain containing characteristic tryptophan repeats that allows them to interact 
with the Interferon Stimulated Response Element (lRSE, consensus: 5'- GAANT/C-3') 
or the Gamma-Activated Sequence (GAS, consensus: 5'- TTTNCNNNAA-3') found in 
the promoter of target genes. IRFs may also contain an IRF Association Domain (lAD) 
that allows protein-protein interactions. Extensive reviews on the IRF family have been 
published (119, 168) and the reader is directed to these for a more thorough overview on 
IRFs. 
IRF-4 and IRF-8 are the two members of the IRF family with the less homology to 
other IRF family members - within the DBD - but the highest homology (70%) to each 
other (reviewed in (168),(176)). IRF-4 and IRF-8 also share a restricted pattern of 
expression: IRF -4 is expressed in T and B lymphocytes, where its expression is 
inducible by PMA treatment, CD3 or Ig crosslinking. IRF -4 can also be expressed in 
macrophages, although the stimuli leading to its upregulation is unknown. IRF-8 
expression is largely restricted to the myeloid and lymphoid compartment. IRF-8 
expression can be rapidly induced in macrophages following IFNy stimulation. IRF-4 
and IRF-8 can bind alone to ISRE sequences and act as transcriptional repressors of 
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IFN-inducible genes such as MHC-I and 2'-5'-01igo-adenylate synthetase. However, it 
appears that the main function of IRF -4 and IRF -8 in lymphocytes and myeloid cells is 
to act as transcriptional activators in partnership with the Ets proteins PU.l and Spi-B 
(176). In this fashion, IRF-4 and IRF-8 regulate many genes essential for lymphoid and 
myeloid development. We take a closer look at each of the se IRFs in the sections below. 
IRF-4. IRF-4 was first described as a transcriptional activator that acted in partnership 
with PU.l to increase transcription ofthe Ig light chain genes (67, 68, 227) but can also 
act as a repressor when it binds to ISRE sequences (24). Thus, IRF-4 may favor 
lymphocyte activation while inhibiting the anti-proliferative effects of IFNa/p. IRF-4 
knockout mi ce are unable to form germinal centers (GCs), lack plasma cells and show 
reduced circulating Ig levels (190). They are also unable to generate T cell-dependent 
cytotoxic or anti-tumor responses (190). Thus IRF -4 is essential for the function of 
mature Band T cells. 
Structurally, IRF-4 is a 450 aa-long protein that contains the N-terminal DBD 
characteristic to all IRFs, followed by a proline-rich domain, an activation-masking 
domain, a glutamine-rich region, and a DBD-inhibitory domain (FIGURE 9). In resting 
cells, IRF-4 is present in a closed conformation, with the N-terminal DBD masked by 
the C-terminal inhibitory domain. Upon stimulation, DNA-bound, phosphorylated PU.l 
recruits IRF-4 by interacting with the a-helical inhibitory domain (aa 399-413) (25). 
This induces a conformational change in IRF-4 that unveils the DBD and allows IRF-4 
to bind with higher affinity to its target sequence. Phosphory lation of PU.l at serine 148 
is essential for interactions with IRF-4. In turn, IRF-4 transcriptional activity is 
modulated by the immunophilin FKBP52, which induces a cis-trans propyl 
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FIGURE 9. Schematic representation of IRF -4 and IRF -8. The DNA-binding domain (DBD) containing the characteristic 
tryptophan repeats is located at the N-terminus whereas the IRF-association homology domain (lAD) is located at the C-terminus. IRF-
4 (top) also contains a proline-rich domain (Pro) followed by the lAD and the DBD-inhibitory region (DBD-I) at the C-terminus. 
Numbers indicate amino acid residues at domain boundaries. The lAD of IRF -4 contains an activation masking domain, an alpha-
helical region (a) and a glutamine-rich (Q) domain. The activation-masking domain and the C-terminal DBD-I fold over the DBD to 
prevent interactions with DNA. The inhibition is relieved by binding to pu.! as weIl as by the action of the immunophilin FKBP52. 
The a-helix is required for interaction with pu.! whereas FKBP52 induces proline isomerization in the Pro-rich region. IRF-8 
(bottom) is 78% homologous to IRF-4 in the DBD. Phosphorylation has been described for IRF-8 within the DBD. 
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isomerization in the proline-rich domain, resulting in the inhibition of IRF -4 interactions 
with PU.1 and transcriptional activity (171). 
In B lymphocytes, IRF -4 expression can be strongly upregulated by stimuli that 
induce B cell activation such as LPS or IgM crosslinking. In addition, co-stimulation 
with CD40 and IL-4 induces a strong expression ofIRF -4 (105), linking IRF -4 to the IL-
4 signaling pathway. Indeed, inducible expression of CD23 - a target of IL-4 and CD40 
signaling - was shown to depend on IRF -4 interactions with ST A T6 at a GAS element 
present in the CD23 promoter. Constitutive expression of IRF -4 in B cells depends on a 
GC-rich element found on the -51 to -28 bp promoter region which is bound by a novel 
60 kDa prote in (205), whereas inducible expression in lymphocytes is regulated by cRel 
(101). 
Expression ofIRF-4 in B cells is bi-phasic: immature B cells express IRF-4, then IRF-
4 expression is lost when B cells enter the GC and recovered at the end of the GC 
reaction to finally be expressed at a high level by plasma cells (77). 
Immunohistochemical analysis of healthy lymphoid tissue thus shows that GC B cells 
are mostly negative for IRF-4, but 3-10% expresses high levels of IRF-4. The IRF-4+ 
cells locate in the light zone of the GC and have varied morphology: sorne have irregular 
nuclei whereas others show immunoblast-like or plasmablast-like characteristics. Thus, 
the beginning IRF -4 expression correlates with the centrocyte state of B cell 
differentiation and it is sustained during the maturation as a plasma cell (88). Klein et al. 
generated a conditional IRF-4 knockout mouse in which IRF-4 is deleted in GC B cells 
(148). The conditional knockout demonstrated that IRF-4 expression is required for 
class-switch recombination and plasma cell development, although not for memory cell 
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development. IRF -4 is required during class-switch recombination to upregulate the 
expression of activation-induced cytidine deaminase (AID). During plasma cell 
development, IRF -4 and Blimp-1 were found to act non-redundantly upstream of XBP-
1. Indeed, expression of XBP-1 in LPS-stimulated mature IRF-4-/- B cells was not 
sufficient for the generation of plasma cells in spite of the presence of normal levels of 
Blimp-1. 
Because IRF-4 expression correlates with B cell exit from the GC reaction and it is 
associated with loss of expression of B-cell Lymphoma 6 prote in (Bcl-6) - a marker of 
Ge B cells -, the expression ofIRF-4, Bcl-6 and the surface marker CD138 (Syndecan-
1) can be used as histogenetic markers ofB cell development (88). Activated B cells that 
have just entered the lymph nodes are IRF-4- Bcl-6- CD138- and they lack somatic 
hypermutations in their Ig genes; during the GC reaction, B cells are Bcl-6+ IRF-4-
CD138- and they have multiple IgV region sequences - denoting active somatic 
hypermutation. Cells that are exiting the GC gain expression of IRF-4 and CD138 and 
lose expression of Bcl-6. Sequencing of the IgV region sequences of post-GC B reveals 
the clonaI expansion of mutant sequences, corresponding to positively selected cells. 
Lymphomas can be classified in much the same manner, as the cancer cells retain most 
histogenetic markers from their normal cellular counterpart. Based on molecular marker 
analysis, PEL cells have been classified as being of late-GC or post-GC origin since 
most PEL cells are IRF-4+ Bcl-6- CD138+. However, as stated above, immunoglobulin 
hypervariable regions mutational analysis has led to somewhat discrepant results (179). 
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fRF-8. IRF-8, also known as Interferon Consensus Sequence Binding Prote in 
(lCSBP), is a ~50 kDa prote in first described as binding to IFN Response Sequences in 
the major histocompatibility complex class 1 (MHC 1) genes (64). IRF-8 is a 424 aa long 
prote in that has the conserved N-terminal DNA binding domain and the C-terminal IRF-
interaction do main (lAD) common to IRF family members (FIGURE 9) (reviewed in 
(281». IRF-8 is expressed in B lymphocytes, activated T cells and 
monocytes/macrophages, where expression ofIRF-8 can be strongly induced by IFN-y 
and to a lesser extent by LPS. IRF-8 is constitutively phosphorylated on tyrosine 
residues in vivo, leading to a downregulation of its DNA binding activity and an 
increased association with IRF-ll2. Thus, phosphorylated IRF-8 can only bind DNA 
through interaction with IRF-1/2 (256). 
The IRF -8 knockout mouse is susceptible to infection with pathogens that depend on 
IFN-y for clearance. These include bacteria such as Listeria monocytogenes and Yersinia 
enterocolitica and parasites such as Leishmania major and Toxoplasma gondii. 
However, the IRF-8-1- mouse survives infection with Vesicular Stomatitis Virus (VSV) 
or influenza A, controlled primarily through the IFN-a/~ response (120). Mounting of a 
Th1-mediated response is greatly impaired in the IRF-8 K.O. mouse. This defect was 
ascribed primarily to the inability ofIRF-8-1- macrophages/dendritic cells to pro duce IL-
12 - more specifically, the IL-12p40 subunit - whose expression is directly controlled by 
IRF-8 (281). Lack ofIL-12 leads to impaired production ofIFN-y in natural killer (NK) 
and CD4+ T eeUs, resulting in an inhibition of the expression of co-stimulatory 
molecules necessary for proper Th1 response. Further study of the knockout mouse 
revealed additional defects in dendritic cell (DC) generation and maturation. IRF -8-1-
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mice were unable to sustain plasmacytoid DC (pDCs) generation or DC maturation in 
response to Toll-like receptor (TLR) stimulation (292). Ectopic expression of IRF-8 in 
pDCs restored their ability to produce IFN-a, suggesting a role for IRF-8 in type 1 IFN 
production in pDCs (291). 
In contrast to the rapidly expanding knowledge of the role of IRF-8 in myeloid 
development, very little is known about its role in lymphocyte development. IRF -8-/-
mice have increased numbers of splenic and lymph node B ce Ils and IRF-8/IRF-4 double 
knockout have a block in the pre-B to B cell transition, owing to impaired 
downregulation of surrogate light chain expression and a profound block in 
rearrangement and upregulation ofIg light chain expression (166). Thus, IRF-4 and IRF-
8 play additional roles in B cell development besides enhancement of light chain 
expression in combination with PU. 1. A recent study by Lee et al. (157) demonstrated 
that IRF -8 expression is modulated during the human GC reaction. IRF -8 is expressed 
by aIl B cells in the GC, but expression is highest during the dark-zone centroblast 
stages and lowest in the Ig-secreting population of plasma cells. IRF-8 expression co-
localized with Bcl-6 nuclear staining, in sharp contrast with IRF-4 expression (see 
above). IRF-8 positively regulates the expression of Bcl-6 and activation-induced 
cytidine deaminase (AID), two proteins essential to the GC reaction. It is not entirely 
clear how IRF-8 and IRF-4 can play such contrasting roles during the GC reaction, given 
that up to now they have been shown to be practically interchangeable in their 
transactivation capacity of target genes. It is possible that stage-specific expression of 
transcription partners might help explain this astonishing observation. 
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2.2.3. Octamer Binding Factors 
The octamer motif (5'-TNATTTGCAT-3') is found in the promoter of numerous 
genes essential for B cell function such as Ig, CD20, CD21 and CD36 as well as in other 
ubiquitously expressed genes such as small nuclear RNAs (snRNA) and histone H2B 
(reviewed in (182)). The octamer motif is recognized by octamer binding proteins (Oct) 
that belong to the POU protein family. POU proteins contain a 150-160 bipartite DNA-
binding domain consisting of a conserved N-terminal POU-specific do main and a C-
terminal POU homeodomain. Two Oct transcription factors interact with the octamer 
motif in B lymphocytes: Oct-1 and Oct-2 (FIGURE 10). Oct-1 is a ubiquitously 
expressed 90-100 kDa prote in whereas Oct-2 (60-75 kDa) is expressed exclusively in 
the lymphoid compartment - predominantly in B cells - and central nervous system. An 
auxiliary factor termed B-cell Oct-binding protein-1 (Bob-l, also known as OBF -1 and 
OCA-B) expressed exclusively in lymphocytes binds to Oct-1I-2 via DNA and POU 
domain interactions and acts as a transcriptional co-activator (102). Bob-1 is largely 
responsible for the specific activity of octamer sites in B lymphocytes and its expression 
is required at multiple stages ofB cell development (115), particularly for GC formation 
(248). 
The generation of Oct-TI- and Bob-rl- mice has identified important roles played by 
these two factors in B cell function. The Oct-2 knockout mouse dies at birth of unknown 
causes (53). B cell lymphopoiesis is normal up to the Ig~ stage, thus Oct-2 is 
dispensable during early B cell development. However, there is a maturation defect in 
Oct-2-1- B cells because they fail to form GCs and secrete immunoglobulin when 
challenged in vitro with LPS (248). Furthermore, when Oct-2 deficient fetal liver cells 
36 
FIGURE 10. Schematic representation of the octamer binding factors Oct-l and Oct-2. Oct-l and Oct-2 belong to the POU-
domain family of transcription factors, which contain a bi-partite DNA-binding domain composed of a POU-specifie domain and a 
homeo-domain separated by a linker. Interactions with the co-activator Bob-l are mediated by the POU domain. Both Oct-l and Oct-2 
contain Glutamine (Q)-rich domains at the N-terminus but Oct-2 also contains a leucine zipper (Zip) domain at the C-terminus. 
Numbers indicate amino acid residues at domain boundaries. 
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were transferred into irradiated recipients, the peripheral B cell pool was decreased, the 
spleen showed predominantly B cells of an immature phenotype and peritoneal BI cells 
were absent. Mice lacking Bob-l are viable and show normal early B cell development 
although they have reduced B cell numbers in the spleen and reduced IgG serum levels 
(146). The humoral immune response in the Bob-l-I- mouse is dramatically impaired and 
germinal eenters do not form. In the Oet-2/Bob-l double knockout, B cells develop 
normally but the mature peripheral B cell pool is strongly reduced. lmmunoglobulin 
gene transcription appears normal yet serum IgG levels are dramatically reduced (248). 
The double knockout animaIs failed to develop GCs in response to antigen challenge. 
Thus, Oct-2 and Bob-l regulate essential aspects of B cell maturation that are 
independent of immunoglobulin gene transcription. 
Although earlier studies had suggested that Oet-l and Oct-2 bound to the oetamer 
sequence interchangeably and that specificity was conferred by the presence or absence 
of the co-aetivator Bob-l, the knockout mouse suggested a distinct role for Oct-2. CD36 
was identified by subtractive cDNA cloning as the first gene dependent on Oct-2 
transcriptional activity (151), although the function of CD36 remains unknown. Analysis 
of the CD36 promoter revealed the presence of the oetamer sequence 5'-ATGCTAAT-
3', which required the expression of Oct-2 to activate transcription in B cells but did not 
support reeruitment of Bob-l (263). Thus, Oct-2 can regulate transcription in B cells 
both dependently and independently of Bob-l. The differential transcriptional activity of 
Oet-2 compared to Oct-l has been mapped to the C-terminus of Oct-2 (282), which is 
also a site for protein phosphorylation, although the relationship between 
phosphorylation and transcriptional activity remains to be elucidated. Further 
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confirmation of the essential role played by Oct-2 in the expression of the late-stage B 
cell transcriptional pro gram came from studies of myeloma cell hybrids (137, 231). 
When the Ig-producing myeloma cellline MPC II is fused to a T cell, expression of B 
cell-specific gene products (Ig, J chain, etc.) ceases, and this correlates with a lack of 
expression of Oct-2. The same phenomenon is observed when fusing an Ig-producing B 
cell to a fibroblast (136). In this last study, Junken et al. observed a rapid depletion in 
nuclear transcription factor expression - including Oct-2 and PU.1 - that preceded Ig 
gene silencing. Constitutive expression of Oct-2 in the B/non-B cell hybrids is enough to 
alleviate gene silencing (136, 137, 231). Thus, expression of Oct-2 is essential to 
maintain the B cell transcriptional program during the late stages of B cell development. 
2.2.4. Nuclear FactorKB (NF-KB) 
The family of NF -KB transcription factors is involved in such diverse cellular 
functions as apoptosis, inflammation and cell differentiation. It is a common target in 
various cancer types and its constitutive activation generally results in an inhibition of 
apoptosis and expression of pro-inflammatory cytokines which results in a chronic 
inflammatory state favorable to cancer development (for reviews refer to (98, 141)). The 
NF-KB transcription factor family consists ofp50 (NF-KBI), p52 (NF-KB2), Rel (cRel), 
p65 (Rel-A), and Rel-B. Each family member contains a Rel-homology domain (RHD), 
which includes a DNA-binding motif, a dimerization motif and a nuclear localization 
sequence (NLS). Rel, p65 and Rel-B also contain aC-terminal transactivation domain. 
AlI members of the NF-KB family associate to form homo- and hetero-dimers able to 
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modulate transcription. NF-KB dimers are kept inactive in the cytoplasm by binding to 
the Inhibitors ofNF-KB (IKB), ofwhich the prototypical member is IKB-a (89). 
The classical pathway of NF -KB activation is triggered foUowing stimulation with a 
myriad of compounds such as TNF-a, IL-6 or CD40L that funnel into the IKB Kinase 
(IKK) complex (138, 220). The IKK complex is composed of two catalytic subunits, 
IKKa and IKK~, and one regulatory subunit calIed NF-KB Essential Modulator 
(NEMOIIKKy). As part of the activated IKK complex, IKK~ phosphorylates IKBa at 
two serine residues (Ser34/36), targeting it for proteasomal-mediated degradation. The 
p65/p50 NF-KB dimer, now free of the inhibitor, translocates into the nucleus and 
activates transcription of target genes. In the non-canonical pathway, the NF -KB 
Inducing Kinase (NIK) activates IKKa, which phosphorylates pl00 triggering its 
cleavage into p52. Target genes for NF-KB include genes that promote celI growth, 
prevent celI death and regulate the immune response. In B lymphocytes, B celI receptor 
(BCR) stimulation and CD40 signaling both lead to NF -KB activation, promoting ceU 
survival and proliferation (191, 192, 298). 
In PEL, constitutive NF-KB activation, specifically ofp65/p50 heterodimers, has been 
observed, resulting in the inhibition of apoptotic pathways and expression of pro-
inflammatory cytokines such as IL-6 (present work and (144». PEL is not associated 
with chromosomal translocations that constitutively activate NF-KB, as it has been 
demonstrated with other cancer types and in particular in Hodgkin's lymphoma (18, 
302). Rather, NF-KB activation seems to be mediated by the action of HHV-8 viral 
genes. Activation ofNF-KB during latent HHV-8 infection is mediated by vFLIP, which 
directly interacts with NEMO/IKKy to activate the IKK complex (103). During the lytic 
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cycle, NF-KB can be further activated by vGPCR and mediate IL-6 expression (251). 
NF -KB activation during the lytic cycle is essential to establish a productive infectious 
cycle (255). Inhibition ofNF-KB with pharmacological inhibitors in PEL cells results in 
apoptosis, highlighting the importance of NF-KB activation in driving survival of the 
malignant cells. It is noteworthy that PEL cells do not exhibit activation of the NF -KB 
subunits cRel or RelB, which are predominantly associated with lymphocyte 
development and function but rather of p65/p50 heterodimers, which regulate genes 
involved in cell survival and proliferation. 
2.2.5 Activator Protein-l (AP-l) 
AP-l is a transcriptional activator composed ofmembers of the Fos (cFos, FosB, Fra-
I, and Fra2), Jun (cJun, JunB, JunD), Maf (cMaf, MatB, MafA, MafG/F/K, Nrl) and 
ATF (ATF2, LRFI/ATF3, B-ATF, JDPI, JDP2) protein families (reviewed in (259)). 
The transforming potential of AP-l is demonstrated by the fact that transforming viruses 
such as the osteogenic sarcoma viruses FBJ and FBR and avian sarcoma virus encode 
for viral homologues of Fos (v-jos) and Jun (v-jun) (187, 204). These viral oncogenes 
are essential for transformation of target cells by sarcoma viruses. Jun and Fos proteins 
associate via their leucine zipper domain to form a variety of homo- and heterodimers 
and bind to their target sequence (5'-TGACTCA-3'), the l2-0-tetradecanoylphorbol-13-
acetate (TPA) response element (TRE) (81). AP-l activity can be induced following a 
variety of stimuli, including growth factors, cytokines, Band T cell receptor cross-
linking and UV irradiation. Stimulation of AP-l activity can be achieved at three levels: 
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1) transcriptional upregulation of AP-l components, 2) stabilization of AP-l proteins 
and 3) stimulation of AP-l activity by post-translational modification. The mitogen-
activated prote in kinase (MAPK) pathway is the classical and best-studied activator of 
AP-l transcription factors (reviewed in (42, 140,259)). 
Activation of the extracellular regulating kinases (ERK-l and ERK-2) leads to 
increased transcription of cFos, which can bind to cJun protein present in the nucleus to 
form AP-l dimers. In contrast, cJun is expressed constitutively in most cell types but its 
expression can be further induced through the cjun TRE, which is activated by cJun-
ATF2 heterodimers. Activation of cJun occurs via phosphorylation of key serine 
residues located in the transactivation domain by the Jun kinases (JNKs). JNKs are 
activated primarily in response to inflammatory stimuli such as TNF -n. They can also be 
activated in response to UV irradiation, cytokines, growth factor deprivation, DNA 
damaging agents, etc. 
Activation of lymphocytes requires two signaling events: signal 1 is delivered by 
cross-linking of the BCR or TCR whereas signal 2 is delivered by co-stimulatory 
molecules such as CD28 (T cells) or CD40 (B cells) (reviewed in (81)). Cross-linking of 
the T and B cell receptors signaIs through prote in tyrosine kinases and activates PKC, 
p21 Ras and PLC-y. Ras activation leads to activation of ERK kinases, phosphory lation of 
Elk -1 and induction of c-fos expression. The p21 Ras pathway can also activate JNK 
kinase via MEKK-l. PKC directly activates the MAPK Fos kinase, whereas it activates 
Erk, p38 and JNK by signaling through the p21 Ras pathway. Finally, PLC-y, through 
production of diacyl-glycerol (DAG) can signal through PKC and activate the MAPK 
pathway. Binding of the T cell co-receptor CD28 leads to the activation of JNK through 
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the guanine-nucleotide exchange factor (GEF) prote in Vay pathway, which activates 
MEKK-l and leads to JNK activation. In B lymphocytes, co-stimulation via CD40-
CD40L interactions also leads to AP-l activation, both by PKC-dependent and PKC-
independent pathways. Activation of transcription mediated by c-fos/c-jun heterodimers, 
in combination with NFAT and NF-KB transcription factors, leads to the upregulation of 
target genes important for lymphocyte survival, differentiation and function such as IL-
2, IL-3, IL-4, IL-5, IL-6 and GM-CSF. In B lymphocytes, AP-l activity - and 
particularly of c-fos/c-jun heterodimers - is required for Blimp-l expression and 
terminal differentiation into plasma cells (209). 
PEL cells harbor constitutive activation of AP-l transcription factors, as demonstrated 
by an increase in DNA binding of c-fos/c-jun heterodimers and increased transactivation 
of target sequences. The activation of AP-l is mediated by two HHV -8 latent gene 
products: LANA-l and vFLIP. LANA-l physically interacts with and activates cJun (7). 
In addition, LANA-l induces DNA binding of c-fos/c-jun heterodimers, although it is 
not itself part of the DNA-binding complex. Viral FLIP activates JNK via association 
with Tumor Necrosis Factor Receptor-Associated Factors (TRAFs), possibly TRAF2, 
leading to increased transactivation of TRE-regulated promoters. Expression of vFLIP 
leads to increased JNK phosphorylation and increased DNA binding of c-fos/c-jun 
heterodimers (8). Activation of AP-I by LANA-I and vFLIP - which also activates NF-
KB - leads to upregulation of cellular IL-6 expression in PEL cells (7, 8). Thus, AP-l 
activation contributes to the survival and proliferation of PEL cells. 
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3. Leukotriene B4 and cancer 
3.1. Inflammation and Cancer 
The link between inflammation and cancer development has long been suspected. 
AIready in the 19th century, Virchow had suggested that tumors might arise from areas 
of chronic inflammation. Recently, compelling scientific evidence linking the 
establishment of a chronic inflammatory state and cancer development has been put 
forth by several groups (14, 15, 97, 139, 269). The inflammatory process involves the 
complex interplay of different cell types that express biological pro-inflammatory agents 
such as cytokines, chemokines, and lipid mediators. The production of these agents in 
the tumor microenvironment can potentiate transformation and drive proliferation and 
survival of cancerous cells (269). Reciprocally, activation of oncogenes in cancer cells 
leads to the production of signaling molecules that recruit inflammatory cells and 
modulate their activity to drive cancer growth (reviewed in (98, 153)). 
Further evidence for the involvement of chronic inflammation and cancer 
development came from clinical evidence that indicated that prolonged use of non-
steroidal anti-infammatory drugs (NSAIDs) such as aspirin lead to a 40-50% reduction 
in the incidence of colon cancer (reviewed in (104)). NSAIDs are inhibitors of the 
cyclooxygenase enzymes COX-l and COX-2, implicated in the synthesis of 
prostaglandins (POs) from arachidonic acid. POs mediate pain and inflammation -
among other physiological functions - and are synthesized in a broad range of tissue 
types. Studies of familial adenomatous polyposis (F AP) in which patients were treated 
with NSAIDs - either non-specific or COX-2 specific - lead to a reduction of size and 
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number of polyps. In the APCâ716 mouse model of FAP, treatment with the COX-2 
specific inhibitor Rofecoxib or with the non-specific inhibitor Sulindac lead to a 
decrease in polyp number and size correlating with a decrease in membrane-bound 
VEGF (215). Elevated levels of COX-2 have been detected in esophageal, head and 
neck, breast, lung, prostate and other cancers, suggesting that the use of NSAIDs may 
have benefits in other malignancies besides colon cancer. 
3.2. Leukotrienes 
Leukotrienes (L T) are a family of lipid mediators involved in inflammation and 
allergy (reviewed in (245)). Leukotrienes are part of the eicosainoids class of paracrine 
hormones, which derive from the oxidative metabolism of arachidonic acid (AA) and 
include prostaglandins, leukotrienes and lipoxins. Leukotrienes can be found at high 
levels in most inflammatory lesions and contribute to the physiological changes 
observed during inflammation. L TB4 is the classic chemoattractant of neutrophils and 
thus regulates PMNL infiltration to the inflammation site whereas cysteinylleukotrienes 
are involved in vascular permeability and smooth muscle tone. 
3.3. Leukotriene Synthesis 
Leukotriene synthesis is initiated by the release of arachidonic acid (AA) from the cell 
membrane by cytosolic phospholipase A2 (cPLA2), making this substrate available to 5-
lipoxygenase (5-Lü). In resting leukocytes, 5-LO is a soluble enzyme, but elevated 
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intracellular calcium levels (26, 225) or phosphorylation by MAPK-activated protein 
(MAPKAP) on Ser-271 (299-301) lead to its translocation to nuclear and perinuclear 
membranes where 5-LO is in close proximity to its substrate AA and to the 5-
lipoxigenase-activating protein (FLAP) (59, 189). 5-LO catalyzes the conversion of AA 
into L T ~ in a two-step enzymatic process: 1) conversion of AA into 5-
hydroperoxyeicosatetraenoic acid, which can be degraded to 5-hydroxyeicosatetraenoic 
acid (5-HETE), and II) subsequent formation of L TA4 (239). L TA4 can then me et two 
fates: it can be conjugated with glutathione by L TC4 synthase to yield L TC4, the parent 
compound of cysteinyl-containing L Ts (LTC4, L TD4, L TE4), or it can be hydrolyzed by 
L T ~H to yield L TB4 (FIGURE HA). 
3.4. Transcellular Biosynthesis 
Enzymatic cooperation between different cell types in the synthesis of certain 
prostaglandins and leukotrienes is a concept that originated from the observation that 
endothelial cells could pro duce prostaglandin h (POh) from platelet-derived 
prostaglandin endoperoxide H2 (175). This process was termed transcellular biosynthesis 
and it involves the concerted action of an "acceptor" cell, with a constitutive enzymatic 
activity for the formation of a biologically active LT/PO but a deficient capacity for 
substrate generation, and a "donor" cell that can provide such substrate. 
The generation of leukotrienes by transcellular biosynthesis has been observed in a 
variety of settings. It involves the participation of myeloid cells - in particular 
neutrophils - as "donors", since these cells possess 5-LO activity, and a variety of other 
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FIGURE 11. Schematic representation ofleukotriene B4 synthesis. A) Synthesis ofleukotrienes is induced by elevated intracellular 
calcium levels, which stimulate phospholipase A2 (PLA2) to cleave arachidonic acid (AA) from the cell membranes (cytoplasmic or 
nucleic membranes), making this substrate available for 5-lipoxigenase (5-Lü). lntracellular calcium also stimulates 5-LO enzymatic 
activity to transform AA into the unstable epoxide leukotriene A4 (LTAt). This process requires the presence of the co-factor molecule 
5-LO activating protein (FLAP). Two fates can occur to LTAt: conversion to LTB4 by LTAt hydrolase (LTAtH) or conversion to 
LTC4 and derived cysteinyl-Ieukotrienes by LTC4 synthase. LTB4 and LTC4 are then released into the extracellular space, where they 
bind their cognate receptors found mainly in granulocytes and smooth muscle cells, respectively. B) Trancellular biosynthesis of 
leukotrienes involves the concerted action oftwo cells: the "donor" ceIl, which possesses 5-LO activity, and the "acceptor" ceIl, which 
has L TA4H activity. Transcellular biosynthesis allows the magnification of leukotriene production, mainly in the case of L TB4 as 
L T AtH undergoes suicide inactivation. 
A 
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cell types with LT~H or LTC4 synthase activity as "acceptors" (FIGURE 11B). 
Examples of acceptors cells inc1ude erythrocytes (80, 184), keratinocytes (128), alveolar 
macrophages (99), platelets (167), endothelial cells (78), and Band T cells (129, 130). 
The use of LTA4H-1- and 5-LO-1- mice in transcellular biosynthesis experiments have 
demonstrated that this process can occur in vivo and that the L Ts produced can 
contribute to the inflammatory response (75). 
3.5. Leukotriene B4 
Leukotriene B4 was initially discovered by Borgeat and Samuelsson (22) and it was 
soon identified as a potent chemoattractant of neutrophils, with activity detectable at 
subnanomolar concentrations (80, (93, 159) (FIGURE 12). L TB4 contributes to the 
inflammatory response primarily by recruiting leukocytes to the injury site and 
augmenting vascular permeability (21) L TB4 is synthesized by myeloid-derived cells 
such as PMNL (in particular neutrophils), dendritic cells, monocytes and macrophages 
and plasma levels of this leukotriene increase from less than 100 pg/ml to over 100 
ng/ml following leukocyte stimulation (262, 275). In the airway passages, bronchial 
epithelial cells are a source of L TB4 (9) as are keratinocytes in the epidermis (131, 238). 
It is now c1ear that L TB4 is a potent mediator of inflammation that affects a larger 
spectrum of cell types including monocytes, T and B cells, with diverse biological 
outcomes. 
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3.6. Leukotriene B4 Receptors 
The activity of L TB4 is mediated by two G protein-coupled seven transmembrane 
domain receptors (GPCR): BLTI and BL T -2 (reviewed in (280)). BL Tl is a high 
affinity receptor initially discovered in 1997 by Yokomizo et al. (305). BL Tl had been 
previously identified as an orphan member of the GPCR superfamily (232) and 
chemoattractant receptor-like 1 (CMKRLl) (217) before further experiments confirmed 
its identity as a receptor for L TB4 (218). Expression of BL Tl is highest in peripheral 
blood leukocytes but it is also detectable in the spleen, thymus, bone marrow, lymph 
nodes, he art, skeletal muscle, brain and liver (216). BL Tl expression is largely restricted 
to the Ieukocyte compartment, with high expression in granulocytes (neutrophils and 
eosinophils) and monocytes (226), low expression in B lymphocytes, and inducible 
expression in macrophages (124), activated T cells (95, 278) and vascular smooth 
muscle cells (12). 
BL T2 is a low affinity receptor (307) with more ubiquitous expression. High BL T2 
levels are detected in human spleen, liver, ovary and peripheral blood leukocytes (307); 
murine BLT2 is highly expressed in small intestine and skin (127). BLT2 binds LTB4 
with less specificity than BL Tl and several other eicosainoids - including 12(S)-HETE, 
12(S)-HPETE and 15(S)-HETE - can bind to BLT2 and trigger calcium mobilization 
(306). 
Both BL Tl and BL T2 are G protein-coupled receptors, but the identity of the G-
protein that transduces intracellular signaIs following L TB4 stimulation remains 
unknown. In fact, different cellular events may require different G proteins as 
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demonstrated by Bordella pertussis toxin treatment of BL T1- and BL T2-transfected 
CHO cells, which completely aboli shed chemotaxis but only partially diminished 
calcium mobilization (305, 307). Thus chemotaxis is mediated exclusively through GUito 
subunit signaling but calcium responses involve additional G proteins. L TB4 signaling 
through BLT1 leads to the activation of the NF-KB pathway(12, 123,183). In human 
monocytes, BLT1 signalling activates ERK1/2 and JNK MAP kinases (MAPK), but not 
p38 MAPK, inducing overexpression of monocyte chemoattractant protein-1 (MCP-
1)(123). Information on BLT2 signaling is limited. Stimulation of mBLT2 with LTB4 
lead to calcium mobilization, phosphorylation of ERK1/2 and inhibition of adenylyl 
cyclase (127). 
3.7. Biological Effects ofLTB4 
As part of the host' s immune response, L TB4 stimulation triggers leukocyte 
chemotaxis, adhesion and activation, contributing to the recruitment of effector 
leukocytes at the sites of pathogen invasion. At subnanomolar concentrations, L TB4 
causes neutrophil chemotaxis and chemokinesis (222). At higher concentrations, (100 
nM), L TB4 stimulation leads to neutrophil aggregation and degranulation(82) as well as 
superoxide anion production. L TB4 also mediates monocyte, macrophage and eosinophil 
chemotaxis and adhesion (268, 279). Additional biological functions of L TB4 in other 
cell types continue to emerge and it is now clear that it mediates a plethora of effects in 
both health and disease. 
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LTB4 participates in immune modulation by activating B cells, T cells and NK-cells 
(reviewed in (51)). LTB4 mediates T cell recruitment to inflammatory sites (278). CD4+ 
T helper (TH) cells upregulate BLTI upon activation and LTB4 stimulation ofboth THl-
and T H2-polarized cells induces chemotaxis and firm arrest of these cells. Two murine 
models of asthma - an inflammatory disease of the lung - demonstrated the importance 
of L TB4 stimulation in early TH cell recruitment (278). CD8+ Cytotoxic T cells also 
upregulate BL Tl upon activation and L TB4 induces chemotaxis and adherence of these 
cells, mediating recruitment of cytotoxic T cells to inflammation sites at both early and 
late time points (95). Thus, L TB4 possibly elicits a rapid activation of integrins at the T 
cell surface that allows for efficient rolling and diapedesis. 
In B lymphocytes, LTB4 induces proliferation, activation (130) and differentiation (65, 
303). LTB4 induces expression of the activation marker CD23 in high-density, resting B 
lymphocytes when used in combination with sub-optimal concentrations ofIL-2 or IL-4 
(65, 130, 303). Concurrently, L TB4 induces DNA synthesis and enhances the production 
ofIgG and IgM (65,303). 
In monocytes, L TB4 can trigger adhesion to the vascular endothelium via rapid 
changes in integrin affinity and/or avidity for its receptor (86). L TB4 stimulation of 
monocytes also increases the production of monocyte chemoattractant protein-1 (MCP-
1) via activation ofERK1I2 or JNK and activation of the NF-KB pathway (123). 
LTB4 can block apoptosis ofneutrophils (112, 271), increasing cell survival. Indeed, 
glucocorticoids such as dexamethasone promote neutrophil survival via upregulation of 
BLTI (271). L TB4 also inhibited apoptosis of carcinoma cells both in-vitro and in-vivo 
(286). 
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L TB4 activates endotheliai cells, vascular smooth muscle cells, keratinocytes and 
osteoclasts (12, 127). LTB4 acts on endothelial cells to increase their adhesiveness - to 
promo te neutrophil binding and endotheliai transmigration - by a yet undetermined 
mechanism independent of PMN activation (221). In vascular smooth muscle cells, 
L TB4 induced proliferation and migration, a phenomenon related to intimaI hyperplasia 
development (12). 
3.8. L TB4 and Inflammatory Diseases 
LTB4-mediated recruitment and activation of leukocytes participates in the 
pathogenesis of a number of inflammatory diseases. Inflammatory bowel disease (258), 
asthma (37, 55, cystic fibrosis {Konstan, 1993 #1933, 262), multiple sclerosis (203), 
atherosclerosis (312), rheumatoid arthritis (3) and other diseases are associated with 
significantly elevated levels of L TB4 in involved tissues. Multiple animal models have 
demonstrated a causative role for L TB4 in these diseases and treatment with L TB4 
receptor inhibitors usually leads to decreased leukocyte recruitment and improvement or 
remis sion of the disease (reviewed in (280)). 
3.9. LTB4 and Cancer 
A clear Hnk between AA metabolites, inflammation and cancer is starting to emerge. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are proving effective in the 
chemoprevention of certain types of cancer (104, 215). L TB4 is a potent mediator of 
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leukocyte recruitment and transcellular biosynthesis of this leukotriene can greatly 
amplify the inflammatory response. The potential role of L TB4 in cancer development 
and the use of pharmacological inhibitors of the L TB4 receptors or L T A4H are actively 
being investigated. 
Increased L T ~H levels were detected in the squamous endothelium of human 
esophageal adenocarcinoma (EAC), colon and lung cancer samples (49). Pleural 
effusions associated with lung cancer showed increased levels of L TB4 and neutrophil 
infiltration, comparable to those found in exudates from tuberculosis patients (219). In a 
rat model of EAC, treatment with the non-specific L T ~H inhibitor Bestatin decreased 
L TB4 levels and tumor incidence and severity (49). Bestatin has also been shown to 
inhibit squamous-cell lung carcinoma relapse (126) and induce apoptosis of human 
leukemic cell lines (253), although the specific involvement of LTA4H was not 
demonstrated. Human pancreatic cancer cell lines expressed both BLT1 and BL T2 
receptors and L TB4 stimulation led to an increase in proliferation. Treatment of these 
ceUs with an inhibitor of the BL T receptors (L Y293111) lead to decreased proliferation 
and apoptosis (286). L TB4 plays a pivotaI role in the activation and proliferation of 
chronic B lymphocytic leukemia cells (B-CLL) in response to CD40 ligation. 
Expression of activation markers in B-CLL cells upon CD40L stimulation was inhibited 
by MK-886 (a FLAP inhibitor) but could be re-established upon LTB4 treatment (242). 
L TB4 has been implicated in Ras-induced transformation as part of the Rac signaling 
pathway. Rac activation of cPLA2 is required for c-fos serum response element (SRE) 
activation and cellular transformation (145, 308). Ras-transformed Rat2 cells (Rat2-
H06) produce more LTB4 and have higher levels of BLT2 (308). Use of the BLT 
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antagonist leukotriene B4-3-aminopropylamine (LTB4-APA) determined BL T2 to be 
required for Ras-induced transformation: in vitro, L TB4-APA reduced Ras-induced 
morphological changes and anchorage independence; in vivo, it could block tumor 
formation by Rat2-H06 in athymie mi ce (308). 
The body of evidence linking chronic inflammation, disregulated production of LTB4 
and cancer is increasing. Many questions remain as to the downstream signaling events 
following BLT stimulation and the transcriptional control of synthetic enzymes. Further 
investigation of transgenic models and the use of pharmacological inhibitors can help to 
shed light on these questions and propose novel therapeutic targets. 
3.10. Leukotriene A4 Hydrolase 
L TA4H is a 610 amino acid-Iong cytosolie enzyme with a molecular mass of 69 kDa 
(87, 230) (FIGURE 13). Based on its zinc signature and aminopeptidase activity, 
LTA4H is c1assified as part of the Ml family of zinc metallopeptidases, which inc1udes 
Aminopeptidase A, Aminopeptidase B, and Aminopeptidase N. LT~H catalyzes the 
final step in the synthesis of L TB4 via its highly specifie hydrolase aetivity. Epoxide 
hydrolysis of L T A4 by L T ~H is the rate-limiting step in the production of L TB4, a 
reaetion that also results in covalent modification of L T A4H leading to suicide 
inactivation (74, 207). 
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FIGURE 13. Leukotriene A4 hydrolase (LTA4H). A) Schematic representation of LT~H, highlighting the Zn2+-containing 
catalytic domain. Residues important for the aminopeptidase and hydrolase activity are indicated. Residues important for both 
enzymatic activities are highlighted in red. P-rich indicates proline-rich domain. Numbers correspond to amino-acid residues. B) 
Crystal structure ofLTA4H. The zinc-containing catalytic domain is shown in green and the proline-rich loop is indicated (courtesy of 
Nat. Struct. Biol. (Thunnissen, M. et al., 2001 (280». 
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3.10.1. Tissue Distribution 
Tissue distribution of L T AtH is very broad, with high expression in spleen, lung and 
small intestine (208). L T AtH is expressed in a variety of hematopoietic and non-
hematopoietic cells, including airway epithelial cells, erythrocytes, neutrophils, and B-
lymphocytes (20). 
3.10.2. Gene Organization 
Ruman LTAtH gene exists as a single copy gene of over 35 kbp on chromosome 
12q22 with a coding sequence divided in 19 exons (172). The putative LTA4H promoter 
is located in the 5 'upstream region of the gene. It lacks a definitive TATA box and it 
contains a phorbol-ester response element (AP-2) and two xenobiotic response elements 
(XRE) (172). These elements were never functionally characterized and their 
significance remains unknown. A study by Zaitsu et al. (311) demonstrated the 
inducibility of the LTA4H gene by IL-4 and IL-13 treatment in polymorphonuclear 
leukocytes (PMN), however specifie regulatory element within the promoter or 
transcriptions factors implicated in LTA4H gene regulation were not identified. 
3.10.3. Protein Structure and Catalytic Activity 
The crystal structure of L T AtH in complex with the competitive aminopeptidase 
inhibitor Bestatin was resolved to 1.95 A resolution to an R-factor of 18.5% (285) 
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(Figure 13B). The enzyme is globular and composed of three domains: N-terminal, 
catalytic and C-terminal. L T ÂlH possesses two (;atalytic activities - hydrolase and 
aminopeptidase - that are exerted in distinct yet overlapping active sites. A hydrophobic 
pocket in the catalytic do main binds L T A4, this pocket is lined by 21 residues that 
compose the catalytic peptide K21. The stereo selective introduction of water to the 
backbone of L T A4 occurs several methy lene groups away from the epoxide moiety, 
presumably through the induction of a carbocation intermediate (240, 241). The epoxide 
hydrolase activity is abolished by suicide inactivation that involves binding of L TA4 to 
Tyr-378, which is located within the K21 peptide. The aminopeptidase activity of 
LTA4H proceeds via a zinc-assisted general base mechanism involving Glu-296 and 
Tyr-383 as general base and proton donor, respectively. LTA4H accepts a variety of 
substrates for its aminopeptidase activity, including arginyl di- and tri- peptides (212) 
and opioid peptides (206). 
3.10.4. LTA4H Knockout Mouse 
LTA4H knockout mice were generated by homologous recombination in a 129/SvEv 
background (29). LTA4H/- mice were obtained in the expected Mendelian ratios, thus 
disruption of L T A4H expression had no effect in fetal development or perinatal survival. 
LTA4H/- animaIs could not be distinguished from LTA4J-t/- or wild-type littermates by 
simple observation or histological analysis. Hematopoiesis and lymphopoiesis of 
LTA4H/- mice was normal. 
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LTA4H/- mice challenged with intra-peritoneal administration of zymosan A did not 
produce LTB4, whereas it was easily detected in wild-type animaIs. Thus, the LTA4H 
knockouts challenged with Zymosan A did not recruit PMN s to the site of inflammation. 
LTA4H/- mi ce also showed impaired inflammatory response triggered by topical 
application of arachidonic acid (AA). LTA4H/- mice were protected against systemic 
shock induced by platelet-activating factor treatment (92.3% survival compared to 50% 
in control group) but not by LPS. Study of the LTA4K/- mouse as well as the 5-LO and 
FLAP knockouts has unveiled the complexity of the inflammatory response to various 
stimuli and how L T production is carefully and dim:rentially orchestrated in each case. 
3.10.5. LTA4H Pharmacological Inhibitors 
L TA4H was identified as a potential target for the development of anti-inflammatory 
drugs based on the specific roles of L TB4 in acute and chronic inflammation and the 
identification of increased levels of L T A4H in esophageal cancer and certain types of 
graft-versus-host disease. The general aminopeptidase inhibitor bestatin and the 
angiotensin-converting enzyme inhibitor captopril inhibit L T A4H in a potent and 
reversible manner (ICso 4 X 10-6 M and Il X 10-6 M respectively)(213), consistent with 
a molecular resemblance of L TA4H and other metallohydrolases at their Zn +2 binding 
sites. Several other more specific inhibitors have been developed in academic and 
industriallaboratories. Notably, the competitive inhibitor SC-57461A (3-[methyl[3-[4-
(phenylmethyl)phenoxy]propyl] amino] propanoic acid HCI) demonstrated potent in-
vitro activity, good cell penetration and oral activity in a mouse model (224). The use of 
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specifie L T A4H inhibitors alone or in combination with other existing drugs for the 
treatment of diseases such as atherosclerosis, rheumatoid arthritis and possibly certain 
types of cancer constitutes an interesting therapeutic approach to cure or improve the 
condition of patients afflicted with these diseases. 
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RESEARCH OBJECTIVE AND SPECIFIC AIMS 
Detailed characterization of the molecular features of lymphomas is essential to their 
accurate classification, choice of appropriate treatment and targeted development of 
novel therapeutic agents. The advent of new technologies -such as microarray - has 
allowed the characterization of complex transcriptional profiles of cancerous as weIl as 
normal lymphocytes. In parallel, the study of the expression and activity of key 
transcription factors in normal and cancerous lymphocytes is essential as they 
orchestrate the cellular transcriptional pro gram that results in the phenotypical features 
observed for each lymphoma. Notable examples of the transcriptional alterations 
observed in mature B cell lymphomas include the constitutive activation of cMyc and 
the inactivation of p53. These common defects however are not observed in PEL but 
rather development of the disease is intimately linked to infection by HHV -8. Our 
hypothesis is that PEL cells possess altered transcription factor expression and/or 
activity and that this contributes to lymphomagenesis by a) favoring HHV -8 replication 
and 2) inducing or suppressing the expression of target genes, which together constitute 
the transcriptional signature of PEL. 
We undertook an investigation of the transcriptional pro gram of PEL cells to identify 
alterations that 1) potentially contribute to lymphomagenesis by favoring HHV-8 
infection and 2) provide a mechanistic explanation for the lack of surface marker 
expression observed in this lymphoma. Next, we used microarray technology to identify 
genes that were differentially expressed in PEL compared to cHD cells. PEL and cHD 
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are derived from B lymphocytes at a similar stage of development -late or post-Ge with 
a partial plasma cell phenotype (34) and share numerous characteristics at the molecular 
level, yet are vastly dissimilar at the clinical level. We investigated if expression of a 
dis crete set of genes could set apart PEL from cH]) cells and help explain the clinical 
features and biological outcomes observed in PEL. The identification of a transcriptional 
signature particular to PEL - composed of both downregulated and upregulated factors -
is crucial to better understand the molecular changes that contribute to the development 
of this lymphoma. 
In order to prove our working hypothesis, we identified the following specific aims: 
1. To investigate if the NF-KB pathway is activated in PEL cells and if activation of 
this pathway contributes to the spread of the HHV -8 virus. 
2. To identify alterations in the B cell-specific transcriptional program in PEL cells 
that contribute to the lack of surface marker expression observed in these cells. 
3. To identify specific genes expressed in PEL that can differentiate at the 
molecular level this lymphoma form other mature B cell malignancies, in particular 
cHD. 
4. Following completion of objective 3, we identified leukotriene ~ hydrolase 
(LTA4H) as being upregulated in PEL, therefore we sought to investigate the 
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transcriptional regulation of the leukotriene A4 hydrolase (L T A4H) gene and identify 
promoter elements responsible for the overexpression of L T A4H in PEL cells, further 
confirming that transcriptional regulation is altered in this lymphoma. 
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CHAPTERII 
Materials and Methods 
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1. Celllines 
BCBL-1, a primary effusion lymphoma (:ell line infected with HHV -8 but 
negative for EBV or HIV-1, and BJAB, an EBV-negative Burkitt's lymphoma cellline, 
were a kind gift from Dr. Jae U. Jung (Harvard Medical School, MA). Both celllines 
were cultured in RPMI 1640 (Wisent Inc., St. Bruno, QC) supplemented with 10% FBS, 
10-5 M [3-mercaptoethanol, and 8 fA-g/mL gentamicin. BC-3 (ATCC no. CRL-2277) is a 
primary effusion lymphoma cell line infected with HHV -8 but negative for both HIV 
and EBV. BCP-1 (ATCC product number CRL-2294) is a HHV-8 positive, HIV and 
EBV negative, clonallymphoma cellline isolated from peripheral blood. Both PEL cell 
lines were maintained in RPMI 1640 supplemented with 20% FBS and 8 fA-g/mL 
gentamicin. CRO-AP6 is a HIV positive, EBV negative PEL cellline established from 
the pleural effusion of a 26-year-old, HIV + patient (described in (33), a kind gift from 
Dr. A. Carbone, Centro di Referimento Oncologico, IRCCS, Italy). KM-H2 and L-428 
are two well characterised Hodgkin' s lymphoma celllines of B cell origin (described in 
(62, 114)), BL-2, BL-30, and BL-41 are Burkitt's lymphoma cell lines previously 
described (66), all a kind gift from Dr. Sigrun Smola. Namalwa cells are a EBV positive 
Burkitt's lymphoma cellline obtained from the ATCC (product number CRL-1432). 
They were cultured in RPMI 1640 with 10% FBS and 1 % sodium pyruvate. 
2. Plasmid constructions 
The B4-TKCAT reporter construct was a kind gift from Dr. H. Singh (University of 
Chicago, Chicago, IL (68)). B4-TKCAT contains 4 copies of the ETS-IRF site found in 
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the immunoglobulin ",B enhancer subc10ned upstream of the HSV thymidine kinase 
promoter in the TK-CAT vector. The PU.l expression vector PU.1/pECE was a kind gift 
from Dr. M. Fenton (Boston University School of Medicine, Boston, MA). The PU.l 
cDNA is placed under the transcriptional control of the SV 40 early promo ter. The 
luciferase reporters under the control of the murine fuIllength Pu. 1 promoter (mPU-
334) and deletions (mPU-86, mPU-39 and mPU+34) as weIl as the Oct-2 and Oct-1 
expression vectors (pCGOct-l and pCGOct-2) were a kind gift from Dr. D. Tenen 
(Harvard University, Cambridge, MA) and are described in (48). 
The L T AtH promoter region was isolated from BJAB genomic DNA using the 
primers: 5'- CTT TCT CAA TGC TGC ATT CCT C - 3' (forward), and 5'- TAC CAG 
ACT CGT CGA T AG AG - 3 ' (reverse). The amplified 2.2 kb fragment was purified 
and subc10ned by blunt-end ligation into the SmaI site of pGL3basic-modified (new 
NcoI site introduced upstream of MCS, missing original fragment spanning from Hind 
III to NcoI restriction sites) to create LTA4HPRO. The presence of the insert in the 
correct orientation was verified by analytical digestion with Hind IIIIXhoI, which 
excised a 1.3 kb fragment. Deletion fragments SI (-1702 to + 105), S2 (-1196 to + 105) 
and S4 (-123 to +105) were amplified using the following forward primers: 5'- ATT 
CTG GTGTTC TCT CAG C - 3',5'- CCT ACC TGG AAG CAT ACT GG- 3',5'-
TCA GCT CCA GGA GCA CGC TTG G - 3' respectively and blunt end c10ned into 
SmaI site of pGL3basic to create SlIpGL3, S2/pGL3, and S4/pGL3. S6/pGL3 (-40 to 
+105) was constructed by digesting LTA4HPRO with NheI and NcoI followed by 
Kleenow treatment and blunt-end re-ligation of the plasmid. 
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3. Whole cell extract (WCE) preparation 
Whole cell extracts (WCE) and immunoblot analysis were performed using 
standard protocols as described (254). Briefly, 107 ceUs were harvested and washed 
twice in PBS. The cells were lysed in Nonidet P-40 (NP-40) lysis buffer (50 mM Tris 
pH 7.4, 150 mM NaCI, 2 mM EDTA, 10% glycerol, 30 mM l3-glycerophosphate pH 
7.45, 1% NP-40, 20 mM NaF, 1 mM sodium orthovanadate, 1 mM Phenylmethyl 
sulfonyl fluoride (PMSF), 5 !Ag/mL aprotinine, 5 !Ag/ mL leupeptine, 5 !Ag/mL pepstatin 
A) for 45 min on ice. CeU debris was removed by centrifugation at 16 000 g for 15 min 
at 4°C. Protein content was quantified by Bradford assay (BioRad Laboratories Inc., 
Hercules, CA) as per manufacturer's instructions. WCE were stored at -80°C. 
4. Immunoblot analysis 
WCE (50-100 !Ag) prepared using Nonidet P-40 lysis buffer were subjected to 
electrophoresis on 7.5-12% SDS-PAGE gels, as appropriate for best resolution of 
prote in of interest. Proteins transferred to Trans-Blot® nitrocellulose membrane (Bio-
Rad Laboratories Inc., Hercules, CA) were blocked in PBS containing 5% nonfat dry 
milk and 0.05% Tween 20, then incubated with 1 !Ag/mL primary antibody dilutions. 
After washes, the blots were incubated with a secondary antibody coupled to horseradish 
peroxidase (HRP). Blots were visualized using the NEN electrochemilumonescence 
(ECL) detection system (Perkin Elmer Life an Analytical Sciences Inc., Wellesley, MA). 
The following antibodies were used at 1 !-tg/mL for the study of B cell transcription 
factor ablation in PEL: Anti-IRF-4 goat polyclonal antibody, anti-ICSBP goat polyclonal 
antibody, anti-PU.l rabbit polyclonal antibody, anti-Oct-2 rabbit polyclonal antibody, 
63 
anti-Bob-1 rabbit polyclonal antibody, anti-Spi-B goat polyclonal antibody, anti-Pax5 
goat polyclonal antibody, all from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 
Anti-a-actin mouse monoclonal antibody was purchased from Sigma-Aldrich Co. (St-
Louis, MO) and used at al: 1 0000 dilution. 
The following primary antibodies were used in the study of upregulation of pro-
inflammatory factors in PEL: anti- LTA4H (rabbit polyclonal, a kind gift from Dr. Jilly 
Evans, Merck & Co., NJ, USA), was used at a 1 :5000 dilution, anti-human Il-16 (goat 
polyclonal, R&D systems inc., cat # AF-316-PB) was used at 0.2 !-tg/mL, anti-
thrombospondin-1 (mouse monoclonal, Medicorp Inc., Montreal, QC) was used at 1 
!-tg/mL, anti-PSGL-1 (mouse monoclonal, Santa Cruz Biotechnology Inc.) was used at 
1 !-tg/mL. AlI antibody dilutions were prepared in blocking solution. Anti-cleaved 
caspase 3 antibody (rabbit polyclonal, Cell Signaling Inc., Danvers, MA) was diluted 
1 :2000 in 5% BSA/0.05% Tween/Tris buffered saline (TBS). Anti-~-actin mouse 
monoclonal antibody was purchased from Sigma-Aldrich Co. and used at al: 10 000 
dilution. 
5. Transient transfection and reporter assays 
Electroporation or BJAB, BCBL-1 and L-428 cells was performed at 950 !-tF and 250 
V using a Gene Pulser IITM apparatus (BioRad Inc.). Luciferase assays were performed 
following a transient transfection of 10 !-tg of the reporter gene (mPU-334, mPU-86, 
mPU-39 or mPU+34) and 1.0 !-tg of the renilla internaI control (pRL-TK) into 10 X 106 
cells. The dose response for Oct-2 was performed in a similar manner, but co-
transfecting 0, 1, 2 or 4 !-tg of the pCGOct-2 expression vector (in which the octamer 
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factor cDNA is under the control of a CMV promoter) along with the reporter gene 
construct. The luciferase assay was performed 48 h after transfection using the Promega 
Dual Luciferase Reporter Assay System (Promega Corporation, Madison, WI) as per 
manufacturer' s instructions. Transfection efficienc:y was normalized using the renilla 
activity counts. 
Luciferase assays using full length L TA4HPRO and deletion constructs were 
performed following transient transfection of 10 !-tg of the reporter gene and 1.0 !-tg of 
the renilla internaI control (pRL-null) into 10 X 106 cells. The luciferase assay was 
performed 48 h post-transfection using the Dual Luciferase Reporter Assay System as 
per manufacturer's instructions. Transfection efficiency was normalized using the 
renilla activity counts. Inhibition of NF -KB and AP-1 with the chemical inhibitors 
aspirin (acetylsalicylic acid, 10 mM) or ibuprofen (1 mM) were carried out as follows: 
10 X 106 BCBL-1 cells were electroporated with 10 !-tg of L TA4HPRO and incubated 
for 42 h, then the appropriate inhibitor or control vehicle (100 mM Tris, pH 7.5) was 
added and incubated for an additional 6 h before harvesting samples and assaying for 
luciferase activity. 
CAT assays were performed after transient transfection of 10 !-tg of the reporter 
constructs B4-TKCAT, TK-CAT, or pEGFP-Cl into 10 X 106 cells. PU.1 dose response 
was performed by co-transfecting 0, 10,50, 150, or 300 ng of the PU.1/pECE expression 
vector. The CAT assay was performed 48 h after transfection as follows: cell pellet was 
resuspended in 0.25 M Tris pH 7.8 and lysed by three rounds of freeze-thaw. Equal 
volumes of prote in extract (50 !-tL) were placed in a 7 mL glass scintillation vial and 
heated at 60°C for 10 min to deactivate deacetylases, then cooled on ice. To the extracts, 
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1 mM chloroamphenicol (Sigma-Aldrich Co., St-Louis, MO) and 0.4 nCi of 3H-acetyl-
coenzyme A (200.00 mCi/mmol, Perkin Elmer Life an Analytical Sciences Inc., 
Wellesley, MA) were added in a total volume of250 f!L buffered with 100 mM Tris pH 
7.8. The mixture was overlayed with Beta Max water immiscible scintillation fluid (ICN 
Radiochemicals, Costa Mesa, CA) and incubated at 37°C for 6 h. The samples were then 
analyzed in a scintillation counter for 3H measurement. Transfection efficiency was 
normalized by %GFP and microgram of protein. 
6. Nuclear extract preparation 
Nuclear extracts were prepared as described elsewhere (214). Briefly, 107 cells 
were harvested and washed twice in PBS. The cell pellet was washed in 1 mL of buffer 
A (10 mM HEPES, pH7.9, 1.5 mM MgCh, 10 mM KCI, 0.5 mM DTT and 0.5 mM 
PMSF) then the cell membrane was lysed by incubating in 60 f!L of buffer AI 0.1 % NP-
40 for 10 min on ice. The intact nuclei were centrifuged down at 16 000 g for 10 min at 
4°C and the cytoplasmic fraction was discarded. The isolated nuclei were lysed in 45 f!L 
of cold buffer B (20 mM HEPES pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCh, 
0.2 mM EDTA, 0.5 mM dithiothreitol (DTT), 0.5 mM PMSF, 5 f!g/mL Leupeptin, 5 
f!g/mL Pepstatin, 0.5 mM Spermidine, 0.15 mM Spermine, 5 f!g/mL Aprotinin) for 15 
min on ice. Nuclear membranes and debris were spun down for 10 min at 16 000 g at 
4°C. Supernatants were collected and quantified for prote in content by Bradford assay 
(BioRad Laboratories Inc.), aliquoted and quick frozen in liquid nitrogen. Nuclear 
extracts were stored at -80°C. 
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7. Electrophoretic Mobility Shift Assay (EMSA) 
EMSA analysis using the oetamer consensus sequence was performed as deseribed in 
Chen et al. (48). Briefly, 2 X 105 epm of the [y}2p] ATP labelled consensus Oetamer 
probe (5'- TGT CGA ATG CAA ATC ACT AGA A - 3', Santa Cruz Bioteehnology 
Ine.) were ineubated with 5-10 !-tg ofnuclear extraets in binding buffer (10 mM HEPES, 
pH 7.5, 50 mM KCI, 5 mM MgCh, 1 mM EDTA, 1mM DTT, 0.1 mg/mL poly(dI/dC), 
0.1 mg/mL BSA, and 5% glyeerol) on iee for 30 min. For supershift experiments, 2 !-tg 
of anti-Oet-2 antibody (Santa Cruz Bioteehnology) or anti-Oet-1 antibody (Santa Cruz 
Bioteehnology Ine.) was added to the reaetion. Competition with mutant probe was 
performed using 25-times molar exeess of a mutated oetamer probe (5' - TGT CGA 
ATG CAA GCC ACT AGA A - 3', Santa Cruz Bioteehnology Ine.). Supershift with an 
unrelated antibody was performed by incubation with 1 !-tL of normal goat serum. 
Binding reaetions were subjeeted to eleetrophoresis on a 5% polyaerylamide gel in 0.25 
X TBE at 160 V for 3 hours. 
Eleetromobility shift assays using the KBI (5'-CTC TGC AAA GCG AAG TCC CCT 
TCG CAC-3'), À.B (S'-AAA TAA AAG GAA GTG AAA CCA AG-3') and KE3' (S'-
CCC TTT GAG GAA CTG AAA ACA GA-3') probes were performed as deseribed 
above. For supershift experiments, 1-2 !-tg of antibodies direeted against eaeh NF-KB 
subunit or anti-IRF-4, anti-PU.1, anti-ICSBP, or anti-Spi-B (Santa Cruz Bioteehnology 
Ine.) were added to the reaetion. 
EMSA analysis using probes derived from the LTA4H promoter was performed as 
follows. S4 and S6 EMSA probes were generated by restriction digestion of S4/pGL3 
and S6/pGL3 plasmids with Kpn 1 and BgI II. The remaining EMSA probes were 
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generated by annealing of complementary primers and had the following sequences: S8, 
5'- ATC ACG CGT CGG CAC CAT GGA ACT TGT AGT TCC TTC ACC CAT CCC 
CCA ACG CTC GTC TGA AAG CTT ATC C -3', S9, 5'- ATC ACG CGT TCC CAG 
GTA GCC AAG CGC CCG CTT GCC GCG CGG CAC CAT GGA ACT TGT AGT 
TCC TTC ACC CAT CCC CCA ACG CTC GTC TGA AAG CTT ATC C -3', S91, 5'-
TCC CAG GTA GCC AAG CGC CCG CTT GCC -3", S92, 5'- GCC GCG CGG CAC 
CAT GGA ACT TGT AGT -3', S93, 5' - CCA AGC GCC CGC TTG CCG CGC GGC 
ACC -3', S94, 5'- CAT GGA ACT TGT AGT TCC TTC -3'. EMSA analysis was 
performed as follows: 2 X 105 cpm of [y)2P]_ATP oflabeled probe was incubated with 
5 fAg ofnuclear extracts in binding buffer (10mM HEPES, pH 7.5,50 mM KCI, 5 mM 
MgCh, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mg/mL poly (dI/dC), 0.1 mg/mL BSA, 
and 5% glycerol) at room temperature for 30 minutes. Competition with cold probe was 
performed using 25-50 fold molar excess unlabelled probe. Binding reactions were 
subjected to electrophoresis on a 5% polyacrylamide gel in 0.25X TBE at 160 V for 3 
hours. 
8. B cell purification 
Fresh B lymphocytes were isolated from human tonsils discarded following 
surgery. The tonsils were thoroughly minced, resuspended in wash medium consisting of 
RPMI 1640 (Gibco by Invitrogen, Corp., Carlsbad, CA) supplemented with 2% FCS 
(Hyclone Laboratories Inc., Logan, UT), and 50 U/ml penicillin, 50 fAg/ml streptomycin, 
and amphotericin B (1/500 w/v) from Life Technologies (Burlington, ON, Canada); and 
then layered onto a Ficoll-Paque (Pharmacia Biote(;h, Uppsala, Sweden) gradient. Tonsil 
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lymphocytes were separated by rosetting with neuraminidase-treated sheep red blood 
cells and Ficoll-Paque density centrifugation. Monocytes were removed from the E-
rosette-negative fraction by adherence depletion; the remaining B cells were routinely 
demonstrated to be > 98% pure on flow cytometry by CD19 staining, with <1 % CDI4+ 
and <1 % CD3+. 
9. RNA isolation and microarray analysis 
Total RNA was extracted from BCBL-l, L-428 and BJAB cells using the 
TRlZOL® method as per manufacturer's instructions (Invitrogen Corp., Carlsbad, CA). 
Concentrations were calculated using the OD26o for each sample and RNA quality was 
determined using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, 
CA). RNA from BCBL-l cells was compared against that ofL-428 or BJAB cells. Ten 
micrograms of RNA from each cell line were œverse transcribed, labeled with the 
appropriate fluorochrome (Cy3 or Cy5, Perkin Elmer Co.) and hybridized to a human 
1.7K chip (versions 4 and 8, University Health Network Microarray Center, Toronto, 
Canada), a double-spotted array containing 1,718 well-characterized human ESTs. Two 
independent experiments comprising three hybridization with corresponding reverse 
labeling were carried out. Data acquisition was performed using GenePix Pro (4000B, 
Axon Instruments, Inc.) at PTM between 600 and 700. Flagging parameters were set to 
reject spots with (F532 mean - B532 AND F635 - B635) intensity values lower than 
200. Data analysis was performed using Iobion Gene Traffic software (V 3.0, Iobion 
Informatics LLC, La Joya, CA.), for a two-class experiment. Data was normalized with 
Lowess (sub-grid) method with background subtraction. Statistical Analysis for 
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Microarray (SAM) was applied on spot tables with a p-value eut-off = 0.05 and a 
differential expression eut-off of 1.5 fold and significant, differentially expressed genes 
in each class were selected. 
10. Reverse transcription and Polymerase Chain Reaction (RT-PCR) 
analysis 
Five micrograms of total RNA isolated using TRIZOL® method from the PEL 
ceIllines BCBL-1, BC-3, BCP-1 and CRO-AP6, the cHD celllines L-428 and KM-H2 
as weIl as BJAB cells was subjected to reverse transcription using SuperScript II, 
RNAseH reverse transcriptase (Invitrogen Corp., Carlsbad, CA) according to 
manufacturer's instructions. Five microliters of the obtained cDNA was then amplified 
by PCR using Taq polymerase (GE HealthCare Co., Fairfield, CT) as per manufacturer's 
instructions. The following primers were used for amplification: LT A4H (product size: 
204 bp), fwd: S'-CCC TAA AGA ACT GGT GGC ACT -3', rev: 5'- GAC TTT TCC 
ACC TGC TCT TTC -3', IL-16 (product size: 333 bp), fwd: 5'- AAG GGG CAT CTC 
CAA CAT CAT CAT -3', rev: 5'- CTC CTG CCA AGC TGA ACC CAA GAC -3', 
TSP-1 (product size: 493 bp), fwd: 5'- ACC GCA TTC CAG AGT CTG GC -3', rev: 
5'- ATG GGG ACG TCC AAC TCA GC -3', BLT-1 (product size: 239 bp), fwd: 5'-
CAC TGC TCC CTT TTT CCT TCA -3', rev: 5'·- CCA GCA GAA AGG ACA ACA 
CC -3', BLT -2 (product size: 173 bp), fwd: 5'- ATC ACC CTG CCA GTC TTT TG 
-3', rev: 5'- TAA GGG CTT GGG TAC AGG TG -5', GAPDH (product size 376 bp), 
fwd: 5'- CCA TGG AGA AGG CTG GGG -3', rev: 5'- CAA AGT TGT CAT GGA 
TGA CC -3'. PCR conditions were as follows for aIl primers except TSP-1: 94°C for 2 
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min, cycles: 94°C for 45 sec, 56°C for 45 sec, 72°C for 45 sec, repeat 20-30 times 
depending on optimal product detection, 72°C for 10 min. For TSP-1 (110), conditions 
were: 94°C for 2 min, cycles: 94°C for 1 min, 60°C for 1 min, 72°C for 2 min, 28 times, 
72°C for 10 min. PCR samples were then resolved in a 2% agarose gel and visualized by 
Ethidium Bromide staining under UV light. 
11. Neutrophil isolation 
Primary hum an neutrophils were isolated from whole blood as follows: 
heparinized whole blood was fractionated using Ficoll™ (GE Healthcare Corp., 
Fairfield, CT) as per manufacturer' s instructions and the red blood cell 
(RBC)/polymorphonuclear cell (PMN) fraction was collected. The pellet was 
resuspended in Hank's balanced salt solution (HBSS) to twice the original volume and 
6% dextran 500 (GE Healthcare Corp.) in 0.9% (w/v) NaCI was added to each sample to 
a final concentration of 1 % dextran. The RBCs were allowed to settle for 1-1.5 hours at 
room temperature. The PMN-rich supernatant was carefully collected and diluted 1:2 in 
HBSS and collected by centrifugation at 600 g for 10 minutes. Remaining RBCs were 
lysed in ammonium chloride lysis buffer (55 mmol/L ammonium chloride; 10 mmol/L 
sodium bicarbonate; 0.1 mmol/L EDTA). The pure PMN fraction was resuspended in 
PBS and analyzed by FACS for CD16, CD19, CD3 and CD14 expression, which 
showed that >98% of the isolated fraction was neutrophils (CD16+) and that there was 
<1 % contamination by B cells, T cells and monocytes. 
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12. Immunofluorescence staining and analysis 
Primary cells were stained with phycoerytrin (PE)-labelled anti-CD16, anti-
CD19, anti-CD3 or anti-CD14 antibodies (BD Pharmingen) for neutrophil 
characterization (CD16+) or with anti-CD19, anti-CD14 and anti-CD3 (BD Pharmingen) 
for B cell characterization (CD19+). After washing twice with PBS, 1 X 106 cells were 
labelled with the appropriate antibody for 30 min in PBS/1 % FBS. After a final wash 
with ice-cold PBS, cells were resuspended in 400 f.lL F ACS® buffer (PBS/CytoFix (BD 
Pharmingen). Flow cytometric analyses (1 X 104 cell/measurement) were performed 
using a F ACScalibour™ flow cyometer with CELLQuest™ software (Becton 
Dickinson). 
13. L TB4 transcellular biosynthesis assay 
Immediately after isolation, neutrophils were used for transcellular biosynthesis 
assay. A total of 0.2 X 106 neutrophils were seeded into 6-well plates in a volume of 1 
mL ofPBS. Subsequently, 107 B cells (BJAB, BCBL-I or L-428) in PBS were added to 
the appropriate wells for a final volume of 2 mL. Leukotriene production was stimulated 
by addition of 2 mM CaCb and 5 nM calcium ionophore A23187 (Sigma-Aldrich Co., 
St-Louis, MO). The reaction was allowed to proceed for 5 minutes at room temperature 
and then the supernatants were collected and diluted 1/100 to 1/200 in fresh PBS. A total 
of 107 neutrophils were assayed as a positive control as well as 107 B cells alone as a 
negative control. All samples were prepared in triplicate. Detection of L TB4 was 
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performed by enzyme-linked immunoassay (Leukotriene B4 ElA Kit, Cayman Chemical 
Co., Ann Arbor, MI) as per manufacturer's instructions. 
13. Trans-weil migration assay 
Migration assay was performed using a 96-well disposable migration chamber 
(ChemoTx, Neuro Probe, Gaithersburg, MD) as described (84). Briefly, BCBL-1 or 
BJAB cells were labelled with the fluorescent dye Calcein AM (Invitrogen Corp., 
Carlsbad, CA) as per manufacturer's instructions and resuspended at a density of 3 X 
106 cells/mL in RPMI 1640/10% FBS. The lower chamber of the migration chamber 
was filled with 29 !-,-L of chemoattractant solution (either LTB4, 10-10 M, or a 1/100 
dilution of supernatant from transcellular biosynthesis assay) or vehicle alone 
(PBS/0.1 % HSA). A total of 25 !-,-L of the cell suspension (75 000 cells) was placed on 
top of a polycarbonate filter (PVP-free, 8 !-,-m pore size, 3.2 mm diameter). The chamber 
was incubated for 1 hour at 37°C in a 5% C02 atmosphere. Non-migrated cells were 
removed with a cell scraper from the top of the filter. Migrated cells were counted on the 
bottom side of the membrane using a fluorescenee microscope. The experiment was 
performed at least three times and every sample was prepared in triplicate. 
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CHAPTERIII 
Constitutive NF -KB activation in PEL cells 
Constitutive activation of the NF -1(B pathway by oncogenic viruses such as EBV, 
human Papilloma virus (HPV) and human T-ceH Leukemia virus-1 (HTLV-1) is a 
common mechanism that promotes transformation (reviewed in (2». Previous 
studies of the HHV-8 virus demonstrated that the lytic HHV-8 protein vGPCR 
could induce persistent NF -1(B activation and promote tumor formation in 
transgenic mice by inducing VEGF expression, .eading to disregulated endothelial 
cell proliferation (251, 304). These results clearly showed a role for NF-KB activity 
in Kaposi's sarcoma development but did not adress this question in PEL. Because 
constitutive activation of NF -1(B has been associated with some mature B cell 
lymphomas, including cHD, we undertook an investigation of the status of NF -1(B 
activation in PEL cells as weil as the effect of NF -1(B activity on HHV -8 lytic 
replication. 
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1. PEL cells have constitutive activation of p65/p50 NF -KB 
heterodimers 
The NF-KB family of transcription factors regulates the expression of genes involved 
in such diverse cellular processes as proliferation, survival, inflammation and migration. 
These powerful transcription factors are often hijacked by viruses to drive viral gene 
expression and dampen the innate and adaptive immune responses. Constitutive NF -KB 
activation was detected in PEL cells as demonstrated by IKB-a phosphorylation and NF-
KB binding and transactivation of target sequences. 
Activation of NF -KB requires phosphorylation of IKB-a by the IKK complex, which 
triggers its proteasome-mediated degradation. Treatment of the PEL cell line BCBL-l 
with the proteasome inhibitor MG 132 for 6 hours lead to the accumulation of 
phosphorylated IKB-a, as detected by immunoblot using a phosphospecific antibody that 
recognizes IKB-a when phosphorylated at Ser 32 (li'IGURE 14A, upper panel). Blotting 
for total IKB-a demonstrated the presence of a slower migrating form that corresponded 
to the phosphorylated protein (FIGURE 14A, lower panel). No such accumulation was 
seen in control BJAB cells treated with MG 132. These results indicate that there is a 
constitutive activation ofNF-KB in BCBL-l cells but not in control BJAB cells. 
IKB-a levels are maintained through an auto-regulatory loop due to the presence of KB 
binding sites in its promoter region. Thus, activation ofNF-KB is rapidly shut down by 
de nova synthesis of IKB-a. Inhibition of protein synthesis by chemical inhibitors such 
as cycloheximide allows the study of IKB-a prote in degradation kinetics without the 
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FIGURE 14. Constitutive activation of NF-KB in PEL ceUs. A) MG-132 treatment to inhibit proteasome-mediated prote in 
degradation leads to the accumulation of phospho-IKB-a in BCBL-l but not in BJAB cells (top panel). The appearance of a slower 
migrating band can be seen when blotting for total IKB-a (lower panel). B) The kinetics oflKB-a degradation in BCBL-l cells (lanes 6 
to 10) compared to control BJAB cells (lanes 1 to 5) was analyzed using cycloheximide to inhibit de novo protein synthesis. After 6 
hours of cycloheximide treatment, there is complete degradation of IKB-a in BCBL-l cells but not in BJAB cells (compare lanes 4 and 
9). Immunoblot for j3-actin (lower panel) demonstrates equalloading. 
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masking effects of de novo prote in synthesis. Prote in synthesis was inhibited in BCBL-1 
and control BJAB cells using the chemical inhibitor cycloheximide and the 
disappearance of IKB-a with time was followed by immunoblot (FIGURE 14B). IKB-a 
levels remained constant in BJAB cells, whereas a marked decrease was se en in BCBL-
1 cells after 30 minutes and it was barely detectable after 1 hour. The half-life of IKB-a 
in BCBL-1 cells was calculated to be about 12 minutes. 
Binding to NF-KB dimers to target DNA sequences was analyzed by EMSA using the 
KB3 binding probe, corresponding to a functional KB site found in the IRF -4 promoter 
(5'-CTCTGCAAAGCGAAGTCCCCTTCGCAC-3'). Formation of two specific 
complexes could be seen in the PEL cell lines BCBL-1 and BC-3 but not in control 
BJAB cells (FIGURE 15). The upper complex could be supershifted by antibodies 
against p65 and p50 whereas the lower complex was supershifted by anti-p50 antibodies 
only. Thus, there is constitutive DNA binding of p65/p50 heterodimers and p50/p50 
homodimers in PEL cells. There was a lower specific complex formed with BJAB 
nuclear extracts but not PEL cells extracts, however the identity of this complex was not 
determined. The ability of NF-KB to activate transcription of KB-containing promoters 
was demonstrated by reporter gene assay using a construct containing two copies of the 
KB site found in the RANTES promoter cloned in front of the CA T gene (P2(2)CAT). 
The activity of the reporter gene was 4.5 times higher in BCBL-1 cells than in control 
BJAB cells (FIGURE 16). Taken together, these results show that PEL cells exhibit 
constitutive activation of the NF-KB classical pathway. This was confirmed by studies 
published while this work was underway, which showed that the classical NF -KB 
pathway was activated by the latent HHV-8 protein vFLIP (8, 79, 103). 
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FIGURE 15. Constitutive NF-KB DNA binding in PEL cells. The activation ofNF-KB in PEL cells was analyzed by EMSA using a 
probe corresponding to the KB1 site found in the IRF-4 promoter (5'-CTCTGCAAAGCGAAGTCCCCTTCGCAC-3'). In the PEL cell 
lines BCBL-l and BC-3, constitutive binding to KBl could be detected as two complexes (lanes 2 and 8). The upper complex could be 
supershifted with anti-p65 antibody (lanes 3 and 9) whereas both complexes were supershifted with anti-p50 antibody (lanes 4 and 10). 
Supershifted complexes are indicated by arrows. The activated NF-KB thus corresponds to p65/p50 heterodimers and p50/p50 
homodimers. In control BJAB cells, the corresponding complexes could not be detected (lane 5). CTL indicates the positive control 
MT4 cells (lane 1). "Cold probe" corresponds to competition with 100-times excess ofunlabelled probe (lane Il). Free probe is shown 
at the bottom. 
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FIGURE 16. The transcriptional activity of an NF-KB dependent construct is increased in BCBL-l cells. A CAT reporter gene 
assay was perfonned in BCBL-1 (yellow bars) and BJAB (blue bars) cells using a plasmid encoding for the CAT gene under the 
control oftwo kB sites (P2(2)-CAT). CAT activity (CPM nonnalized to !Ag of prote in) was followed over time (hrs). BCBL-1 cells 
demonstrated roughly twice as much CA T activity than control BJAB ce Ils after 8-16 hours of measurement. 
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2. NF-KB activation during the HHV-8 Iytic cycle is required for de 
novo infection 
NF -KB is also activated during the HHV -8 lytic cycle, as demonstrated by 
electromobility shift assay of whole cell extracts from BCBL-l cells induced with TP A 
to stimulate HHV-8 lytic replication (FIGURE 17A, lane 6). In extracts from TPA-
induced cells, there is a late activation of NF -K B 65 hours post-stimulation, 
corresponding to p65/p50 heterodimers (FIGURE 17B). Activation ofNF-KB coincides 
with late stages of viral repli cation, as demonstrated by the presence of the lytic viral 
protein encoded by ORF26 (FIGURE 17C). This activation can be abrogated by using 
the inhibitor of lytic gene transcription methotrexate (MTX) (FIGURE 17 A, lane 12), 
demonstrating the need for active HHV-8 replication. In contrast, the early NF-KB 
activity induced by TP A treatment after one hour (:annot be inhibited by MTX and it is 
therefore independent of HHV -8 replication (FIGURE 17 A, lanes 2 and 8). The 
activation ofNF-KB during the HHV-8 replicative cycle in BCBL-l cells was essential 
to produce virions capable of infecting endothelial cells de nova. Virus produced by 
TPA-treated BCBL-l cells was capable of infecting the endothelial cellline EA.hy926, 
establishing a lytic infection with spontaneous production of the lytic genes ORF26 and 
ORF K8.l (FIGURE 18). However, virus produced in BCBL-I cells encoding for the 
NF-KB super-repressor IKB-a 2Nd4 were incapable of productive de nova infection, as 
demonstrated by the lack of ORF26 and ORF K8.1 expression. 
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FIGURE 17. Late NF-KB activation in BCBL-1 cells correlates with HHV-8lytic replication. A) The kinetics ofNF-KB activation 
in BCBL-l cells following TPA treatment were analyzed by electromobility shift assay (EMSA). Nuclear extracts from BCBL-l cells 
treated with TPA or with a combination of TPA and Methotrexate (MTX, an inhibitor of lytic prote in production) for various time 
points were analyzed for NF-KB binding to the PRDII probe. The positions of the NF-KB complex as well as a non-specific band are 
indicated. Free probe is shown at the bottom. NF -KB binding was detected after 65 hours of TP A treatment alone (lane 6) but not in the 
presence of TPA plus methotrexate (lane 12). B) Nuclear extract from BCBL-l cells after 65 h of TPA stimulation was further 
analyzed by EMSA supershift with specific antibodies against the NF-KB subunits p50, p65, c-Rel, RelB and p52, as indicated. C) 
Nuc1ear extracts from (A) were analyzed for lytic prote in production by immunoblotting with an antibody against the product of ORF-
26 (minor capsid protein). Immunoblotting with an antibody against TFIID was used as a control for equal protein loading. 
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FIGURE 18. De-novo HHV-8 infection of endothelial Ea.hy926 cells. Wild-type (WT), Neo and 2NA4 BCBL-l cells were 
stimulated with TPA and Ionomycin for 24 h to induce the HHV-8 lytic cycle and supematants were collected 65 h post-induction. 
After ultracentrifugation, the virus was used to de-nova infect Ea.hy926 cells with a calculated MOI of 5 400. Whole cell extracts from 
Ea.hy926 cells at 72 h post-infection with HHV -8 derived from WT (lanes 1 and 2), Neo (lanes 3 and 4) and 2NA4 (lanes 5 and 6) 
BCBL-l cells were analyzed by immunoblot using antibodies against ORF 26 (top panel) and ORF K8.1 (middle panel) viral products. 
Lanes 2, 4 and 6 show viral protein levels after de-nova infection. Lanes 1, 3 and 5 show viral protein levels when the viral 
preparations are treated by 60 sec of UV crosslinking. A blot against f3-actin (bottom panel) was performed to ensure equalloading. 
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Based on this and other studies, NF -KB activity seems to be required both during latent 
and lytic HHV -8 infection. In PEL cells, constitutive activation of p65/p50 NF -KB 
dimers is important for IL-6 production and survival of the tumor cells (8, 83), whereas 
further activation during HHV -8 lytic replication allows the production of viral progeny 
capable of spreading infection to neighboring cells. 
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CHAPTER][V 
Analysis of B cell-specific transcription factor expression and 
activity in PEL cells 
Primary Effusion Lymphoma is characterized by a lack of B cell-specific surface 
marker expression. In particular, PEL cells do not express the B cell receptor 
(BCR) in spite of productive immunoglobulin gene rearrangement in most cases. In 
order to elucidate if transcriptional defects are at heart of this lack of BCR 
expression, we undertook an investigation of the expression and activity of key 
transcription factors known to govern BeR expression and the B cell program. 
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1. Constitutive expression of IRF -4 in PEL is concomitant with a 
downregulation of PU. 1. 
The transcription factor IRF-4 requires physical association with PU.1 in order to 
efficiently bind and transactivate target Ets-IRF sequences found in the light chain gene 
enhancers (67). Analysis of IRF-4 protein levels by immunoblot demonstrated 
constitutive IRF-4 levels in ail PEL cell lines examined (BCBL-1, BC-3, and BCP-1), 
compared to the control Burkitt's lymphoma BJAB cells which showed no IRF-4 
expression (FIGURE 19A). In contrast, PU.1 protein could not be detected in any of the 
PEL cell lines (FIGURE 19B). Surprisingly, the expression pattern of IRF-8, the IRF 
family member most closely related to IRF-4, was inversely related to IRF-4; i.e. IRF-8 
was expressed in BJAB but not in PEL cells (FIGURE 19C). The levels of Spi-B, 
another Ets family member that binds similar DNA elements and activates man y of the 
same target genes as PU. 1, remained constant in two of three PEL celllines compared to 
BJAB (FIGURE 19D). 
To determine if the abrogation of PU.l expression in PEL cells disrupted the 
regulation of B cell specific genes, EMSA analysis was performed using the composite 
Ets-IRF elements found in the ",B and KE3' light chain enhancers (FIGURE 20). In 
control BJAB cells, a protein-DNA complex was easily observed using the ",B or the 
KE3' probe (FIGURE 20, lane 1) and the protein-DNA complex was supershifted with 
anti-PU.l antisera (FIGURE 20, lane 2) but not with anti-SpiB antisera (FIGURE 20, 
lane 5). Anti-IRF-8/ICSBP antibody supershifted both the lower PU.l-containing 
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FIGURE 19. Expression of IRF-4, PU.I, IRF-8 and Spi-B in PEL cells. Immunoblot analysis was performed on whole cell extracts 
(WCE) from PEL ceIllines BCBL-l, BC-3 and BCP-l as weIl as control Cos7 and BJAB celllines. Immunoblots were probed with 
anti-IRF-4 (A), anti-ICSBP/IRF-8 (B), anti-PU.l (C), and anti-Spi-B (D) antisera. In A, C, and D the membranes were re-blotted with 
anti-~-actin antibody to verify equal protein loading. These immunoblots are representative of at least 3 independent experiments. 
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FIGURE 20. PU.l does not bind to the Ets-IRF composite element in the Â. and te light chain enhancers in PEL cells. Nuclear 
extracts from the PEL cellline BCBL-l were analyzed by EMSA for binding of PU.l , IRF-4, ICSBP/lRF-8, and Spi-B to the Ets-IRF 
composite element found in the À (5'-AAA TAA AAG GAA GTG AAA CCA AG-3') and K (5'-CCC TTT GAG GAA CTG AAA 
ACA GA-3') immunoglobulin light chain enhancers. Nuclear extracts from BJAB cells were used as a positive control. Lanes 1-5 and 
6-10 are BJAB and BCBL-l nuclear extracts, respectively. Lanes 1 and 6 represent binding ofBJAB and BCBL-l nuclear extracts to 
the y-32P-ATP-labeled EMSA probes. Supershift reactions were performed by adding the following antibodies: lanes 2 and 7, 
supershift with anti-PU.l antibody (PU); lanes 3 and 8, supershift with anti-IRF-4 antibody (F4); lanes 4 and 9, supershift with anti-
IRF-8/1CSBP antibody (F8), lanes 5 and 10, supershift with anti-Spi-B antibody (SB). Lane 11 represents competition with 25-fold 
excess cold probe. Lane 12 represents supershift with normal goat serum (isotype). Asterix indicates a non-specifie complex. 
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complex as weIl as the upper complex formed with the KE3' probe (FIGURE 20 lane 4, 
lower panel), thus demonstrating that in BJAB ceIls, PU.I can bind alone or in 
partnership with IRF-8 to the Ets-IRF elements present in both light chain enhancers. As 
expected, anti-IRF-4 antibody did not supershift any of the complexes, consistent with 
the lack of IRF-4 expression in BJAB cells (FIGURE 20, lane 3). In contrast, nuclear 
extracts of PEL cells failed to form complexes containing either PU.1 or IRF-4 
(FIGURE 20, lane 6), thus indicating that the heterodimer composed by PU.I and IRF-4 
-which is required for the normal function of composite Ets-IRF elements found in IgL 
chain enhancers (24, 25) - does not form in PEL cells. 
2. The B ce Il-specifie transcription factor Oct-2 and the co-activator 
Bob-l/OCA-B are not expressed in PEL cells 
In B cells, the PU.I promoter is regulated mainly through an octamer motif located at 
position -57 to -51 upstream of the PU.1 mRNA start site (48). The octamer site can be 
occupied by either member of the Octamer Binding Factor (Oct) family: the ubiquitous 
Oct-I or the B cell-specific factor Oct-2, with the latter displaying the highest 
transactivation capacity in B cells. To examine the status of Oct-I and Oct-2 binding and 
its role in transcriptional activation, EMSA analysis was performed with a consensus 
octamer sequence (FIGURE 21 A). A dramatic reduction in Oct-2 binding was detected 
specifically in PEL cells. In control BJAB ceUs, two complexes were observed 
(FIGURE 21A, lane 1), the upper complex containing Oct-I (FIGURE 21A, lane 2) and 
the lower complex containing Oct-2 (FIGURE 21A, lane 3), as detected by supershift 
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FIGURE 21. The B cell-specific factor Oct-2 is not expressed in PEL cells. A) Nuclear extracts from PEL celllines BCBL-1 (lanes 
4-6), BC-3 (lanes 7-9) and BCP-1 (lanes 10-12) were analyzed by EMSA for binding of octamer factors to a consensus octamer 
binding site (5'- TGT CGA ATG CAA ATC ACT AGA A - 3'). Nuclear extracts from BJAB cellline were used as a positive control 
(lanes 1-3). The antibodies used for supershift (either anti-Oct-1 or anti-Oct-2 polyclonal antibodies) are indicated above the lanes. In 
lanes 13-15, mOct indicates competition with a mutated octamer unlabeled probe (5'- TGT CGA ATG CAA GCC ACT AGA A- 3'), 
NGS indicates supershift with an unrelated antiserum (goat serum), and Cold Probe indicates competition with 25-fold excess of 
unlabeled octamer probe. Oct-l and Oct-2 DNA-protein complexes as well as supershift complexes (SS) are indicated by arrows. B) 
Whole cell extracts (100 ug) from BCBL-1, BC-3 and BCP-1 were analyzed by immunoblot. BJAB whole cell extract was used as a 
control. Blot was probed with anti-Oct-2 polyclonal antibody, and re-blotted with anti-~-actin antibody to demonstrate equal sample 
loading. C) Immunoblot analysis of whole cell extracts from BCBL-1, BC-3 and BPC-l. BJAB whole cell extract was used as a 
control. Blot was probed with anti-Bob-1I0CA-B antibody, and re-blotted with anti-j3-actin antibody to demonstrate equal sample 
loading. Blots Band C are representative of at least 3 independent experiments. 
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with Oct-l and Oct-2 specifie antibodies, whereas in the PEL cells only the upper, Oct-
l-containing complex was observed (FIGURE 21 A, lanes 4-12). Immunoblot analysis 
revealed that Oct-2 prote in expression was completely absent in all three PEL celllines 
(FIGURE 21 B). 
Since the transactivation potential of the Oct factors is enhanced by binding of the co-
activator Bob-l (48), the expression of the cofactor was also examined. Protein 
expression of the co-activator Bob-1/0ca-B was downregulated in PEL cells to different 
extents depending on the cellline (FIGURE 21 C); Bob-1 was highly expressed in 
BJAB (FIGURE 21 C, lane 1), whereas Bob-1 levels were about 75% lower in BCBL-1 
cells compared to control BJAB (FIGURE 21 C, lane 2); in BC-3 and BCP-l expression 
ofBob-l was below detection limits (FIGURE 21 C, lanes 3 and 4). 
3. PU.I, OCT -2, Bob-1I0CA-B and BSAP/Pax5 expression in other 
mature-B celllymphomas 
Recent studies have indicated that disruption of B cell specifie transcription factor 
activity may also occur in other forms of B cell lymphoma, particularly in classical 
Hodgkin's disease (reviewed in (41,60)). To directly compare transcription factor levels 
in PEL with other mature B cell-derived lymphomas, protein levels were assessed in a 
panel of celllines derived from Burkitt's Lymphoma, a disease originating from pre-
germinal center B cells and characterized by c-myc gene rearrangement (reviewed in 
(113)), cHD, a clonaI disease of B cell origin that arises from late germinal center B 
lymphocytes (reviewed in (41)), and PEL, also oflate/post GC origin (32,36) (FIGURE 
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22). Immunoblot analysis demonstrated that PU.l and Oct-2 expression was consistently 
found in Burkitt's lymphoma derived celllines (BJAB, Namalwa, BL-2, BL-30, and 
BL-41; Fig. 6, lanes 1, 8, 9, 10 and Il). As previously reported (233, 288), PU.1 and 
Oct-2 expression was strongly downregulated in the cHD celllines L-428 (FIGURE 22, 
lane 6) and KM-H2 (FIGURE 22, lane 7), mirroring the results obtained in PEL cell 
lines (FIGURE 22, lanes 2 to 5). Additionally, expression of BSAP/Pax-5 and IRF-
8IICSBP was assessed in both PEL and cHD cell lines, since it has been reported that 
BSAP/Pax-5 expression is downregulated in cHD cells (114) and we have found a 
downregulation ofIRF-8 levels in PEL cells. The levels ofboth BSAP/Pax5 and IRF-8 
transcription factors were dramatically decreased and, furthermore, the expression 
patterns were once again comparable between cHD and PEL. However the decrease in 
prote in expression was more profound in PEL cell lines. These results demonstrate that 
transcription factor silencing is not exclusive of PEL cells but rather shared among 
certain types of mature B celllymphomas. 
4. Ectopie expression of Oct-2 restores the activity of the PU.1 
promoter in PEL cells 
To examine the functional role of Oct-2 expression on the PU.l promoter, a luciferase 
assay was performed with the full-Iength murine PU.l promoter as well as truncated 
promoter constructs lacking the Oct and Ets sites (FIGURE 23). In control BJAB cells, 
full-Iength PU.l promoter activity was approximately 200-fold higher than the activity 
of the truncated PU.1 +34 promoter (FIGURE 23, compare lanes 1 and 4). The 
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FIGURE 22. Expression of B lymphocyte-specifie transcription factors in mature B cell Iymphoma cell Unes. Immunoblot 
analysis were performed on WCE from the Burkitt's lymphoma celllines BJAB (lane 1), Namalwa, BL-2, BL-30, and BL-41 (lanes 8-
Il), Hodgkin's lymphoma celllines L-428 and KM-H2 (lanes 6 and 7), and the PEL celllines BCBL-1, BC-3, BCP-1 and CRO-AP6 
(lanes 2-5). Immunoblots were probed with anti-sera raised against IRF-4, IRF-8, Oct-2, Pax5, PU.1 and Spi-B, as indicated. 
Immunoblot with an anti-actin antibody showed equalloading of the samples. The immunoblots shown are representative of at least 
three independent experiments. 
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FIGURE 23. The activity of the PU.I promoter is abrogated in PEL eeUs but ean be recovered by ectopie expression of Oct-2. 
The luciferase reporter gene was placed under the control of the full-Iength murine PU.I promoter (mPU-334, yellow bar) or truncated 
promoter constructs Iacking the distal 5' region (mPU-86, violet bar), the Oct and SpI sites (mPU-39, light blue bar), or the Oct, SpI 
and PU.I sites (mPU+34, white bar). The schematic representation of the mPU-Luc plasmids includes the location of the Oct site ~), 
the Sp I site (i) and the PU.l site p). For the transactivation assay, each construct was electroporated into BCBL-I (lanes 5 to 9) or 
BJAB (lanes I to 4) cells. An Oct-2 dose response was performed in BCBL-I cells by co-transfecting increasing amounts ofpCGOct-2 
expression vector along with the mPU-334 reporter construct (lanes 6 to 9). Transfection efficiency was determined by co-transfection 
ofpRL-TK renilla reporter gene. Fold induction was calculated by comparing the activity of the full-Iength promoter (mPU-334) to 
that of the truncated promoter (mPU+34). Data represents a typical experiment performed in duplicate. 
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importance of the octamer site in regulating PU.l expression in B cells was substantiated 
by the low activity of the mPU-39 construct, which contains the promoter proximal PU.l 
binding site but lacks the Oct motif (FIGURE 23, lane 2). The 5' distal region (from 
-334 to -86), does not contain important regulatory sites for promoter activity in B cells, 
since the mPU-86 construct has equivalent transactivation potential as the full-Iength 
promoter in BJAB cells (FIGURE 23, compare lanes 3 and 4). In contrast, in BCBL-l 
cells, only a basal level of PU.1 promoter activity was observed with the full-Iength 
promoter (FIGURE 23, compare lanes 1 and 5). Significantly, co-expression of 
increasing amounts of an Oct-2 expression plasmid in PEL cells resulted in a dose-
dependent increase in promoter activity, comparable to that observed in BJAB cells 
(FIGURE 23, lanes 6 to 8). Thus, the absence ofPU.1 protein in PEL cells appears to be 
directly related to the transcription block imposed by the complete lack of Oct-2 
expression in PEL cells. 
5. The activity of a composite Ets-IRF site is restored by ectopie PU.1 
expression 
Activity of the ",B and KE3' enhancer elements requires the synergistic activity of 
PU.l and IRF-4 on the composite Ets-IRF site found in both enhancers. To test the 
activity of the ",B site in PEL cells, the construct B4-TKCAT, which contains four 
copies of the Ets-IRF site found in the ",B enhancer element was transfected into control 
BJAB or PEL BCBL-I cells. In control BJAB cells, B4-TKCAT displayed a 6-fold 
increase in promoter activity compared to the empty vector TK-CAT (FIGURE 24 A, 
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FIGURE 24. A composite Ets/IRF site is inactive in PEL cells but its activity can be recovered by ectopie expression ofPU.l. A) 
The activity of the Ets/IRF site was assessed in BCBL-l cells (lanes 1-3) and BJAB cells (lanes 4-6) using a CAT reporter gene assay. 
The reporter gene B4-TKCAT (green bars) or the empty vector TK-CAT (yellow bars) were electroporated into each cellline and the 
CAT activity was measured at 48h post-transfection. A GFP expression vector was used as a negative control (white bars). B) A PU.l 
dose response curve was performed by co-transfection of increasing amounts of PU.l expression vector along with the B4-TKCAT 
construct in BCBL-l cells. Lane 1, TK-CAT; lane 2-6, B4-TKCAT; lanes 3 to 6, increasing amounts of pECE-PU.l expression 
plasmid; lane 7, GFP negative control. Normalization of CPM values was performed based on percent GFP positive cells and 
micrograms of protein. Data represents the mean and the standard error of the mean of four independent experiments. 
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columns land 2). However, in BCBL-l cells, the activity of the composite Ets-IRF 
construct was approximately equivalent to that of the empty vector (FIGURE 24 A, 
columns 4 and 5). Increasing amounts of PU.l transfected together with B4-TKCAT 
restored the activity of the ÀB-derived construct to levels comparable to those observed 
in BJAB cells (FIGURE 24 B, columns 2-6), thus indicating that functional activity of 
the Ets-IRF sites in PEL cells could be restored by PU.l expression. 
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CHAPTERV 
Differentiai gene expression analysis of 
the PEL cellline BCBL-l versus the cHD cellline L-428 
Primary Effusion Lymphoma cells and the Reed-Sternberg cells of classical 
Hodgkin's disease originate from mature B lymphocytes at a similar stage of 
development: post-GC with partial plasma cell differentiation. PEL and cHD cells 
share numerous characteristics at the molecular level, including lack of expression 
of the transcription factors Oct-2, Bob-I/OCA-B, PU.I, IRF-8 and Pax-Sleading to 
a "null" phenotype as weil as constitutive activation of NF -1d) and AP-l 
transcription factors. However, these two lymphomas differ widely in their clinical 
presentation and response to chemotherapy. In order to identify genes whose 
expression can differentiate PEL from cHD and provide a PEL "transcriptional 
signature", we undertook a microarray analysis of the PEL cellline BCBL-I 
compared to the cHD cellline L-428 and the Burkitt's lymphoma cellline BJAB. 
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1. Microarray analysis of the PEL cellline BCBL-l compared to the 
cHD cellline L-428. 
In order to elucidate the signature genes that distinguish PEL from cHD at the 
molecular level, microarray analysis was performed using total RNA isolated from the 
PEL cell line BCBL-l and compared it to the cHD cell line L-428 as weIl as the 
Burkitt's lymphoma (BL) cellline BJAB (FIGURE 25). A subset of about 40 genes out 
of 1700 was differentially regulated exclusively in BCBL-l cells (TABLE 1); from this 
list, four genes involved in inflammation at the level of chemotaxis and/or cell motility 
were significantly upregulated in BCBL-l. Given that the localization of PEL to serous 
body cavities involves migration of the tumor B cells from the lymph nodes to the 
peritoneal, pleural or pericardial space, it was therefore of interest to further characterize 
the expression of leukotriene A4 hydrolase (LT A4H, >5 fold induction), 
thrombospondin-l (TSP-l, >6 fold induction), interleukin-16 (lL-16, >4 fold induction), 
and P-selectin glycoprotein ligand (PSGL-l, 4-5 fold induction). 
2. Leukotriene A4 hydrolase, thrombospondin-l, interleukin-l6 and P-
selectin glycoprotein Iigand-l are overexpressed in PEL cells. 
To confirm the results obtained by microarray, the expression of LT A4H, IL-16, 
PSGL-l and TSP-l was examined at the mRNA (FIGURE 26 A, left panel) and/or 
prote in (FIGURE 26 A, right panel) level by using three additional PEL celllines (BC-3, 
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FIGURE 25. Gene expression profile of BCBL-l cells compared to BJAB and L-428 cells. Gene expression is shown as a color 
representation of ratio values, with red being above and green being below the row/column median level of expression as shown by the 
scale. Each column represents the average for BCBL-1 cells compared to either BJAB or L-428 cells and each row represents one 
gene. The dendogram comprises a partial gene list after SAM statistical analysis with a p-value cut-off = 0.05 and a differential 
expression cut-off of 1.5 fold. Genes in bold were confirmed by RT-PCR or immunoblot. 
BCBL-l vs. 
BJAB L-428 
thrombospondin 1 
endothelin receptor type 8 
CD48 antigen (B-cell membrane protein) 
2'-5'-oligoadenylate synthetase 2, 69171kDa 
leukotriene A4 hydrolase 
interleukin 16 (Iymphocytechemoattractant factor) 
selectin P ligand 
B-cell receptor-associated protein 31 
proteoglycan 1, secretory granule 
S 100 calcium binding protein A6 (calcyclin) 
omithine decarboxylase antizyme inhibitor 
X-box binding protein 1 
lectin, galactoside-binding, soluble, 1 (galectin 1) 
interferon regulatory factor 4 
Rho GDP dissociation inhibitor (GDI) beta 
beta-2-microglobulin 
bleomycin hydrolase 
phosphorylase kinase, alpha 2 (liver) 
chaperonin containing TCPl, subunit 5 (epsilon) 
CDW52 antigen (CAMPATH-I antigen) 
CD79B antigen (irnmunoglobulin-associated beta) 
CD79A antigen (irnmunoglobulin-associated alpha) 
heat shock 70kDa protein 9B (mortalin-2) 
tumor necrosis factor receptor superfamily, member 5 
BCL2-like 1 
E74-like factor 1 (ets domain transcription factor) 
autocrine motility factor receptor 
immunoglobulin J polypeptide 
major histocompatibility complex, c1ass II, DQ beta 1 
major histocompatibility complex, class II, DP alpha 1 
glutathione S-transferase pi 
CD74 antigen 
major histocompatibility complex, class II, DQ alpha 1 
major histocompatibility complex, class II, DR beta 3 
transcription factor 4 
dual specificity phosphatase 6 
lipase A, Iysosomal acid, cholesterol esterase 
ARPI actin-related protein 1 homolog A 
dihydrolipoamide dehydrogenase 
cyclin Gl 
thyrnosin, beta 4, X-linked 
baculoviral JAP repeat-containing 3 
chromosome 14 open reading frame 147 
Table J. List of genes specifically expressed in BCBL-l cells compared with L-428 and BJAB cells. The list was generated based 
on significant genes identified by microarray analysis. Gene names, fold change and function are indicated. Fold change value 
represents the average of two independent experiments carried out in triplicate. Functions are based on GO annotations and/or 
published data. 
GENE NAME FUNCTION BJAB l-428 
FOlO FOlO 
CHANGE CHANGE 
leukotriene A4 hydrolase INFLAMMATION, CHEMOT AXIS -18.96 -18.22 
selectin P ligand CELL ADHESION, MIGRATION -4.38 -5.37 
thrombospondin 1 CELL ADHESION, CHEMOTAXIS -6.35 -4.12 
interleukin 16 CHEMOTAXIS -5.18 -6.05 GENES 
lectin, galactoside-binding, soluble, 1 CELL ADHESION -4.99 -1.72 UPREGULATED 
CD48 antigen B-Iymphocyte activation marker -3.06 -5.51 in BCBL-1 
Selectin L CELL ADHESION -3.61 -2.93 
S100 calcium binding protein A6 Calcium binding, cell cycle progression -5.49 -2.31 
endothelin receptor type B G-protein cou pied receptor -2.89 -6.25 
2'-5'-oligoadenylate synthetase 2, 
69n1kDa Interferon response gene -16.79 -11.53 
interferon regulatory factor 4 transcription factor -27.74 -2.79 
B-cell receptor-associated protein 31 Transport -1.90 -2.12 
MHC complex, class Il, OP alpha 1 antigen presentation 2.21 1.87 
thymosin, beta 4, X-linked cytoskeleton organization 1.91 8.27 
MHC complex, class Il, DO beta 1 antigen presentation 2.67 3.43 GENES 
transcription factor 4 transcription factor 6.34 6.12 DOWNREGULA TED 
MHC complex, class Il, DR beta 3 antigen presentation 5.54 5.48 IN BCBL-1 
MHC complex, class Il, DO alpha 1 antigen presentation 7.79 7.18 
glutathione S-transferase pi xenobiotic metabolism 34.42 20.21 
CD74 antigen antigen presentation 15.54 6.74 
X-box binding protein 1 transcription factor -3.60 -1.53 GENES 
ornithine decarboxylase antizyme 
inhibitor polyamine biosynthesis -3.57 -1.65 UPREGULATED 
proteoglycan 1, secretory granule granule component -3.18 -1.15 IN BCBL-1 AND L-428 1 
GENE NAME FUNCTION BJAB l-428 
FOlO FOlO 
CHANGE CHANGE 
E74-like factor 1 transcription factor 3.51 
BCL2-like 1 apoptosis 2.16 1.36 
phosphorylase kinase, alpha 2 (Iiver) glycogen metabolism 2.48 1.11 
immunoglobulin J polypeptide immune response, Ig production 11.63 
autocrine motility factor receptor tumor motility 4.69 GENES 
CD79B antigen B-cell receptor 5.71 -1.03 DOWNREGULA TED 
CD79A antigen B-cell receptor 18.32 -1.12 IN BCBL-1 AND 
CD40 antigen B-cell activation 8.14 1.84 L-428 
bleomycin hydrolase unknown. Inactivation of bleomycin 3.65 0.35 
heat shock 70kDa protein 9B (mortalin-2) cell proliferation, chaperone 2.62 -0.03 
chaperonin containing TCP1, subunit 5 chaperone 2.50 1.05 
CDW52 antigen (CAMPATH-1 antigen) unknown 17.08 -1.13 
baculovirallAP repeat-containing 3 apoptosis -1.06 2.56 
dihydrolipoamide dehydrogenase mitochondria 1.32 2.78 GENES 
ARP1 actin-related protein 1 homolog A cytoskeleton organization 1.51 2.26 UPREGULATED 
lipase A, Iysosomal acid, cholesterol 
esterase lipid metabolism 5.69 IN L-428 
dual specificity phosphatase 6 MAP kinase pathway 38.80 
cyclin G1 cell cycle 1.49 3.81 
Rho GDP dissociation inhibitor (GDI) Cell adhesion. Cytoskeleton 
beta organization 1.76 -14.71 DOWNREGULA TED 
beta-2-microglobulin antigen presentation -1.22 -3.37 IN L-428 
FIGURE 26. Four cellular factors involved in chemotaxis and ceU migration are upregulated in PEL ceUs. A) LT~H, IL-16, 
TSP-l and PSGL-l rnRNA and/or prote in levels in PEL cells vs. cHD cells. Left panel: Total RNA isolated from 4 PEL celllines and 
2 cHD celllines as well as BJAB cells was analyzed for LT~H, IL-16 and TSP-1 mRNA levels by RT-PCR. Lane 1, BJAB, Lane 2, 
BCBL-1, lane 3, BC-3, lane 4, BCP-l, lane 5, CRO-AP6, lane 6, L-428, lane 7, KM-H2. GAPDH amplification was used to ensure 
equal RNA levels. Right panel: Protein expression of L T ~H, pro-IL 16, TSP-l and PSGL-l in PEL cells compared to primary tonsilar 
B cells and cHD cells was assessed by immunoblot with specifie antibodies as indicated. Lane 1, primary tonsilar B cells, lane 2, 
control BJAB cells, lanes 3-6, PEL celllines (BCBL-1, BC-3, BCP-l, CRO-AP6), lanes 7-8, cHD celllines (L-428, KM-ID). An 
antibody against (3-actin was used to ensure equalloading. B) Irnrnunoblot for cleaved caspase 3 allowed the detection of the active 17 
kDa forrn when blotted with an antibody against active caspase 3. Lane 1, primary tonsilar B cells, lanes 2-5, PEL celllines (BCBL-1, 
BC-3, BCP-1, CRO-AP6), lanes 6-7, cHD celllines (L-428, KM-H2), lane 8, control BJAB cells. C) Irnrnunoblot against secreted 
TSP-1 present in growth media after 24h incubation. Cells were seeded into 6-well plates and left for 24 h at 37°C, with 5% CO2• After 
the incubation period, the supematants were harvested and blotted with a specifie antibody against TSP-1. Lanes 1-3, BJAB cells 
(negative control), lanes 4-6, BCBL-1 cells, lane 7, media alone. Experiment was perforrned in triplicates. 
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BCP-1, CRO-AP6), and comparing these cells to the cHD celllines L-428 and KM-H2 
as well as the BL cellline BJAB and primary tonsitar B cells. Analysis of the expression 
of LTA4H mRNA by RT-PCR identified a single 204 bp amplification product, white 
immunoblot analysis revealed the presence of a 69 kDa protein corresponding to LTA4H 
(Figure 26 A, top row). The mRNA induction level in PEL cells as measured by RT-
PCR was greater than lO-fold whereas the protein level averaged a 5-fold increase 
compared to cHD and BJAB cells. 
RT-PCR amplification of IL-16 mRNA detected the expected 333 bp product in all 
PEL and BJAB cells but not in cHD cells (Figure 26 A, second row). Induction levels in 
PEL cells ranged from 2.7- to 21-fold increase compared to the EBV negative BJAB 
cells. Other EBV+ BL celllines analyzed by RT-PCR also exhibited high IL-16levels 
(data not shown), indicating that both EBV and HHV -8 can induce expression of this 
chemokine. IL-16 is synthesized as a large 80 kDa precursor molecule - Pro-IL16 - that 
is cleaved to the bioactive 20 kDa IL-16 molecule by Caspase 3 (13). Immunoblot 
analysis of intracellular precursor protein levels closely mirrored the results obtained at 
the mRNA level, with high yet variable protein levels in PEL cell lines (Figure 2A, 
second row). No band was detected at 20 kDa, as expected for the secreted active IL-16. 
Immunoblot for activated Caspase 3 detected low levels of active, 17 kDa caspase 3 
protein in aIl PEL cell lines but not in cHD and BJAB cells (FIGURE 26 B), thus 
suggesting that bioactive IL-16 is produced and secreted by PEL ceIls. 
TSP-1levels were also increased in PEL ceIls compared to cHD and BJAB cells, both 
at the mRNA and protein levels (FIGURE 26 A, third row). RT -PCR analysis of TSP-l 
mRNA levels identified a single 493 bp product in PEL cells; this transcript was 
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undetectable in BJAB and cHD cells. Immunoblot analysis under reducing conditions 
revealed the intracellular presence of the 145-185 kDa protein in PEL cells only; 
furthermore, TSP-1 protein was detected in supernatants from BCBL-1 cells, 
demonstrating that this extracellular matrix prote in is produced and secreted by PEL 
cells (FIGURE 26 C). Similarly, intracellular PSGL-1 protein level was elevated in 
PEL cells but not detectable in cHD or BJAB cells (FIGURE 26 A, fourth row). 
Protein expression of LTA4H, TSP-1, PSGL-1 and IL-16 in PEL cells was also 
compared to expression in primary tonsilar B cells (Figure 26 A right panel, compare 
lane 1 to PEL samples). LTA4H, TSP-1 and PSGL-1 were 5- to lO-fold higher in PEL 
compared to primary B ceIls; however IL-16levels as weIl as caspase 3 activation were 
comparable in PEL and primary tonsilar B lymphocytes, suggesting that during PEL 
development, malignant B cells have acquired expression of LTA4H, TSP-1 and PSGL-
1, while retaining the capacity to produce IL-16. 
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CHAPTERVI 
Analysis of the transcriptional control 
of the Leukotriene A4 Hydrolase Promoter 
The results from our microarray analysis demonstrated a strong upregulation of 
the enzyme Leukotriene A4 hydrolase (L T A4H) in PEL cells compared to cHD and 
BL cells. To date, no reports exist on the regulation of L T A4H at the transcriptional 
level. In order to elucidate if regulatory elements in the promoter of the LTA4H 
gene were at the origin of the overexpression of this enzyme in PEL, we isolated the 
putative promoter region and assayed its activity in BeBL-l, L-428 and BJAB cells 
using a reporter gene assay. 
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1. Isolation of the LTA4H gene promoter region 
Altered transcriptional regulation has been shown to play an important role in aberrant 
gene expression in PEL, both in the case of expressed (lL-6, IL-8) and silenced (BCR) 
genes (8, Il,274). For this reason, we sought to investigate iftranscriptional regulatory 
elements were involved in LTA4H overexpression in PEL. The LTA4H promoter was 
initially described by Mancini and Evans in 1995 (172) but to date has not been 
functionally characterized. The promoter region of the LTA4H gene was located using 
NCBI software tools (National Center for Biotechnology Information, Bethesda, MA). A 
2.1 kb fragment upstream of the transcriptional start site, as weIl as 105 bp of the 5' 
UTR was amplified from genomic DNA isolated from BJAB cells. After PCR 
amplification, the fragment was cloned upstream of the luciferase gene by blunt-end 
ligation into the pGL3basic/modified plasmid (LTA4HPRO, see schematic in FIGURE 
29 A). The presence of the insert in the correct orientation was confirmed by restriction 
digest. Deletion constructs were created from L T A4HPRO by amplifying the desired 
fragment by PCR and blunt-end cloning into pGL3basic. 
2. LTA4H promoter activity in PEL ceUs. 
The activity of the LTA4H promoter was assessed in the PEL cellline BCBL-1 and 
compared to promoter activity in the Burkitt's lymphoma ceIlline BJAB and the cHD 
cell line L-428. A 130-fold induction in reporter gene activity was observed with the 
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LTA4Hpromoter relative to the empty vector (pGL3basic) in BCBL-1 cens, compared 
to 40- and 60-fold in BJAB and L-428 cens, respectively (FIGURE 27). 
Expression of the HHV -8 latent gene vFLIP in PEL cens has been shown to modulate 
the activity of important transcription factors such as NF-KB and AP-1, which are 
constitutively active in PEL cens (present work, (7, 30, 144, 178). In order to assess if 
NF -KB or AP-l transcription factors mediated the observed upregulation of L TA4H in 
PEL cens, we transfected a vFLIP expression plasmid or a p65 expression plasmid along 
with the LTA4HPRO construct into BJAB cens. Activity of the LTA4Hpromoter was 
not further stimulated in BJAB cens by overexpression of vFLIP or p65 (FIGURE 28 
A). To confirm that transcriptional modulation by NF-KB or AP-l is not involved in 
L TA4H overexpression in PEL cells, we used pharmacological inhibitors of these 
transcription factors in BCBL-1 cells and observed their effects on LTA4H promoter 
activity. Neither ibuprofen, acetylsalicylic acid nor the specific AP-1 inhibitor 8P600125 
had a significant influence in promoter activity in BCBL-l (FIGURE 28 B). Therefore, 
neither NF-kB nor AP-l appears to be involved in LT~H expression in PEL. 
3. Identification of a L T A4H promoter element active only in PEL ceUs 
Four deletion fragments of the LTA4H promoter were constructed to identify potential 
regulatory elements active in PEL cens (FIGURE 29 A). In both BJAB and BCBL-l, 
fragment 81, in which the distal 319 bp were deleted, exhibited roughly the same 
activity as the full-length promoter. Fragment 82, from -1196 to + 1 05, exhibited a 1.5 
fold increase in activity compared to 81, demonstrating the existence of a negative cis 
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FIGURE 27. Activity of the LTA4H promoter in BCBL-l ceUs vs. L-428 and BJAB ceUs. The putative promoter region and partial 
5' UTR of the LTA4H gene (-2021 to +105 bp) was subcloned in front of the luciferase gene to create LTA4HPRO. LTA4HPRO 
(yellow bars) or the empty vector (pGL3basic, white bars) were electroporated into BCBL-l, L-428 or control BJAB cells along with 
Renilla (pRLnull) as internaI control. Fold activity of the promoter was calculated as the ratio ofLTA4HPRO activity to empty vector. 
Values were normalized according to Renilla activity. The experiment shown is representative of at least 3 independent experiments 
carried in duplicate. 
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FIGURE 28. NF -lCB is not involved in the regulation of the LTA4H promoter. A) Activation of NF -KB by transfection of vFLIP or 
p65 did not affect the activity of L TA4HPRO. BJAB cells were electroporated with L TA4HPRO plus the appropriate expression 
plasmid and then incubated for 42 hrs before assaying for luciferase activity. B) Inhibition ofNF-KB and AP-I activity in BCBL-I 
cells with the chemical inhibitors aspirin (acetylsalicylic acid), ibuprofen (NF-KB inhibitor only) or the JNK inhibitor SP600125 did 
not affect the activity of LTA4HPRO. The appropriate inhibitor was added to transfected BCBL-l cells 6 hrs prior to harvesting 
samples and assaying for LTA4HPRO luciferase activity. Fold induction was calculated as the ratio between LTA4HPRO activity to 
empty vector (pGL3basic) after normalization using renilla as an internaI control (pRLnull). Representative experiments performed in 
duplicate are shown. At least three independent experiments were performed. 
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FIGURE 29. Identification of a positive regulatory region between -123 and -40 bp in the LTA.H promoter active only in 
BCBL-l cells but not in BJAB or L-428 cells. A) Schematic representation ofLTA4HPRO and deletion constructs. B) Activity of 
deletion constructs SI, S2 and S4. BCBL-l or BJAB cells were electroporated with each deletion construct or empty vector 
(pGL3basic), and assayed for luciferase activity. Fold induction was calculated as the ratio of luciferase activity of the deletion 
construct to empty vector. Values were normalized using renilla activity (pRLnull) as an internaI control. C) Activity of S4 and S6 
deletion constructs. BCBL-l, L-428 or BJAB cells were electroporated with S4 or S6 construct and assayed as in B. A representative 
experiment carried out in duplicate is shown. At least 3 independent experiments were performed. 
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regulatory element between -1702 and -1196. Between S2 and S4 there was a 1.5 to 2-
fold loss in activity, indicating the presence of one or more positive element(s) between 
-1196 and -123 (FIGURE 29 B). Interestingly, between S4 and S6 a 50% loss of 
activity was observed exclusively in BCBL-l cells, whereas no significant change in 
promoter activity was seen in BJAB or in L-428 cens (FIGURE 29 C). Thus, at least 
one positive cis regulatory element is present in the LTA4H promoter that is active only 
in BCBL-l cens; moreover, this element is locat~~d in the promoter proximal region, 
between -123 to -40 bp from the transcriptional start site. 
4. Two protein-DNA complexes form in the -76 to -40 region of the 
LTA4Hpromoter in BCBL-l ceUs. 
Further investigation of the transcriptional control of the LTA4H promoter was 
performed by electrophoretic mobility shift assay (EMSA). Nuclear extracts from 
BCBL-l, BJAB and L-428 cells were incubated with probes corresponding to the S4 and 
S6 regions of the L TA4H promoter (FIGURE 30, left panels). With probe S4, the 
presence of a protein-DNA complex was observed in BCBL-l cens but not in BJAB or 
L-428 cens. This complex disappeared when S6 was used as probe, thus demonstrating 
that binding occurred in the -123 to -40 bp region. This observation is in agreement 
with results from the reporter gene assay, where S4 contained a transactivating element 
that produced 2-fold higher activity than S6 in BCBL-l cells. 
To further delineate the factor(s) binding region, smaller probes were designed to fine-
tune the position of the binding site. Probe S9 spanned nucleotides -76 to +5, and probe 
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FIGURE 30. Formation of a specifie protein-DNA eomplex in the -76 to +5 bp region of the LTA4H promoter in BCBL-l eeUs. 
Nuclear extracts from BCBL-l, BJAB or L-428 cells were analyzed by EMSA with different probes spanning the LTA4H promoter 
proximal region, as indicated, to identify specifie complexes formed exclusively in BCBL-l. Probe S4 spans from -123 to + 105 bp, 
probe S6 from -40 to +105 bp, probe S9 from -76 to +5 bp, probe S8 from -46 to +5 bp. Specifie complexes are indicated by an 
arrow. 
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S8 from -46 to +5. Using these two probes in EMSA analysis, formation of a complex 
could be clearly seen in BCBL-l cells but not BJAB nor L-428 with both probes, 
although S9 probe yielded a sharper band than S8 (FIGURE 30, right panel). Four 
additional probes: S91 (-76 to -49) and S92 (-51 to -25), S93 (-66 to -40) and S94 (-40 
to -19) were used in EMSA analysis (FIGURE 31), to refine the mapping of the 
binding site(s). S91 showed formation of a faint, diffuse complex in BCBL-l cells and a 
stronger higher complex present in all cell lines. S92 lead to the formation of two 
specifie complexes in BCBL-1 cells: complex A was stronger and had lower motility, 
whereas complex B was very faint and migrated faster than complex A. S93 showed the 
presence of one strong band that roughly co-migrated with complex B. The S94 probe 
showed no prote in binding in any cell line. The specificity of the binding was 
demonstrated by cold probe competition, which disrupted the formation of the higher 
specifie complexes but not of a lower non-specifie band. Therefore, there are at least two 
distinct binding sites in this region: binding site A is approximatively centered at 
position -41/42 and truncations beyond -40 bp abrogate binding to this site. Binding site 
B is upstream of A, approximatively centered at position -46/48 (see FIGURE 32 for 
schematic). Identification of the binding protein(s) is still under investigation. 
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FIGURE 31. Fine mapping of the protein-DNA complex formed in BCBL-l ceUs. Shorter probes spanning the region from -76 to 
+5 were assayed for specifie eomplex formation by EMSA analysis. Probe S91 eontains the -76 to -49 bp region, probe S92, -51 to 
-25 bp, probe S93, -66 to -40 bp, probe S94, -40 to -19 bp. Blaek circles (lanes 1,4, 7, and 10): BJAB nuclear extract, white circles 
(lanes 2, 5, 8, Il, 13-15): BCBL-1 nuclear extracts, gray circles (lanes 3, 6, 9, and 12): L-428 nuclear extraets. Lanes 13-15: 
competition with S91, S92 and S93 eold probe at 25-fold molar excess, respective1y. Specifie complexes are indicated by arrows. A 
non-specifie eomplex is indicated by an asterix. 
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FIGURE 32. Schematic representation of the putative binding sites for complexes A and B formed exclusively in BCBL-l cells. 
The overlapping regions between S91, S92, S93 and S94 are indicated by boxes. The putative binding sites A and B are underlined. 
S91 
S92 A ACTTGT AGT 
S93 CCA AGC GCC CGC 
S94 CATGGAACTTGTAGT .. 
CHAPTERVII 
Functional significance of L T A4H upregulation in PEL ceUs 
Leukotriene A4 hydrolase is a key enzyme in the production of the potent pro-
inflammatory mediator leukotriene B4 (L TB4)' L T A4H is the limiting reagent in the 
production of L TB4, as the enzyme undergoes suicide inactivation during the 
reaction. Recently, it has been realized that two ceUs can co-operate to increase 
L TB4 production by a mechanism known as transceUular biosynthesis. In order to 
establish a biological significance to the overexpression of L T A4H in PEL ceUs, we 
investigated if this overexpression led to an increased production of L TB4 by 
transceUular biosynthesis. 
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1. Transcellular biosynthesis ofLTB4 is increased in BCBL-1 cells 
L TB4 is a potent lipid mediator that acts as a potent chemoattractant of neutrophils, 
monocytes, macrophages and T cells. L TB4 can also induce B cell proliferation and 
antibody secretion. Because B cells normaUy lack 5-LO activity, we postulated that 
upregulation of L T A4H in PEL cells may contribute to increased production of L TB4 by 
transcellular biosynthesis. To examine this possibility, BCBL-l cells were co-cultured at 
a 1 :50 ratio with primary neutrophils stimulated with calcium ionophore to induce 5-LO 
activity. In parallel, control BJAB and L-428 cells were assayed. Supernatants were 
collected and analyzed by enzyme-linked immunoassay (ElA) for LTB4. Co-culture with 
BCBL-l cells resulted in LTB4 levels of 620 pg/mL (+/- 65 pg/mL), whereas coculture 
with BJAB or L-428 produced 295 pg/mL (+/- 44 pg/mL) or 201 pg/mL (+/- 7 pg/mL), 
respectively (FIGURE 33 A). Therefore, BCBL-l cells have the capacity to produce 2-3 
fold more L TB4 than control B cells in the presenc(;~ of stimulated neutrophils. 
2. L TB4 receptors are expressed in PEL cells 
B lymphocytes have been shown to express both LTB4 receptors, BLT-l and BLT-2, 
and therefore also have the capacity to respond to exogenous L TB4. AU PEL cell lines 
had strong expression ofBLT-l and BLT-2 mRl\fA as demonstrated by RT-PCR, and 
the se levels were comparable to those of BJAB and L-428 cells (FIGURE 33 B). This 
suggests that PEL cells have retained the potential to respond to L TB4 stimulation. 
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FIGURE 33. Formation of LTB4 by transcellular biosynthesis is increased in BCBL-l cells. A) Transcellular biosynthesis of 
LTB4 measured by ElA. BCBL-l, BJAB or L-428 cells were incubated with calcium ionophore-stimulated primary neutrophils at a 
ratio of 50:1. Supematants were diluted 100-fold and assayed for secreted LTB4 by ElA. Experiment performed in triplicate. Data 
significance was assessed using paired Student's ttest, * P= 0.010, ** P= 0.004. B) RNA levels ofthe LTB4 receptors BLTI and BLT2 
in BJAB, BCBL-l and L-428 cells. Total RNA from each cellline was subjected to RT-PCR using specifie primers for BLT-l and 
BLT-2. GAPDH primers were used as a control for equal RNA content. Representative results are shown. At least 3 independent 
experiments performed. 
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3. BCBL-l cells do not migrate or proliferate in response to L TB4 
Migration experiments demonstrated that BCBL·· l ceUs migrate 50 to 100 times more 
readily across a porous membrane than control BJAB ceUs (FIGURE 34, compare 
panels A and B), even in the absence of chemotactic stimulus. Although the underlying 
mechanism for such an increase in motility has not been studied, it is possible that the 
overexpression of adhesion molecules such as L seIectin and PSGL-I might be involved 
in this process. L TB4 stimulation consistently failed to induce a further increase in 
migration of BCBL-I ceUs (FIGURE 34, panels B, C and D). It is possible that LTB4 
produced by PEL ceUs acts in a paracrine way to induce activation of endothelial ceUs 
and promote transmigration in this way, a hypothesis that requires further investigation. 
LTB4 failed to induce BCBL-I ceU proliferation (FIGURE 35) when used alone or in 
combination with IL-4 or IL-6. Indeed, L TB4 appeared to have a slight inhibitory effect 
on BCBL-I ceU proliferation when used in combination with IL-4 and high dose IL-6. 
The reasons for such inhibition remain unclear. Failure of L TB4 to induce BCBL-I ceU 
proliferation cornes as no surprise, as addition of exogenous stimuli has consistently 
failed to induce further PEL ceU proliferation because ceU growth is almost exclusively 
driven by autocrine mechanisms involving vIL-6 and IL-IO (135). LTB4 seems to be no 
exception, and although this leukotriene can increase proliferation and maturation of 
normal B ceUs, its effects - if any - on PEL ceUs remain unknown. 
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FIGURE 34. BCBL-l ceUs migrate readily across a porous membrane. A-C, Representative fields of Calcein-AM labeled ceUs 
migrated to the bottom side of a polycarbonate membrane in a transwell migration experiment. A) Control BJAB ceUs plus PBS/O.l % 
HSA. B) BCBL-l cells plus PBS/O.l % HSA. C) BCBL-l ceUs plus L TB4 (10-1OM). D) Quantitation of migration experiment. The total 
number of migrated BCBL-I cells on the bottom side of the polycarbonate filter were counted under the fluorescent microscope. Error 
bars correspond to SD on triplicate readings. 
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FIGURE 35. LTB4 do es not induce proliferation of BCBL-l cells. A) BCBL-I cells were incubated with LTB4 alone (black bars) or 
in combination with IL-4 (2 V/mL, vertical hatched bars; 20 V/ mL, horizontal hatched bars) and cell number was monitored by trypan 
blue staining. Vntreated cells (white bars) and cells treated with IL-4 alone (2 V/mL) were included as controls. B) Same as A, but 
BCBL-I cells were treated with L TB4 alone or in combination with IL-6 (1 or lOng/mL). 
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CHAPTER VIII 
Discussioll 
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1. Disruption of the B eell-specifie transeriptional program in Primary 
Effusion Lymphoma 
The current study demonstrates that PEL cells have undergone a severe disruption in 
the expression of B cell specifie transcription factors - specifically PU.1, Oct-2, BOB-l, 
BSAPIPax5 and IRF-8 concomitant with an overexpression of IRF-4 - a marker of a 
post-GC stage of differentiation. The absence of Oct-2 and the co-activator BOB-1 is 
noteworthy as these transcription factors are essential for the generation of germinal 
centers and are expressed by B-Iymphocytes until the plasma cell stage. The 
downregulation of Oct-2 and BOB-1 plays a role in the ablation of PU.1 expression in 
PEL cells as the activity of the PU.1 promoter in mature B cells is largely dependent on 
the presence of an octamer binding site at position -57 to -51 bp from the transcriptional 
start site (our work and (48)). In the PEL cellline BCBL-1 - where Oct-2 expression is 
completely absent - the activity of the full-Iength PU.1 promoter was negligible. 
Transient expression of Oct-2 restored the activity of the PU.1 promoter to levels 
comparable to the control cell line BJAB. Interestingly, the endogenously expressed 
Oct-1 failed to activate the PU.1 promoter in BCBL-1 cells and thus could not 
functionally replace Oct-2, in spite of its high level of expression. Our studies thus 
suggest that loss of Oct-2 expression contributes to the transcriptional shut-off of PU.1 
in PEL cells and thus might be at the he art of the lack of expression of B lymphocyte-
specifie molecules in PEL. Indeed, studies by Radomska et al. (231) and Junker et al. 
(137) using a Band non-B cell fusion model demonstrated that extinction of the B cell 
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transcriptional pro gram correlates with the rapid downregulation of the expression of B 
cell specific transcription factors including Oct-2 and PU.I. The expression of B cell 
immunoglobulin genes could be recovered by ectopic expression of Oct-2. 
Protein expression of the Ets transcription factor pu. 1 is completely absent in PEL 
cells. The ablation of this important transcription factor leads to the impaired activity of 
PU.I-responsive elements such as the AB and KE3' enhancers that regulate the 
expression of the immunoglobulin light chains. These enhancer elements contain 
composite Ets-IRF sites that are activated by the c:o-operative action of PU.I and IRF-
4/IRF-8. In control BJAB cells, electromobility shift assay using the À.B or the KE3' Ets-
IRF site sequence as probe demonstrated that this site could be bound by PU.I 
independently or co-operatively with IRF-8. Co-operative binding with IRF-4 could not 
be shown as BJAB cells lack IRF-4. In PEL cells, no binding to these Ets-IRF sites was 
observed. The activity of the AB Ets-IRF site in reporter gene assay is negligible in PEL 
cells - in spite of the overexpression of IRF-4 in these cells - correlating with the results 
obtained by EMSA analysis. Ectopic expression of PU.I in BCBL-I cells could restore 
the activity of the Ets-IRF site in a dose-dependent manner, demonstrating the 
specificity of this site for pu.I. Remarkably, although the Ets factor Spi-B - which has 
been reported to have redundant activity with PU.ll - was expressed to normal levels in 
PEL cells, it could not replace PU.I in the transactivation of the AB element. The 
reasons for such discrepancy with previous reports (68, 227) could lie in differences in 
experimental models as, to our knowledge, we are the first ones to assess the activity of 
a composite Ets-IRF site in PEL celllines. 
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The role of IRF-4 in the context of PEL cells that lack expression of PU.l has not been 
studied. However, IRF-4 has been shown to regulate important events in the last stages 
of mature B cell differentiation such as class-switch recombination and plasma cell 
development. IRF-4 regulates the expression of activation-induced cytidine deaminase, 
most likely at the transcriptionallevel, and controls as yet undetermined events upstream 
of XBP-l in the path towards plasma cell differel1ltiation (148). Whether IRF-4 acts in 
partnership with PU.l or with additional transcription factors in controlling these events 
remains to be determined. IRF-4 overexpression has been shown to occur in HTL V-l 
infected leukemia T cells (257), in which IRF-4 acts as a global transcriptional repressor. 
IRF-4 was shown to downregulate the expression of genes involved in cell cycle control, 
apoptosis, DNA repair and cell adhesion (170). IRF-4 overexpression in T cells led to 
the downregulation of critical DNA repair genes, leading to increased sensitization to 
genotoxic stress and increased risk of DNA mutations (169). IRF-4 can also directly 
inhibit IRF-l transactivation of interferon-responsive genes by competitively binding to 
target sequences (309) and it can inhibit cytokine production following TLR-4 
stimulation. It will be interesting to determine if IRF-4 can act as a global repressor of B-
cell specifie genes in PEL cells and if IRF-4 overexpression combined with PU.l 
downregulation plays a role in the transformation of B lymphocytes. 
2. PEL is characterized by the overexpression of pro-inflammatory 
molecules 
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The detailed characterization of B ceIl lymphomas contributes to its accurate 
classification as weIl as the design of new treatments, specificaIly targeted towards 
molecular features known to contribute to the development of a particular lymphoma. 
PEL and classical HD derive from B lymphocytes at a similar developmental stage -late 
GC or post-GC with a partial plasma cell phenotype - and they share a peculiar lack of 
surface marker expression leading to an indeterminate phenotype. This lack of surface 
marker expression, and in particular of surface immunoglobulin, has been attributed to 
an ablation in B cell-specific transcription factor expression. Thus, both PEL and cHD 
cells lack PU. 1, IRF-8, Oct-2, Bob-1 and Pax-5 expression yet they normally express 
Spi-B and IRF-4. PEL and cHD also share a constitutive activation of the transcription 
factors NF-KB and AP-1, although the molecular mechanisms leading to this activation 
are quite different. The similarities at the molecular level between PEL and cHD are not 
translated to the clinical level, where the presentation and response to treatment of each 
lymphoma are diametrically opposed. In this study, we addressed the question of 
identifying a set of genes that could set apart PEL from cHD and other mature B cell 
lymphomas by using microarray technology. Amongst a set of 1 700 ESTs, we identified 
a small group (approx. 40) of genes differentially expressed in PEL (TABLE 1). Four 
genes involved in cell migration, chemotaxis and inflammation - LTA4H, IL-16, TSP-l 
and PSGL-l - were highly expressed in PEL cells but not in cHD cells. These genes are 
particularly interesting because PEL cells aberrantly localize to serous body cavities -
pointing to cell migration defects - and because chronic inflammation is a major player 
in the development of Kaposi' s sarcoma - a disease that like PEL is caused by the HHV-
8 virus. 
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LTA4H. LTA4H catalyzes the last step in the synthesis of LTB4, a pote nt 
chemoattractant of neutrophils with numerous pro-inflammatory properties. LTA4H also 
possesses an aminopeptidase activity thought to play a role in extracellular matrix 
remodelling, although no physiological substrates have been identified to date. LTB4 
stimulates leukocyte generation of reactive oxygen species, degranulation and 
phagocytosis. LTB4 augments human peripheral blood monocyte production of IL-6 as 
weil as IL-2 production by CD4+ T cells (195, 237). LTB4 can also stimulate production 
of IFN-y, IL-4 and IL-lO in a model of murine splenocytes (10). In B cells, LTB4 
enhances activation, proliferation and Ig secretion. LTB4 also acts on endothelial cells to 
increase their adhesiveness, thus promoting transendothelial migration. Finally, LTB4 
can inhibit apoptosis in several cancer cell models. 
In the case of PEL, increased LTB4 production by transcellular biosynthesis could 
contribute in numerous ways to the development of this Iymphoma. The first obvious 
effect of LTB4 would be the enhancement of B cell proliferation and inhibition of 
apoptosis. LTB4 could also drive the early HHV -8 infected B cells towards the plasma 
cell phenotype - in as much as LTB4 seems to promote B cell activation. Indeed, a study 
of B-cell chronic Iymphocytic leukemia (B-CLL) cells showed that LTB4 plays a pivotai 
role in the activation of these cells by CD40 ligation and suggests that the use of 
leukotriene biosynthesis inhibitors has therapeutic potential for this Iymphoma (242). 
Secondly, LTB4 could increase the production of IL-6 and IL-10 - two cytokines 
involved in PEL cell survival and proliferation - either by PEL cells or by bystander 
cells. Enhancement of IFN-y production by LTB4 could lead to induction of the HHV-8 
lytic cycle in infected B cells, promoting further rounds of infection of healthy B-
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lymphocytes. Endothelial activation by LTB4 - leading to increased adhesiveness -
could promote aberrant transvasation of PEL celIs from the circulation into body 
cavities. 
Increased expression of genes involved in leukotriene synthesis has been observed in 
several cancer types. Overexpression of 5-LO has been observed in B-CLL and human 
pancreatic cancer celIs, whereas LTA4H overexpression has been described for human 
esophageal carcinoma and increased LTB4 levels have been detected in oral squamous 
cancer celIs, suggesting a role for LTB4 in he ad and neck cancer pathogenesis. We have 
now identified an overexpression of LTA4H in PEL cells - both at the mRNA and at the 
protein level that leads to an increased LTB4 production. The implications of LTA4H 
overexpression in the pathogenesis of PEL are multiple and our results grant further 
investigation of the role of LT A4H overespression in PEL development using in vivo 
models of this disease. 
IL-16. IL-16 is synthesized as an 80 kDa precursor that is cleaved by caspase 3 into a 
20 kDa active peptide. IL-16 acts on CD4+ cells such as T helper cells, dendritic celIs, 
monocytes/macrophages, eosinophils and neuronal cells. IL-16 multimerizes and binds 
to the CD4 receptor, triggering multiple responses including chemoattraction of CD4+ 
cells. IL-16 enhances IL-2- or IL-15-induced proliferation of CD4+ T cells. Bioactive 
IL-16 secreted by B lymphocytes is a major player in the chemoattraction of CD4+ T 
and dendritic cells to sites of T -B cell interaction in the lymph nodes (142) and IL-16 
can be detected in the mantle zone and GC regions of lymphatic tissue colocalized with 
CD20. 
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Sorne inflammatory diseases such as asthma and inflammatory bowel disease are 
associated with increased IL-16 levels. Similarly, increased IL-16levels were found in 
the serum of multiple myeloma patients and higher levels of this cytokine correlated 
with decreased survival time (5). We have identified an upregulation of IL-16 precursor 
protein in PEL celIs as weIl as low levels of caspase 3 activation, suggesting the 
production of bioactive IL-16 by PEL cells. The production of IL-16 by PEL cells could 
lead to the recruitment of CD4+ celIs to serous body cavities and the establishment of a 
chronic inflammatory state favorable to disease progression. Furthermore, during the 
early stages of the lymphoma, the recruitment of T helper cells could provide pro-
survival signaIs that maintain aberrant B celIs alive and promote the emergence of a 
transformed PEL clone. 
TSP-l. TSP-l is a large trimeric protein found in the extracellular matrix that can bind 
to multiple receptors such as CD36 (the classical TSP-l receptor), intergrins avl33, 
a3131, a4131, a5131, aIIbl33, a2131, CD47 and heparin sulfate proteoglycans such as 
syndecans 1, 2, 3 and 4 (reviewed in (264». Through its multiple domains, TSP-l is 
involved in processes such as chemotaxis, celI ad he sion and neo-vascularization with 
sometimes conflicting and even opposite effects. TSP-l can support celI attachment, 
adhesion and spreading. TSP-l has been associated with T celI adhesion and a 
synergistic effect on the activation of the MAPK and Ras pathways by CD3. TSP-l 
induced RhoA inactivation via activation of Focal Adhesion Kinase (FAK), leading to 
focal adhesion disassembly, a process required for cell migration. No studies up to date 
have looked into the effects of TSP-l in B lymphocytes. 
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Predicting the effects of TSP-l upregulation in PEL can be a daunting task. Because 
PEL cells express CD138/syndecan-l, TSP-l could mediate cell adhesion and migration. 
Similarly, interactions between TSP-l and integrins on PEL cells could activate the p38 
MAPK and JNK pathways and mediate cell adhesion. The anti-angiogenic properties of 
TSP-l are weIl documented, and they are usually associated with decreased tumor 
growth. Nonetheless, in sorne instances, such as gastric cancer, elevated TSP-l 
expression is associated with increased angiogenesis and cancer progression. It would be 
extremely interesting to study the effect of TSP-l antagonists in PEL cell migration or in 
disease progression in in vivo models of this lymphoma. 
PSGL-l. PSGL-l is the sialo-mucin ligand for P-selectin, an adhesion molecule 
important for leukocyte rolling and adhesion (194). P-selectin expression is rapidly 
induced at the surface of endothelium or activated platelets in response to histamines or 
thrombin whereas E-selectin is expressed on endothelium following activation with 
inflammatory cytokines. P-selectin and E-selectin mediate the adhesion of leukocytes to 
the vascular endothelium. P-selectin glycoprotein ligand-l (PSGL-l) is a heterodimer 
that binds P-selectin with high affinity and L-selectin at significant lower levels. PSGL-l 
interactions with P-selectin mediate neutrophil rolling on endothelial cells, a process 
essential in for extravasation to sites of inflammation. 
Upregulation of PSGL-l in PEL cells could be a factor contributing to the 
extravasation of the malignant cells from the circulation into the body cavities. Increased 
expression of adhesion molecules su ch as L-selectin and several integrins has been 
identified by our study and others (133). It is very likely that the combined expression of 
these molecules increases the migration capacity of PEL cells. Indeed, an in vitro 
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migration experiment using BCBL-l cells demonstrated that the PEL cell line migrates 
50- to 100-fold more readily across a porous membrane th an control BJAB ceIls, even in 
the absence of chemotactic stimulus. 
Considering that PEL's exclusive localization to body cavities requires the migration 
of the B cell from the lymph node to the periphery and its extravasation from the 
circulation into serous body cavities, it is likely that the overexpression of chemotactic, 
adhesion and migration factors play an important role in PEL formation. HHV -8 has 
been shown to require the establishment of an inflammatory milieu to induce KS onset 
and progression, suggesting that factors involved in inflammation may play a role in the 
development of PEL as weIl. Unfortunately, detection of PEL usually occurs at the late 
stages of the disease and therefore the sequential progression of this Iymphoma has not 
been studied. 
3. Other genes identified as differentially expressed in PEL 
B cel! receptor components: CD79A and B.Microarray analysis of the PEL ceIlline 
BCBL-l and the cHD cell line L-428 identified components of the B cell receptor 
(BCR) or B cell co-stimulatory molecules to be downregulated in these cells. Among 
them, CD79A and CD79B (Iga and Ig~ chains) - which constitute the signaling 
components of the BCR - were downregulated in PEL and cHD cells. This is in 
agreement with previous reports that have found a lack of expression of B cell-specific 
surface molecules in both PEL and cHD. 
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Phospholipase Cy-2 (PLC-y2). Crosslinking of the BCR by antigen triggers a complex 
signaling cascade that culminates in the activation of multiple transcription factors such 
as NF-KB, NFAT, Elk, cFos and cJun. Although multiple reports exist on the lack of 
BCR components and co-stimulatory molecules in PEL, no reports to date have looked 
into the downstream signaling pathways. Initial microarray analysis demonstrated a 
downregulation in PLCy2 levels in BCBL-l cells and this result was confirmed by 
immunoblot in PEL and cHD cell lines. A study published by Marafioti et al. (174) 
consistently found a lack of PLCy2, Syk and BLNK expression in biopsy samples and 
cell lines derived from cHD, further confirming the parallei between PEL and cHD. 
Thus, lack of expression of PLC-y2 is another common trait between PEL and cHD 
cells, although the expression of Syk and BLNK in PEL has not been investigated. 
Major Histocompatibility Comp/ex class II (MHC II). Microarray analysis showed a 
decreased expression of aIl MHC II chains in BCBL-I cells compared to BJAB and L-
428 cells. Analysis of HLA-DR expression in a panel of PEL cell lines by RT -PCR 
demonstrated a significant decrease in MHC II expression, although this was not 
consistent accross our panel of cellline nor was it demonstrated for aIl MHC II alleles. 
This was in contrast to cHD cell lines, which demonstrated normal levels of MHC II 
mRNA. 
Other. Microarray analysis revealed altered expression of additional molecules 
essential for B cell function in PEL celIs: the expression of CD40 and CD74 was found 
to be downregulated in BCBL-I cells whereas expression of Rho GDP dissociation 
inhibitor (GDI) 13 was upregulated (TABLE 1). However, these results await 
confirmation by RT-PCR. 
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Genes such as Immunoglobulin J polypeptide (downregulated), L selectin 
(upregulated), CD48 (upregulated), immunoglobulin light chains À. and K 
(downregulated), have already been described in the literature as altered in PEL ceUs 
and the agreement of the microarray results with previous findings confers an additional 
level of confidence to this study. 
4. L T A4H transcriptional regulation in PEL and functional significance 
of its overexpression 
The involvement of lipid mediators in inflammation and cancer has been established 
both at the c1inical and basic level. Long-term treatment with non-steroidal anti-
inflammatory drugs, compounds that inhibit the synthesis of eicosainoids, reduces the 
incidence of colorectal cancer in large population-based studies as weIl as in rodent 
models (reviewed in (104». The leukotriene LTB4, which induces a vigorous 
inflammatory response, has been equaIly implicated in cancer development and the use 
of LTB4 antagonists or LTA4H inhibitors reduced cancer incidence in animal and in vitro 
models (49, 242). LTA4H upregulation in PEL cells was initially identified by 
microarray analysis and further confirmed by RT-PCR and immunoblot. Our results 
showed that LTA4H expression was at least 5-foldl higher in PEL ceIls than in other B 
celllines or in primary tonsilar B cells. 
The present work focused on the transcriptional elements responsible for LTA4H 
upregulation in PEL as weIl as establishing a physiological role such as increased LTB4 
synthesis by PEL ceUs. Isolation of the LTA4H promoter demonstrated that expression 
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of this enzyme is controlled at the transcriptional level and that promoter activity was 
over 3-fold higher in the PEL cell line BCBL-l than in the control cell line BJAB. The 
use of truncated promoter construct in reporter gene assays identified potential 
regulatory sites in the LTA4H promoter: the distal -1996 to -1702 bp region contained 
negative regulatory sites whereas the -1196 to -123 bp region contained positive 
regulatory elements active in aIl celllines. Interestingly, the promoter proximal -123 to-
40 bp region contained a positive cis-acting element active only in BCBL-l cel1s. 
Deletion of this region lead to a 50% decrease in promoter activity in BCBL-l cells but 
had no effect in control BJAB or L-428 cells. EMSA analysis demonstrated the presence 
of two protein-DNA complexes in the -51 to -40 bp region in BCBL-l cells but not 
control cells. Thus, we identified a positive regulatory site that controls LTA4H 
expression in PEL cells and leads to its overexpression. Although candidate transcription 
factors that could potentially bind this element were identified by computer modeling 
(TESS, (249», EMSA analysis using the corresponding consensus probes and/or 
antibodies (C/EBP, E2F-l, Oct, Myc, Myb and others) were unsuccessful. We speculate 
that this site might be regulated by a novel GC-rich element binding protein. 
There is increasing evidence that leukotriene synthesis in vitro as weIl as in vivo can 
be achieved by transcellular biosynthesis. This is particularly interesting in the case of 
LTB4 for two reasons: 1) 5-LO expression is restricted to myeloid-derived cells and 2) 
LTA4H undergoes suicide inactivation after synthesis of one molecule of LTB4. LTA4H 
expression is largely ubiquitous and therefore transcellular synthesis of LTB4 would play 
an important role in the amplification of the inflammatory response by increasing the 
overall amount of LT A4H available to catalyze the last step of the synthesis. The 
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increased ability of PEL cells to produce LTB4 by transcellular biosynthesis was 
demonstrated by co-culturing BCBL-l cells with calcium ionophore-stimulated primary 
neutrophils at a 1:10 and 1:50 ratio. Measurement of LTB4 production by enzyme-linked 
immunosorbent assay (ELISA) showed that BCBL-l cells were able to produce up to 
50% more LTB4 th an control BJAB or L-428 cells, thus demonstrating the ability of 
PEL cells to magnify LTB4 production even under limited neutrophil infiltration. 
PEL cells appear to have retained the capability to respond to LTB4, as suggested by 
the strong mRNA expression of both LTB4 receptors (BLT-l and BLT-2). However, the 
effect of this leukotriene on PEL cells remains to be determined. LTB4 did not trigger 
BCBL-l cell proliferation or chemotaxis at physiological concentrations. Proliferation 
was not induced by LTB4 even when used in combination with IL-6 or IL-4. This is not 
totally surprising, since exogenous addition of most B- cell growth factors - including 
the potent cytokine IL-6 - have no proliferative effect in PEL cell lines. This is 
attributable to the fact that PEL cell lines de pend mostly on autocrine signais such as 
vIL-6 to promote growth. However, during the early stages of PEL, before the 
malignant cells are growth-factor independent, it is not unlikely that LTB4 can play a 
role in cell proliferation and survival, as demonstrated with normal mature B cells. 
Moreover, LTA4H possesses an aminopeptidase activity that is thought to participate in 
extracellular matrix remodeling. It cannot be ruled out that this activity of LT A4H may 
be involved in PEL establishment in serous body cavities, a possibility that remains to be 
explored. 
In conclusion, we have found that PEL cells are characterized at the molecular level by 
an ablated expression of B-cell specifie transcription factors such as PU.l, Oct-2, IRF-8 
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and BSAPlPax-5 while exhibiting a concomitant upregulation of mediators of 
inflammation and cell migration such as LTA4H, IL-16, TSP-l and PSGL-l (see 
schematic representation in FIGURE 36). Whereas transcripton factor ablation provides 
a plausible cause for the lack of expression of B cell-specific surface markers in PEL, 
the identification LTA4H, IL-16, PSGL-l and TSP-l as molecules exclusively 
upregulated in PEL cells suggests that overexpression of factors involved in cell 
motility, inflammation and/or chemotaxis are involved in the aberrant localization of this 
lymphoma to the serous body cavities. Further experiments that delineate the role of 
each of these factors in the increased migration potential observed for PEL cells are 
required to understand the mechanisms governing the establishment of these cells in 
body cavities. 
Identifying new molecules that are specifically overexpressed in PEL provides an 
interesting framework for the development of novel therapeutic approaches for this 
lymphoma. For example, the effect of the metalloproteinase inhibitor Bestatin - an anti-
cancer agent that inhibits LTA4H - could be assayed as a potential inhibitor of PEL, 
either by blocking LTB4 formation or the metalloproteinase activity of LTA4H. As weIl, 
the effect of anti-inflammatory drugs on PEL cell survival and migration should be 
explored. However, the development of an appropriate in-vivo model for PEL is 
essential to clearly demonstrate the role of cell migration and inflammation in the 
development of this lymphoma. 
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FIGURE 36. Schematic representation of the molecular alterations identified in PEL cells. PEL cells have ablated expression of 
the transcription factors PU.I, Oct-2, Bob-l, BSAP/Pax-5 and IRF-8, resulting in decreased expression immunoglobulin genes and 
other surface and signaling molecules. Concomitantly, PEL cells overexpress factors involved in cell migration and inflammation such 
as L T ~H, IL-l6, TSP-I and PSGL-I. This may contribute to the localization of PEL to serous body cavities. 
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CONTRIBUTIONS TO ORIGINAL KNOWLEDGE 
1. Identified a lack of B cell-specific transcription factor expression in PEL ceIls, which 
contributes to the null phenotype characteristic of this lymphoma. Furthermore, this 
study delineated the functional significance of this ablation by confirming its effect on 
the activity of B cell specific promoter elements such as the PU.l promoter and the Â.B 
and KE3' light chain enhancers. 
2. Identified by microarray analysis a cluster of genes that are differentially expressed in 
PEL cells and therefore can be of practical relevance in the classification and diagnosis 
of this lymphoma. Four molecules involved in the inflammatory processes of 
chemotaxis, cell adhesion and migration were identified as upregulated at the mRNA 
and protein level in PEL ceIls: LTA4H, IL-16, PSGL-l and TSP-l. PEL cells also 
expressed - at least at the mRNA level- both LTB4 receptors: BLT-l and BLT-2 
3. Functionally characterized the LTA4H promoter, demonstrating that LTA4H 
expression is regulated at the transcriptional level by cis-regulatory elements that are 
active only in PEL cells and determine LT A4H overexpression in this lymphoma. The 
regulatory site was recognized by a yet unidentified transcription factor active only in 
PEL cells. 
4. Established that overexpression of LTA4H in PEL cells results in an increased 
capability of synthesizing LTB4 by transcellular biosynthesis. Considering that LTA4H 
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and LTB4 are implicated in the development of certain types of cancers, LTA4H 
potentially represents a novel target for PEL treatment. 
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(2601-4) 
9. Extremity Dosimetry 
The licensee shall ensure that any person who handles a container 
which con tains more than 50 MBq of phosphorus 32, strontium 89, 
yttrium 90, samarium 153 or rhenium 186 wears a ring dosimeter. The 
dosimeters must be supplied and read by a dosimetry service licensed 
by the Commission. 
(2578-0) 
9. Contamination Criteria 
The licensee shall ensure that for nuclear substances listed in the 
licence application guide table titled ·Classification of 
Radionuclides"; 
(a) non-fixed contamination in all areas, rooms or enclosures where 
unsealed nuclear substances are used or stored does nct e~<ceed: 
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(ii) 30 becquerels per square centimetre for all Class B 
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radionuclides; 
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(b) the release of Any area, roorn or enclosure containing fixed 
contamination, i5 approved in writing by the Commission or persan 
authorized by the Commission; 
(e) all nuclear substances and radiation devices have been 
transferred in accordance with the conditions of this licence; and 
(d) all radiation warning signs have been removed or defaced. 
(2571-2) 
11. Storage 
The licensee shall: 
(a) ensure that when in storage radioactive nuclear substances or 
radiation devices are accessible only to persans authorized by the 
licensee: 
(b) ensure that the dose rate at any occupied location outside the 
storage area, room or enclosure resulting frem the substances or 
devices in storage does not exceed 2.5 microSv/h; and 
(c) have measures in place to ensure that the dose limits in the 
Radiation Protection Regulations are nct exceeded as a result of the 
substances or devices in storage. 
(2575-0) 
12. Disposal (Laboratories) 
Wh en disposing of unsealed nuclear substances to municipal garbage or 
sewer systems, the licensee shall ensure that the following lirnits 
are not exceeded: 
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